(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
25 August 2022 (25.08.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/178315 A1

(51) International Patent Classification:
C07D 403/12 (2006.01) *C07D 405/14* (2006.01)

(21) International Application Number:
PCT/US2022/017086

(22) International Filing Date:
18 February 2022 (18.02.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/151,605 19 February 2021 (19.02.2021) US

(71) Applicant: **MAZE THERAPEUTICS, INC.** [US/US]; 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(72) Inventors: **LEE, Patrick Sang Tae**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **EWING, Todd Jonathan August**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **REID, Adam Neil**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **SINZ, Christopher Joseph**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ZHANG, Birong**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **BRONNER, Sarah M.**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **MORGANS, David John Jr.**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **HOEK, Maarten**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US). **ASSIMON, Victoria Anne**; c/o Maze Therapeutics, Inc., 171 Oyster Point Blvd, Suite 300, South San Francisco, California 94080 (US).

(74) Agent: **MCBRIAR, Mark D.** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: APOL1 INHIBITORS AND METHODS OF USE



(A')

(57) **Abstract:** Provided herein are compounds of formula (A'): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, R^a, R^b, R^c, L, Q, and Y are as defined herein. Also provided are methods of inhibiting APOL1 and methods of preparing compounds of formula (A'). Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.

WO 2022/178315 A1

APOL1 INHIBITORS AND METHODS OF USE

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No. 63/151,605 filed on February 19, 2021, the content of which is incorporated herein by reference in its entirety.

BACKGROUND OF THE INVENTION

[0002] Apolipoprotein L1 (APOL1) is a pore forming innate immunity factor, protecting individuals from trypanosome parasites (Vanhamme, L. et al. *Nature* (2003) 422, 83-87). The secreted form of APOL1 circulates in blood as part of distinct high-density lipoprotein (HDL) complexes, known as trypanosome lytic factors (TLFs) (Rifkin, M. R. *Proc. Natl. Acad. Sci. USA.* (1978) 75, 3450-3454; Raper, J. et al. *Infect. Immun.* (1999) 67, 1910-1916). TLFs are internalized by the parasites through endocytosis (Hager, K. M. et al. *J. Cell Biol.* (1994) 126, 155-167). Within trypanosomes, APOL1 forms cation pores, causing ion flux, swelling, and eventual lysis (Rifkin, M. R. *Exp. Parasitol.* (1984) 58, 81-93; Molina-Portela, M. P. et al. *Mol. Biochem. Parasitol.* (2005) 144, 218-226; Pérez-Morga, D. et al. *Science.* (2005) 309, 469-472; Thomson, R. & Finkelstein, A. *Proc. Natl. Acad. Sci. USA.* (2015) 112, 2894-2899).

[0003] Several *Trypanosoma brucei* subspecies (*T.b. rhodesiense* and *T.b. gambiense*) developed resistance mechanisms to APOL1-dependent killing (Pays, E. et al. *Nat. Rev. Microbiol.* (2014) 12, 575-584). Positive selection resulted in APOL1 variants, G1 (S342G, I384M) and G2 (N388Δ, Y389Δ), capable of interfering with these resistance mechanisms (Genovese, G. et al. *Science.* (2010) 329, 841-845). However, individuals with any binary combination of these variants (G1/G1, G2/G2, or G1/G2), have a greater risk of developing a variety of chronic kidney diseases, including focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN) (Genovese, G. et al. *Science.* (2010) 329, 841-845; Tzur, S. et al. *Hum. Genet.* (2010) 128, 345-350; Kopp, J. B. et al. *J. Am. Soc. Nephrol.* (2011) 22, 2129-2137), sickle cell nephropathy (Ashley-Koch, A. E. et al. *Br. J. Haematol.* (2011) 155, 386-394), lupus nephritis (Freedman, B. I. et al. *Arthritis Rheumatol.* (2014) 66, 390-396), and an increased rate of Glomerular Filtration Rate (GFR) decline in diabetic kidney disease (Parsa, A. et al. *N. Engl. J. Med.* (2013) 369, 2183-2196). The APOL1 high-risk genotype has also been associated with

COVID-19 associated nephropathy and other viral nephropathies (Shetty, A. et al. *J. Am. Soc. Nephrol.* (2021) 32, 33-40; Chang, J. H. et al. *Am. J. Kidney Dis.* (2019) 73, 134-139). Moreover, decreased renal allograft survival has been observed after deceased-donor kidney transplantations from APOL1 high-risk genotype donors (Freedman, B. I. et al. *Transplantation.* (2016) 100, 194-202). In addition, having two APOL1 risk alleles increases risk for preeclampsia (Reidy, K. J. et al. *Am. J. Hum. Genet.* (2018) 103, 367-376) and sepsis (Chaudhary, N. S. et al. *Clin. J. Am. Soc. Nephrol.* (2019) 14, 1733-1740). There are no approved therapies for APOL1-associated nephropathy, and patients are treated based on the standard of care for their underlying form of chronic kidney disease. This presents a clear unmet need for therapies targeted to people with the APOL1 high-risk genotype.

[0004] Numerous studies have shown that APOL1 risk variants are toxic when overexpressed in human cells (Wan, G. et al. *J. Biol. Chem.* (2008) 283, 21540-21549; Lan, X. et al. *Am. J. Physiol. Renal Physiol.* (2014) 307, F326-F336; Olabisi, O. A. et al. *Proc. Natl. Acad. Sci. USA.* (2016) 113, 830-837; Ma, L. et al. *J. Am. Soc. Nephrol.* (2017) 28, 1093-1105; Lannon, H. et al. *Kidney Int.* (2019) 96, 1303-1307). Recent findings suggest that this toxicity is associated with APOL1 pore function (Giovinazzo, J. A. et al. *eLife.* (2020) 9, e51185). Thus, there is a need to develop compounds suitable for inhibiting APOL1 activity and methods for inhibiting the activity of APOL1 using such compounds.

BRIEF SUMMARY OF THE INVENTION

[0005] This disclosure describes compounds and compositions that may be useful for the treatment of APOL1-mediated diseases, including a variety of chronic kidney diseases such as FSGS, hypertension-attributed kidney disease, HIVAN, sickle cell nephropathy, lupus nephritis, diabetic kidney disease, viral nephropathy, COVID-19 associated nephropathy, and APOL1-associated nephropathy. The compounds and compositions may also find use in treating other APOL1-mediated disorders such as preeclampsia and sepsis. Additionally, for individuals with the APOL1 high-risk genotype, the disclosed compounds and compositions could have utility in preventing the onset of non-diabetic renal disease and/or delaying the progression of any form of chronic kidney disease. The disclosed chemical matter could also have utility in preventing and/or delaying progressive renal allograft loss in patients who have received a kidney transplant from a high-risk APOL1 genotype donor.

[0006] In one aspect, provided herein is a compound of formula (A'):



(A'),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl;

L is selected from the group consisting of:

(i)  , wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^x is H,

or R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^1 and R^2 are independently H, halo, or -OH,

or one of R^1 and R^2 is taken together with R^x, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH;

R^3 is H, -OH, halo, or C_{1-6}alkoxy; and

R^4 and R^5 are independently H,

or R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that either:

(1) R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C_{1-6}alkyl, or C_{1-6}alkoxy, or

(2) R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(ii) 

, wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^6 is H or -OH;

R^y is H,

or R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

or R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^7 is H,

or R^7 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^8 and R^9 are independently H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl; and

R^{10} is H,

or R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that:

(1) R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(2) R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(3) one of R^8 and R^9 is taken together with R^{10} and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and

(iii) 

, wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^z is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl;

R^{11} and R^{12} are independently H, -OH, halo, or C_{1-6}alkyl; and

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5 wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

[0007] In one aspect, provided herein is a compound of formula (A):



(A),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl;

L is selected from the group consisting of:

(i)  , wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^x is H,

or R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^1 and R^2 are independently H, halo, or -OH,

or one of R^1 and R^2 is taken together with R^x, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH;

R^3 is H, -OH, halo, or C_{1-6}alkoxy; and

R^4 and R^5 are independently H,

or R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that either:

(1) R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C_{1-6}alkyl, or C_{1-6}alkoxy, or

(2) R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(ii) 

, wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^6 is H or -OH;

R^y is H,

or R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

or R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^7 is H,

or R^7 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^8 and R^9 are independently H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl; and

R^{10} is H,

or R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that:

(1) R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(2) R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(3) one of R^8 and R^9 is taken together with R^{10} and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and

(iii) 

, wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^z is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl;

R^{11} and R^{12} are independently H, -OH, halo, or C_{1-6}alkyl; and

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

[0008] Any embodiments provided herein of a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, are also embodiments of a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0009] In one aspect, provided herein is a compound of formula (I):



(I),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^a, R^b, R^c, R^x, A, Q, and Y are as defined for a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In another variation, X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^a, R^b, R^c, R^x, A, Q, and Y of formula (I) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0010] In one aspect, provided herein is a compound of formula (II):



(II),

[0011] or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, R^6, R^7, R^8, R^9, R^{10}, R^a, R^b, R^c, R^y, p, E, Q, and Y are as defined for a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In another variation, X^1, X^2, X^3, X^4, R^6, R^7, R^8, R^9, R^{10}, R^a, R^b, R^c, R^y, p, E, Q, and Y of formula (II) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.In one aspect, provided herein is a compound of formula (III):



(III),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^z, G, Q, and Y are as defined for a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In another variation, X^1, X^2, X^3, X^4, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^z, G, Q, and Y of formula (III) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0012] In one aspect, provided herein is a compound of formula (B-2):



(B-2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, and L are as defined for a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In another variation, X^1, X^2, X^3, X^4, and L of formula (B-2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0013] In one aspect, provided herein is a compound of formula (B-5):



(B-5),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, and L are as defined for a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In another variation, X^1, X^2, X^3, X^4, and L of formula (B-5) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0014] In one aspect, provided herein is a compound of formula (C-1):



(C-1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, X^4, and L are as defined for a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof. In another variation, X^1, X^2, X^3, X^4, and L of formula (C-1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0015] In one aspect, provided herein is a pharmaceutical composition, comprising (i) a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a pharmaceutical composition, comprising (i) a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0016] In one aspect, provided herein is a method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a

pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0017] In one aspect, provided herein is a method of inhibiting APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of inhibiting APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0018] In one aspect, provided herein is a method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual an effective amount of a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients. In another variation, provided herein is a method of treating an APOL1-mediated disease, disorder, or condition in an

individual in need thereof, comprising administering to the individual an effective amount of a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition comprising (i) a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0019] In one aspect, provided herein is a kit, comprising (i) a compound of formula (A), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof. In another variation, provided herein is a kit, comprising (i) a compound of formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof.

[0020] In some aspect, provided herein are methods of preparing a compound of formula (A) or (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

DETAILED DESCRIPTION OF THE INVENTION

[0021] Unless clearly indicated otherwise, the terms "a," "an," and the like, refer to one or more.

[0022] As used herein, "about" a parameter or value includes and describes that parameter or value per se. For example, "about X" includes and describes X per se.

[0023] "Individual" refers to mammals and includes humans and non-human mammals. Examples of individuals include, but are not limited to, some primates and humans. In some embodiments, individual refers to a human.

[0024] As used herein, an "at risk" individual is an individual who is at risk of developing a disease or condition. An individual "at risk" may or may not have a detectable

disease or condition, and may or may not have displayed detectable disease prior to the treatment methods described herein. "At risk" denotes that an individual has one or more so-called risk factors, which are measurable parameters that correlate with development of a disease or condition and are known in the art. An individual having one or more of these risk factors has a higher probability of developing the disease or condition than an individual without these risk factor(s).

[0025] "Treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired results may include one or more of the following: decreasing one or more symptom resulting from the disease or condition; diminishing the extent of the disease or condition; slowing or arresting the development of one or more symptom associated with the disease or condition (*e.g.*, stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition); and relieving the disease, such as by causing the regression of clinical symptoms (*e.g.*, ameliorating the disease state, enhancing the effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival).

[0026] As used herein, "delaying" development of a disease or condition means to defer, hinder, slow, retard, stabilize and/or postpone development of the disease or condition. This delay can be of varying lengths of time, depending on the history of the disease and/or individual being treated. As is evident to one skilled in the art, a sufficient or significant delay can, in effect, encompass prevention, in that the individual does not develop the disease or condition.

[0027] As used herein, the term "therapeutically effective amount" or "effective amount" intends such amount of a compound of the disclosure or a pharmaceutically salt thereof sufficient to effect treatment when administered to an individual. As is understood in the art, an effective amount may be in one or more doses, *e.g.*, a single dose or multiple doses may be required to achieve the desired treatment endpoint. An effective amount may be considered in the context of administering one or more therapeutic agents, and a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desirable or beneficial result may be or is achieved.

[0028] As used herein, "unit dosage form" refers to physically discrete units, suitable as unit dosages, each unit containing a predetermined quantity of active ingredient, or compound, which may be in a pharmaceutically acceptable carrier.

[0029] As used herein, by "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, *e.g.*, the material may be incorporated into a pharmaceutical composition administered to an individual without causing significant undesirable biological effects.

[0030] The term "alkyl", as used herein, refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1-20 carbons (*i.e.*, C_{1-20}alkyl), 1-16 carbons (*i.e.*, C_{1-16}alkyl), 1-12 carbons (*i.e.*, C_{1-12}alkyl), 1-10 carbons (*i.e.*, C_{1-10}alkyl), 1-8 carbons (*i.e.*, C_{1-8}alkyl), 1-6 carbons (*i.e.*, C_{1-6}alkyl), 1-4 carbons (*i.e.*, C_{1-4}alkyl), or 1-3 carbons (*i.e.*, C_{1-3}alkyl). Examples of alkyl groups include, but are not limited to, methyl, ethyl, propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, iso-pentyl, neo-pentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named by chemical name or molecular formula, all positional isomers having that number of carbon atoms may be encompassed—for example, "butyl" includes n-butyl, sec-butyl, iso-butyl, and tert-butyl; and "propyl" includes n-propyl and iso-propyl. Certain commonly used alternative names may be used and will be understood by those of ordinary skill in the art. For instance, a divalent group, such as a divalent "alkyl" group, may be referred to as an "alkylene".

[0031] The term "alkoxy", as used herein, refers to an -O-alkyl moiety. Examples of alkoxy groups include, but are not limited to, methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, *tert*-butoxy, *sec*-butoxy, *n*-pentoxy, *n*-hexoxy, and 1,2-dimethylbutoxy.

[0032] The term "aryl", as used herein, refers to a fully unsaturated carbocyclic ring moiety. The term "aryl" encompasses monocyclic and polycyclic fused-ring moieties. As used herein, aryl encompasses ring moieties comprising, for example, 6 to 20 annular carbon atoms (*i.e.*, C_{6-20}aryl), 6 to 16 annular carbon atoms (*i.e.*, C_{6-16}aryl), 6 to 12 annular carbon atoms (*i.e.*, C_{6-12}aryl), or 6 to 10 annular carbon atoms (*i.e.*, C_{6-10}aryl). Examples of aryl moieties include, but are not limited to, phenyl, naphthyl, fluorenyl, and anthryl.

[0033] The term "cycloalkyl", as used herein, refers to a saturated or partially unsaturated carbocyclic ring moiety. The term "cycloalkyl" encompasses monocyclic and polycyclic ring moieties, wherein the polycyclic moieties may be fused, branched, or spiro. Cycloalkyl includes cycloalkenyl groups, wherein the ring moiety comprises at least one annular double bond. Cycloalkyl includes any polycyclic carbocyclic ring moiety comprising at least one non-aromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, cycloalkyl includes rings comprising, for example, 3 to 20 annular carbon atoms

(*i.e.*, a C_{3-20}cycloalkyl), 3 to 16 annular carbon atoms (*i.e.*, a C_{3-16}cycloalkyl), 3 to 12 annular carbon atoms (*i.e.*, a C_{3-12}cycloalkyl), 3 to 10 annular carbon atoms (*i.e.*, a C_{3-10}cycloalkyl), 3 to 8 annular carbon atoms (*i.e.*, a C_{3-8}cycloalkyl), 3 to 6 annular carbon atoms (*i.e.*, a C_{3-6}cycloalkyl), or 3 to 5 annular carbon atoms (*i.e.*, a C_{3-5}cycloalkyl). Monocyclic cycloalkyl ring moieties include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic groups include, for example, bicyclo[2.2.1]heptanyl, bicyclo[2.2.2]octanyl, adamantyl, norbomyl, decalinyl, 7,7-dimethyl -bicyclo [2.2.1]heptanyl, and the like. Still further, cycloalkyl also includes spiro cycloalkyl ring moieties, for example, spiro[2.5]octanyl, spiro[4.5]decanyl, or spiro [5.5]undecanyl.

[0034] The term "halo", as used herein, refers to atoms occupying groups VIIA of The Periodic Table and includes fluorine (fluoro), chlorine (chloro), bromine (bromo), and iodine (iodo).

[0035] The term "heteroaryl", as used herein, refers to an aromatic (fully unsaturated) ring moiety that comprises one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heteroaryl" includes both monocyclic and polycyclic fused-ring moieties. As used herein, a heteroaryl comprises, for example, 5 to 20 annular atoms (*i.e.*, a 5-20 membered heteroaryl), 5 to 16 annular atoms (*i.e.*, a 5-16 membered heteroaryl), 5 to 12 annular atoms (*i.e.*, a 5-12 membered heteroaryl), 5 to 10 annular atoms (*i.e.*, a 5-10 membered heteroaryl), 5 to 8 annular atoms (*i.e.*, a 5-8 membered heteroaryl), or 5 to 6 annular atoms (*i.e.*, a 5-6 membered heteroaryl). Any monocyclic or polycyclic aromatic ring moiety comprising one or more annular heteroatoms is considered a heteroaryl, regardless of the point of attachment to the remainder of the molecule (*i.e.*, the heteroaryl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heteroaryl moiety). Examples of heteroaryl groups include, but are not limited to, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzofuranyl, benzothiazolyl, benzothiadiazolyl, benzonaphthofuranyl, benzoxazolyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, isoquinolyl, isoxazolyl, naphthyridinyl, oxadiazolyl, oxazolyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, phenazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, thiazolyl,

thiadiazolyl, triazolyl, tetrazolyl, and triazinyl. Examples of the fused-heteroaryl rings include, but are not limited to, benzo[d]thiazolyl, quinolinyl, isoquinolinyl, benzo[b]thiophenyl, indazolyl, benzo[d]imidazolyl, pyrazolo[1,5-a]pyridinyl, and imidazo[1,5-a]pyridinyl, wherein the heteroaryl can be bound *via* either ring of the fused system.

[0036] The term "heterocyclyl", as used herein, refers to a saturated or partially unsaturated cyclic moiety that encompasses one or more annular heteroatoms independently selected from the group consisting of nitrogen, oxygen, and sulfur. The term "heterocyclyl" includes both monocyclic and polycyclic ring moieties, wherein the polycyclic ring moieties may be fused, bridged, or spiro. Any non-aromatic monocyclic or polycyclic ring moiety comprising at least one annular heteroatom is considered a heterocyclyl, regardless of the point of attachment to the remainder of the molecule (*i.e.*, the heterocyclyl moiety may be attached to the remainder of the molecule through any annular carbon or any annular heteroatom of the heterocyclyl moiety). Further, the term heterocyclyl is intended to encompass any polycyclic ring moiety comprising at least one annular heteroatom wherein the polycyclic ring moiety comprises at least one non-aromatic ring, regardless of the point of attachment to the remainder of the molecule. As used herein, a heterocyclyl comprises, for example, 3 to 20 annular atoms (*i.e.*, a 3-20 membered heterocyclyl), 3 to 16 annular atoms (*i.e.*, a 3-16 membered heterocyclyl), 3 to 12 annular atoms (*i.e.*, a 3-12 membered heterocyclyl), 3 to 10 annular atoms (*i.e.*, a 3-10 membered heterocyclyl), 3 to 8 annular atoms (*i.e.*, a 3-8 membered heterocyclyl), 3 to 6 annular atoms (*i.e.*, a 3-6 membered heterocyclyl), 3 to 5 annular atoms (*i.e.*, a 3-5 membered heterocyclyl), 5 to 8 annular atoms (*i.e.*, a 5-8 membered heterocyclyl), or 5 to 6 annular atoms (*i.e.*, a 5-6 membered heterocyclyl). Examples of heterocyclyl groups include, *e.g.*, azetidinyl, azepinyl, benzodioxolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzopyranyl, benzodioxinyl, benzopyranonyl, benzofuranonyl, dioxolanyl, dihydropyranyl, hydropyranyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, furanonyl, imidazolinyl, imidazolidinyl, indolinyl, indolizinyl, isoindolinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, oxiranyl, oxetanyl, phenothiazinyl, phenoxazinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, tetrahydropyranyl, trithianyl, tetrahydroquinolinyl, thiophenyl (*i.e.*, thienyl), thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Examples of spiro heterocyclyl rings include, but are not limited to, bicyclic and tricyclic ring systems, such as

oxabicyclo[2.2.2]octanyl, 2-oxa-7-azaspiro[3.5]nonanyl, 2-oxa-6-azaspiro[3.4]octanyl, and 6-oxa-1-azaspiro[3.3]heptanyl. Examples of fused heterocyclyl rings include, but are not limited to, 1,2,3,4-tetrahydroisoquinolinyl, 4,5,6,7-tetrahydrothieno[2,3-c]pyridinyl, indolinyl, and isoindolinyl, where the heterocyclyl can be bound via either ring of the fused system.

[0037] The terms "optional" and "optionally", as used herein, mean that the subsequently described event or circumstance may or may not occur and that the description includes instances where the event or circumstance occurs and instances where it does not. Accordingly, the term "optionally substituted" infers that any one or more (*e.g.*, 1, 2, 1 to 5, 1 to 3, 1 to 2, etc.) hydrogen atoms on the designated atom or moiety or group may be replaced or not replaced by an atom or moiety or group other than hydrogen. By way of illustration and not limitation, the phrase "methyl optionally substituted with one or more chloro" encompasses -CH_3, -CH_2Cl, -$CHCl_2$, and -CCl_3 moieties.

[0038] It is understood that aspects and embodiments described herein as "comprising" include "consisting of" and "consisting essentially of " embodiments.

[0039] The term "pharmaceutically acceptable salt", as used herein, of a given compound refers to salts that retain the biological effectiveness and properties of the given compound and which are not biologically or otherwise undesirable. "Pharmaceutically acceptable salts" include, for example, salts with inorganic acids, and salts with an organic acid. In addition, if the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. *See*, *e.g.*, *Handbook of Pharmaceutical Salts Properties, Selection, and Use*, International Union of Pure and Applied Chemistry, John Wiley & Sons (2008), which is incorporated herein by reference. Those skilled in the art will recognize various synthetic methodologies that may be used to prepare nontoxic pharmaceutically acceptable addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic or organic acids. Salts derived from inorganic acids include, *e.g.*, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Salts derived from organic acids include, *e.g.*, acetic acid, propionic acid, gluconic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid,

mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, trifluoroacetic acid, and the like. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic or organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, aluminum, ammonium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

[0040] Isotopically labeled forms of the compounds depicted herein may be prepared. Isotopically labeled compounds have structures depicted herein, except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into the disclosed compounds include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ^{2}H, ^{3}H, ^{11}C, ^{13}C, ^{14}C, ^{13}N, ^{15}N, ^{15}O, ^{17}O, ^{18}O, ^{31}P, ^{32}P, ^{35}S, ^{18}F, ^{36}Cl, ^{123}I, and ^{125}I, respectively. In some embodiments, a compound of formula (A), or formula (A') is provided wherein one or more hydrogen is replaced by deuterium or tritium.

[0041] Some of the compounds provided herein may exist as tautomers. Tautomers are in equilibrium with one another. By way of illustration, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown and regardless of the nature of the equilibrium among tautomers, the compounds of this disclosure are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, for example, amide-containing compounds are understood to include their imidic acid tautomers. Likewise, imidic-acid containing compounds are understood to include their amide tautomers.

[0042] Also provided herein are prodrugs of the compounds depicted herein, or a pharmaceutically acceptable salt thereof. Prodrugs are compounds that may be administered to an individual and release, *in vivo*, a compound depicted herein as the parent drug compound. It is understood that prodrugs may be prepared by modifying a functional group on a parent drug compound in such a way that the modification is cleaved *in vivo* to release the parent drug compound. *See*, *e.g.*, Rautio, J., Kumpulainen, H., Heimbach, T. et al. Prodrugs: design and

clinical applications. *Nat Rev Drug Discov* 7, 255–270 (2008), which is incorporated herein by reference.

[0043] The compounds of the present disclosure, or their pharmaceutically acceptable salts, may include an asymmetric center and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (*R*)- or (*S*)- (or as (D)- or (L)- for amino acids). The present disclosure is meant to include all such possible isomers, as well as their racemic and optically pure forms and mixtures thereof in any ratio. Optically active (+) and (-), (*R*)- and (*S*)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or may be resolved using conventional techniques, for example, chromatography and/or fractional crystallization. Conventional techniques for the preparation/isolation of individual enantiomers include chiral synthesis from a suitable optically pure precursor or the resolution of the racemate (or the racemate of a salt or derivative) using, for example, chiral high pressure liquid chromatography (HPLC), and chiral SFC (supercritical fluid chromatography). When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless specified otherwise, it is intended that the present disclosure includes both E and Z geometric isomers. Likewise, cis- and trans- are used in their conventional sense to describe relative spatial relationships.

[0044] A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds, but having different three-dimensional structures, which are not interchangeable. The present disclosure contemplates various stereoisomers, or mixtures thereof, and includes "enantiomers," which refers to two stereoisomers whose structures are non-superimposable mirror images of one another. "Diastereomers" are stereoisomers that have at least two asymmetric atoms, but which are not mirror images of each other.

[0045] Where enantiomeric and/or diastereomeric forms exist of a given structure, flat bonds indicate that all stereoisomeric forms of the depicted structure may be present, *e.g.*,



[0046] Where enantiomeric forms exist of a given structure, flat bonds and the presence of a " * " symbol indicate that the composition is made up of at least 90%, by weight, of a single isomer with unknown stereochemistry, *e.g.*,



[0047] Where enantiomeric and/or diastereomeric forms exist of a given structure, wedged or hashed bonds indicate the composition is made up of at least 90%, by weight, of a single enantiomer or diastereomer with known stereochemistry, *e.g.*,



[0048] Where enantiomeric and/or diastereomeric forms exist of a given structure with two stereocenters, flat bonds and the presence of two "&1" symbols indicate the composition is made up of a pair of enantiomers with unknown relative stereochemistry, *e.g.*,



[0049] Where enantiomeric and/or diastereomeric forms exist of a given structure with two stereocenters, wedged and/or dashed bonds and the presence of two "&1" symbols indicate the composition is made up of a pair of enantiomers with known relative stereochemistry, *e.g.*,



[0050] Where enantiomeric and/or diastereomeric forms exist of a given structure with two stereocenters, wedged and/or dashed bonds and the presence of two "or1" symbols indicate the composition is made up of at least 90%, by weight, a single stereoisomer with known relative stereochemistry but unknown absolute stereochemistry, *e.g.*,



[0051] Where enantiomeric and/or diastereomeric forms exist of a given structure with two stereocenters, flat bonds and the presence of two " * " symbols indicate the composition is made up of at least 90%, by weight, of a single enantiomer or diastereomer with unknown stereochemistry, *e.g.*,



[0052] Abbreviations used are those conventional in the art and are in accordance with the Periodic Table of the Elements, CAS version, *Handbook of Chemistry and Physics,* 75th Ed. The following examples are intended to be illustrative only and not limiting in any way.

°C	degrees Celsius	LiHMDS	lithium bis(trimethylsilyl)amide
µL	microliter	mCPBA or m-CPBA	meta-chloroperoxybenzoic acid
$[M+XX]^+$	observed mass	MeOH	methanol
AC_{50}	half-maximal activity concentration	MeCN	acetonitrile
AcOH	acetic acid	m	multiplet (NMR)
AIBN	azobisisobutyronitrile	mg	milligrams
app	apparent (NMR)	min	minutes
b	broad (as in "br s" to indicate a broad singlet)	mL	milliliter
BH_3·THF	borane-tetrahydrofuran complex	mmol	millimole
BBr_3	boron tribromide	mM	millimolar
Calc'd	calculated	M	molarity or molar
Cbz-Cl or CbzCl	benzyl chloroformate	MS	mass spectrometry
CO_2	carbon dioxide	MsCl	methanesulfonyl chloride
Cs_2CO_3	cesium carbonate	MTBE	methyl *tert*-butyl ether
d	deuterated (NMR solvents)	n/a	not applicable
d	doublet (NMR)	NH_4	ammonium
dd	doublet of doublets (NMR)	NH_4OH	ammonium hydroxide
DCE	1,2-dichloroethane	NH_4HCO_3	ammonium bicarbonate
DCM	dichloromethane	Na_2SO_4	sodium sulfate

DIAD	diisopropyl azodicarboxylate	$NaBH_3CN$	sodium cyanoborohydride
DMF	*N*,*N*-dimethylformamide	NMR	nuclear magnetic resonance
DMP	Dess–Martin periodinane	NaOH	sodium hydroxide
EC_{50}	half-maximal effective concentration	$Pd(dppf)Cl_2$	[1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
EtOAc	ethyl acetate	Pd/C	palladium on carbon
EtOH	ethanol	pH	potential of hydrogen
g	grams	PPh_3	triphenyl phosphine
h	hours	s	singlet (NMR)
H	hydrogen	SFC	supercritical fluid chromatography
HCl	hydrochloric acid	t	triplet (NMR)
HPLC	high-performance liquid chromatography	TBAB	tetrabutylammonium bromide
In vacuo	in a vacuum	TEA	triethylamine
IUPAC	International Union of Pure and Applied Chemistry	TFA	trifluoroacetic acid
MHz	megahertz	THF	tetrahydrofuran
J	J-coupling value (NMR)	TMAD	tetramethylazodicarboxamide
K_2CO_3	potassium carbonate	TMSCl	trimethylsilyl chloride

COMPOUNDS

[0053] Provided herein is a compound of formula (A'):



(A'),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl;

L is selected from the group consisting of:

(i) 

, wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^x is H,

or R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^1 and R^2 are independently H, halo, or -OH,

or one of R^1 and R^2 is taken together with R^x, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH;

R^3 is H, -OH, halo, or C_{1-6}alkoxy; and

R^4 and R^5 are independently H,

or R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that either:

(1) R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C_{1-6}alkyl, or C_{1-6}alkoxy, or

(2) R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(ii) 

, wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^6 is H or -OH;

R^y is H,

or R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

or R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^7 is H,

or R^7 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^8 and R^9 are independently H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl; and

R^{10} is H,

or R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that:

(1) R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(2) R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(3) one of R^8 and R^9 is taken together with R^{10} and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and

(iii) 

, wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^z is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl;

R^{11} and R^{12} are independently H, -OH, halo, or C_{1-6}alkyl; and

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5 wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

[0054] Provided herein is a compound of formula (A):



(A),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl;

L is selected from the group consisting of:

(i) 

, wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^x is H,

or R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^1 and R^2 are independently H, halo, or -OH,

or one of R^1 and R^2 is taken together with R^x, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-

6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH;

R^3 is H, -OH, halo, or C_{1-6}alkoxy; and

R^4 and R^5 are independently H,

or R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that either:

(1) R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is optionally substituted with one or more -OH, C_{1-6}alkyl, or C_{1-6}alkoxy, or

(2) R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(ii) 

, wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^6 is H or -OH;

R^y is H,

or R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

or R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^7 is H,

or R^7 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^8 and R^9 are independently H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl; and

R^{10} is H,

or R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that:

(1) R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(2) R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(3) one of R^8 and R^9 is taken together with R^{10} and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and

(iii)  , wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^z is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl;

R^{11} and R^{12} are independently H, -OH, halo, or C_{1-6}alkyl; and

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

[0055] Any embodiments provided herein of a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof, are also embodiments of a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0056] In some embodiments, provided is a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,



wherein L is , such that the compound of formula (A) is a compound of formula (I):



(I),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, the X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^a, R^b, R^c, R^x, A Q, and Y of formula (I) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0057] In some embodiments, provided herein is a compound of formula (A) or formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is O, such that the compound is of formula (I-A1):



(I-A1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, the X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^a, R^b, R^c, R^x, Q, and Y of formula (I-A1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0058] In some embodiments, provided herein is a compound of formula (A) or formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is NH, such that the compound is of formula (I-A2):



(I-A2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, A is N(C_{1-6}alkyl). In some embodiments, A is N(CH_3). In some variations, X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^a, R^b, R^c, R^x, Q, and Y of formula (I-A2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0059] In some embodiments, provided herein is a compound of formula (A) or formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is CH_2, such that the compound is of formula (I-A3):



(I-A3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, A is CH(C_{1-6}alkyl). In some embodiments, A is CH(CH_3). In some variations, X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^a, R^b, R^c, R^x, Q, and Y of formula (I-A3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0060] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), (I-A2), or (I-A3), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy. In some embodiments, R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-6 membered heterocyclyl, wherein the 3-6 membered heterocyclyl is substituted with *n*

independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy. In some embodiments, R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl, wherein the 5-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy. In some embodiments, R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-6 membered heterocyclyl, wherein the 5-6 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy. R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy. R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy. In some variations, the the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0061] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-B1):



(I-B1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-B1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0062] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A2), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-B2):



(I-B2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-B2) are as defined of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0063] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A3), or a pharmaceutically acceptable salt of any

of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-membered heterocyclyl, wherein the 5-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-B3):



(I-B3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-B3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0064] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-C1):



(I-C1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-C1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0065] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A2), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-C2):



(I-C2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-C2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0066] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A3), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-C3):



(I-C3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-C3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0067] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-D1):



(I-D1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-D1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0068] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A2), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-D2):



(I-D2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-D2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0069] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A3), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-D3):



(I-D3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-D3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0070] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-E1):



(I-E1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-E1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0071] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A2), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-E2):



(I-E2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-E2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0072] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A3), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 6-membered heterocyclyl, wherein the 6-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-E3):



(I-E3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-E3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0073] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-E1), (I-E2), or (I-E3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0.

[0074] In some embodiments, provided herein is a compound of formula (A') or formula (I), such as a compound of formula (I-E1), (I-E2), or (I-E3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0 or 1. In some embodiments, *n* is 0. In some embodiments, *n* is 1.

[0075] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 7-membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-F1):



(I-F1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-F1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0076] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A2), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 7-membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-F2):



(I-F2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-F2) are as defined for compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0077] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A3), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 7-membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-F3):



(I-F3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-F3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0078] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), or a pharmaceutically acceptable salt of any

of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 7-membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-G1):



(I-G1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-G1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0079] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A2), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 7-membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-G2):



(I-G2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and *n* of formula (I-G2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer

thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0080] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A3), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 7-membered heterocyclyl, wherein the 7-membered heterocyclyl is substituted with n independently selected R^g substituents, wherein n is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the compound is of formula (I-G3):



(I-G3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^g, R^x, Q, Y and n of formula (I-G3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0081] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), or (I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein n is an integer from 0-6. In some embodiments, n is an integer from 0-5. In some embodiments, n is an integer from 0-4. In some embodiments, n is an integer from 0-3. In some embodiments, n is an integer from 0-2. In some embodiments, n is 0 or 1. In some embodiments, n is an integer from 1-6. In some embodiments, n is an integer from 1-5. In some embodiments, n is an integer from 1-4. In some embodiments, n is an integer from 1-3. In some embodiments, n is 1 or 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some variations, the embodiments provided herein also apply to a

compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0082] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), or (I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy. In some embodiments, R^g is -OH, C_{1-6}alkyl, or C_{1-6}alkoxy. In some embodiments, R^g is -OH, halo, C_{1-3}alkyl, or C_{1-3}alkoxy. In some embodiments, R^g is -OH, methyl, or methoxy. In some embodiments, R^g is -OH. In some embodiments, R^g is C_{1-6}alkyl. In some embodiments, R^g is methyl. In some embodiments, R^g is C_{1-6}alkoxy. In some embodiments, R^g is methoxy. In some embodiments, R^g is halo. In some embodiments, R^g is fluoro. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0083] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), or (I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 1 and R^g is C_{1-6}alkyl. In some embodiments, *n* is 1 and R^g is methyl. In some embodiments, *n* is 2 and each R^g is C_{1-6}alkyl. In some embodiments, *n* is 2 and each R^g is methyl. In some embodiments, *n* is 1 and R^g is -OH. In some embodiments, *n* is 1 and R^g is C_{1-6}alkoxy. In some embodiments, *n* is 1 and R^g is methoxy.

[0084] In some embodiments, provided herein is a compound of formula (A') or formula (I), such as a compound of formula (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), or (I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 1 and R^g is C_{1-6}alkyl. In some embodiments, *n* is 1 and R^g is methyl. In some embodiments, *n* is 2 and each R^g is C_{1-6}alkyl. In some embodiments, *n* is 2 and each R^g is methyl. In some embodiments, *n* is 1 and R^g is -OH. In some embodiments, *n* is 1 and R^g is C_{1-6}alkoxy. In some embodiments, *n* is 1 and R^g is methoxy. In some embodiments, *n* is 2, one or R^g is methyl, and the other of R^g is –OH.

[0085] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), or (I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^4 and R^5 are independently H. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0086] In some embodiments, provided herein is a compound of formula (A) or formula (I), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl. In some embodiments, R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl. In some embodiments, R^4 and R^5 are taken, together with the atoms to which they are attached, to form cyclobutyl. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0087] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^4 and R^5 are taken, together with the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (I-H1):



(I-H1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^x, Q, and Y of formula (I-H1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0088] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A2), or a pharmaceutically acceptable salt of any

of the foregoing, wherein R^4 and R^5 are taken, together with the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (I-H2):



(I-H2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^x, Q, and Y of formula (I-H2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0089] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A3), or a pharmaceutically acceptable salt of any of the foregoing, wherein R^4 and R^5 are taken, together with the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (I-H3):



(I-H3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^3, R^4, R^5, R^a, R^b, R^c, R^x, Q, and Y of formula (I-H3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0090] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-H1), (I-H2), or (I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 and R^2 are each H. In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-H1), (I-H2), or (I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is H. In some embodiments, R^1, R^2, and R^x are each H. In some embodiments, the embodiments provided

herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0091] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), or (I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is H, -OH, halo, or C_{1-6}alkoxy. In some embodiments, R^3 is H. In some embodiments, R^3 is -OH, halo, or C_{1-6}alkoxy. In some embodiments, R^3 is H or -OH. In some embodiments, R^3 is -OH. In some embodiments, R^3 is halo. In some embodiments, R^3 is C_{1-6}alkoxy. In some embodiments, R^3 is methoxy.

[0092] In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), or (I-G3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3, R^4, and R^5 are each H. In some embodiments, provided herein is a compound of formula (A) or formula (I), such as a compound of formula (I-H1), (I-H2), or (I-H3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1, R^2, R^3, and R^x are each H. In some embodiments, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.In some embodiments, provided herein is a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is



. In some embodiments, L is



, and the compound of formula (A) is a compound of formula (II):



(II),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^7, R^8, R^9, R^{10}, R^a, R^b, R^c, R^y, p, E, Q, and Y of formula (II) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0093] In some embodiments, provided herein is a compound of formula (A) or formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein E is O, wherein the compound is of formula (II-A1):



(II-A1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^7, R^8, R^9, R^{10}, R^a, R^b, R^c, R^y, p, Q, and Y of formula (II-A1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0094] In some embodiments, provided herein is a compound of formula (A) or formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein E is NH, wherein the compound is of formula (II-A2):



(II-A2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, E is $N(C_{1\text{-}6}alkyl)$. In some embodiments, E is $N(CH_3)$. In some variations, X^1, X^2, X^3, X^4, R^6, R^7, R^8, R^9, R^{10}, R^a, R^b, R^c, R^y, p, Q, and Y of formula (II-A2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0095] In some embodiments, provided herein is a compound of formula (A) or formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein E is CH_2, wherein the compound is of formula (II-A3):



(II-A3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, E is $CH(C_{1\text{-}6}alkyl)$. In some embodiments, E is $CH(CH_3)$. In some variations, X^1, X^2, X^3, X^4, R^6, R^7, R^8, R^9, R^{10}, R^a, R^b, R^c, R^y, p, Q, and Y of formula (II-A3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0096] In some embodiments, provided herein is a compound of formula (A) or formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl. In some embodiments, R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-6 membered heterocyclyl. In some

embodiments, R^y is taken together with R^7, and the atoms to which they are attached, to form a 5-8 membered heterocyclyl. In some embodiments, R^y is taken together with R^7, and the atoms to which they are attached, to form a 5-6 membered heterocyclyl. In some embodiments, R^y is taken together with R^7, and the atoms to which they are attached, to form a 5-membered heterocyclyl. In some embodiments, R^y is taken together with R^7, and the atoms to which they are attached, to form a 6-membered heterocyclyl. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0097] In some embodiments of the foregoing, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A1), (II-A2), or (II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *p* is 1. In other embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A1), (II-A2), or (II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *p* is 0. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0098] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 6-membered heterocyclyl, and *p* is 1, wherein the compound is of formula (II-B1):



(II-B1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-

B1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0099] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 5-membered heterocyclyl, and p is 0, wherein the compound is of formula (II-C1):



(II-C1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-C1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0100] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 5-membered heterocyclyl, and p is 0, wherein the compound is of formula (II-C2):



(II-C2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-C2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0101] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 5-membered heterocyclyl, and p is 0, wherein the compound is of formula (II-C3):



(II-C3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-C3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0102] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 6-membered heterocyclyl, and p is 0, wherein the compound is of formula (II-D1):



(II-D1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-D1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0103] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7,

and the atoms to which they are attached, to form a 6-membered heterocyclyl, and *p* is 0, wherein the compound is of formula (II-D2):



(II-D2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-D2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0104] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 6-membered heterocyclyl, and *p* is 0, wherein the compound is of formula (II-D3):



(II-D3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-D3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0105] In some embodiments of the foregoing, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), or (II-D3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is -OH. In some embodiments, R^6 is -OH, R^8 is $C_{1\text{-}6}$alkyl, and R^9 is $C_{1\text{-}6}$alkyl. In some embodiments, R^6 is -OH, R^8 is methyl, and R^9 is methyl. In some embodiments, R^6 is -OH, R^8 is H, and R^9 is H. In some

variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0106] In some embodiments, provided herein is a compound of formula (A) or formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl. In some embodiments, one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-6}cycloalkyl. In some embodiments, one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-4}cycloalkyl. In some embodiments, one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form cyclobutyl. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0107] In some embodiments, provided herein is a compound of formula (A) or formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form cyclobutyl, wherein the compound is of formula (II-E1):



(II-E1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^6, R^8, R^9, R^{10}, R^a, R^b, R^c, Q, and Y of formula (II-E1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0108] In some embodiments, provided herein is a compound of formula (A) or formula (II), such as a compound of formula (II-E1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is -OH and R^7 is H. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a

stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0109] In some embodiments, provided herein is a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,



wherein L is . In some embodiments, provided herein is a compound of formula (A), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is



, wherein the compound is of formula (III):



(III),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^z, G, Q, and Y of formula (III) are as defined for a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0110] In some embodiments, provided herein is a compound of formula (A) or formula (III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G is O, wherein the compound is of formula (III-A1):



(III-A1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^z, Q, and Y of formula (III-A1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0111] In some embodiments, provided herein is a compound of formula (A) or formula (III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G is NH, wherein the compound is of formula (III-A2):



(III-A2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, G is $N(C_{1\text{-}6}alkyl)$. In some embodiments, G is $N(CH_3)$. In some variations, X^1, X^2, X^3, X^4, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^z, Q, and Y of formula (III-A2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0112] In some embodiments, provided herein is a compound of formula (A) or formula (III), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein G is CH_2, wherein the compound is of formula (III-A3):



(III-A3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, G is $CH(C_{1\text{-}6}alkyl)$. In some embodiments, G is $CH(CH_3)$. In some variations, X^1, X^2, X^3, X^4, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^z, Q, and Y of formula (III-A3) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0113] In some embodiments, provided herein is a compound of formula (A) or formula (III), such as a compound of formula (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^z is H. In some embodiments, R^z is C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl. In some embodiments, R^z is unsubstituted C_{1-6}alkyl. In some embodiments, R^z is unsubstituted C_{1-3}alkyl. In some embodiments, R^z is unsubstituted methyl or unsubstituted ethyl. In some embodiments, R^z is unsubstituted ethyl. In some embodiments, R^z is C_{1-6}alkyl, wherein the C_{1-6}alkyl is substituted with one or more C_{3-8}cycloalkyl. In some embodiments, R^z is C_{1-6}alkyl, wherein the C_{1-6}alkyl is substituted with one or more C_{3-6}cycloalkyl. In some embodiments, R^z is methyl, wherein the methyl is substituted with cyclopropyl. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0114] In some embodiments, provided herein is a compound of formula (A) or formula (III), such as a compound of formula (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^{11} and R^{12} is -OH and the other of R^{11} and R^{12} is H, halo, or C_{1-6}alkyl. In some embodiments, one of R^{11} and R^{12} is -OH and the other of R^{11} and R^{12} is H. In some embodiments, one of R^{11} and R^{12} is -OH and the other of R^{11} and R^{12} is C_{1-6}alkyl. In some embodiments, one of R^{11} and R^{12} is -OH and the other of R^{11} and R^{12} is methyl. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0115] In some embodiments, provided herein is a compound of formula (A) or formula (III), such as a compound of formula (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{13} and R^{14} are both H. In some embodiments, R^{13} and R^{14} are both C_{1-6}alkyl. In some embodiments, R^{13} and R^{14} are both methyl. In some embodiments, one of R^{13} and R^{14} is H and the other of R^{13} and R^{14} is C_{1-6}alkyl or C_{3-8}cycloalkyl. In some embodiments, one of R^{13} and R^{14} is H and the other of R^{13} and R^{14} is C_{1-6}alkyl. In some embodiments, one of R^{13} and R^{14} is H and the other of R^{13} and R^{14} is methyl. In some embodiments, one of R^{13} and R^{14} is H and the other of R^{13} and R^{14} is C_{3-8}cycloalkyl. In some embodiments, one of R^{13} and R^{14} is H and the other of R^{13} and

R^{14} is cyclopropyl. In some embodiments, R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl. In some embodiments, R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl. In some embodiments, R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 5-8 membered heterocyclyl. In some embodiments, R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 5-6 membered heterocyclyl. In some embodiments, R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form tetrahydrofuranyl. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0116] In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo, provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo. In some embodiments, three of X^1, X^2, X^3, and X^4 are H and one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo. In some embodiments, two of X^1, X^2, X^3, and X^4 are H and two of X^1, X^2, X^3, and X^4 are independently halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

[0117] In some embodiments, provided herein is a compound of formula (A'), such as a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF^5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo, provided that at least one of X^1, X^2,

X^3, and X^4 is halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF^5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo. In some embodiments, three of X^1, X^2, X^3, and X^4 are H and one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF^5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo. In some embodiments, two of X^1, X^2, X^3, and X^4 are H and two of X^1, X^2, X^3, and X^4 are independently halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF^5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

[0118] In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1 and X^2 are each H, one of X^3 and X^4 is H, and the other of X^3 and X^4 is halo. In some embodiments, X^1 and X^2 are each H, one of X^3 and X^4 is H, and the other of X^3 and X^4 is chloro. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X^1 and X^2 is H and the other of X^1 and X^2 is C_{1-6}alkyl, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is ethyl, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is C_{1-6}alkoxy, wherein the C_{1-6}alkoxy is optionally substituted with one or more halo, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is methoxy, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is -O-CHF_2, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is halo, and one of X^3 and X^4 is H and the other of X^3 and X^4 is halo. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is chloro, and one of X^3 and X^4 is H and the other of X^3 and

X^4 is chloro. In some embodiments, X^1 and X^2 are each H, and X^3 and X^4 are each halo. In some embodiments, X^1 and X^2 are each H, and X^3 and X^4 are each chloro. In some embodiments, X^1 and X^2 are each H, and one of X^3 and X^4 is H and the other of X^3 and X^4 is -CN. In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X^1 and X^2 is H and the other of X^1 and X^2 is $C_{1\text{-}6}$alkyl, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is ethyl, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is $C_{1\text{-}6}$alkoxy, wherein the $C_{1\text{-}6}$alkoxy is optionally substituted with one or more halo, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is methoxy, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is -O-CHF_2, and X^3 and X^4 are each H. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is -O-CHF_2, and one of X^3 and X^4 is H and the other of X^3 and X^4 is chloro. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is halo, and one of X^3 and X^4 is H and the other of X^3 and X^4 is halo. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is $C_{1\text{-}6}$alkyl, and one of X^3 and X^4 is H and the other of X^3 and X^4 is halo. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is methyl, and one of X^3 and X^4 is H and the other of X^3 and X^4 is halo. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is $C_{1\text{-}6}$alkoxy, one of X^3 and X^4 is H and the other of X^3 and X^4 is halo. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is methoxy, one of X^3 and X^4 is H and the other of X^3 and X^4 is halo. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is chloro, and one of X^3 and X^4 is H and the other of X^3 and X^4 is chloro. In some embodiments, X^1 and X^2 are each H, and X^3 and X^4 are each halo. In some embodiments, X^1 and X^2 are each H, and X^3 and X^4 are each chloro. In some embodiments, X^1 and X^2 are each H, one of X^3 and X^4 is chloro and the other of X^3 and X^4 is fluoro. In some embodiments, X^1 and X^2 are each H, and one of X^3 and X^4 is H and the other of X^3 and X^4 is –CN. In some embodiments, X^1 and X^2 are each H, and one of X^3 and X^4 is H and each of X^3 and X^4 is –CN. In some embodiments, X^1 and X^2 are each H, and one of X^3 and X^4 is $C_{1\text{-}6}$alkyl and the other of X^3 and X^4 is –CN. In some

embodiments, X^1 and X^2 are each H, and one of X^3 and X^4 is halo and the other of X^3 and X^4 is –CN. In some embodiments, X^1 and X^2 are each H, and one of X^3 and X^4 is $–CF_3$ and the other of X^3 and X^4 is –CN. In some embodiments, one of X^1 and X^2 is H and the other of X^1 and X^2 is C_{1-6}alkyl, one X^3 and X^4 is halo and the other of X^3 and X^4 is –CN. In some embodiments, X^1 and X^2 are each H, one of X^3 and X^4 is H and the other of X^3 and X^4 is $–SF_5$.

[0119]

In some embodiments, the phenyl ring bearing moieties X^1, X^2, X^3, and X^4 is selected from the group consisting of  ,  ,  ,  ,  ,  , and  . In some embodiments, the phenyl ring bearing moieties X^1, X^2, X^3, and X^4 is  . In some embodiments, the phenyl ring bearing moieties X^1, X^2, X^3, and X^4 is selected from the group consisting of  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  . In some embodiments, the phenyl ring bearing moieties X^1,

X^2, X^3, and X^4 is selected from the group consisting of 

, 

, and 

. In some embodiments, the phenyl ring bearing moieties X^1, X^2, X^3, and X^4 is 

.

[0120] In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is absent. In some embodiments, provided herein is a compound of formula (A), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (B):



(B),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^a, R^b, R^c, L and Y of formula (B) are as defined for formula (B) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0121] In some embodiments, provided herein is a compound of formula (A) or formula (B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y is O, wherein the compound is of formula (B-1):



(B-1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^a, R^b, R^c, and L of formula (B1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0122] In some embodiments, provided herein is a compound of formula (A), formula (B), or formula (B-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is ,



[0123] In some embodiments, provided herein is a compound of formula (A'), formula (B), or formula (B-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is



[0124] In some embodiments, provided herein is a compound of formula (A), formula (B), or formula (B-1), or a stereoisomer or tautomer thereof, or a pharmaceutically

acceptable salt of any of the foregoing, wherein any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form oxetanyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some variations, the embodiments provided herein also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0125] In some embodiments, provided herein is a compound of formula (A), formula (B), or formula (B-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each H, wherein the compound is of formula (B-2):



(B-2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, and L of formula (B-2) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0126] In some embodiments, provided herein is a compound of formula (A), formula (B), formula (B-1), or formula (B-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X^1 and X^2 is H and the other of X^1 and X^2 is chloro, X^3 is H, and X^4 is H, wherein the compound is of formula (B-3):



(B-3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, L of formula (B-3) is as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0127] In some embodiments, provided herein is a compound of formula (A) or formula (B), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y is -N(C_{1-6}alkyl). In some embodiments, Y is -N(CH_3), wherein the compound is of formula (B-4):



(B-4),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^a, R^b, R^c, and L of formula (B-4) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0128] In some embodiments, provided herein is a compound of formula (A), formula (B), or formula (B-4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In

some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is,



[0129] In some embodiments, provided herein is a compound of formula (A'), formula (B), or formula (B-4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is,



[0130] In some embodiments, provided herein is a compound of formula (A), formula (B), or formula (B-4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form oxetanyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl.

[0131] In some embodiments, provided herein is a compound of formula (A'), formula (B), or formula (B-4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl.

In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form oxetanyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form azetidinyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl.

[0132] In some embodiments, provided herein is a compound of formula (A), formula (B), or formula (B-4), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each H, wherein the compound is of formula (B-5):



(B-5),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, and L of formula (B-5) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0133] In some embodiments, provided herein is a compound of formula (A), formula (B), formula (B-4), or formula (B-5), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X^1 and X^2 is H and the other of X^1 and X^2 is chloro, X^3 is H, and X^4 is H, wherein the compound is of formula (B-6):



(B-6),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, L of formula (B-6) is as defined for is a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0134] In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is -N(C_{1-6}alkyl). In some embodiments, Q is -N(CH_3). In some embodiments, provided herein is a compound of formula (A), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (C):



(C),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, R^a, R^b, R^c, and L of formula (C) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0135] In some embodiments, provided herein is a compound of formula (A) or formula (C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-}

$_{6}$alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is  ,  , or  .

[0136] In some embodiments, provided herein is a compound of formula (A') or formula (C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, two of R^a, R^b, and R^c are independently H, and one of R^a, R^b, and R^c is  ,  ,  ,  ,  , or  .

[0137] In some embodiments, provided herein is a compound of formula (A) or formula (C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some embodiments, any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form oxetanyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl. In some variations, the embodiments provided herein

also apply to a compound of formula (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0138] In some embodiments, provided herein is a compound of formula (A) or formula (C), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each H, wherein the compound is of formula (C-1):



(C-1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, X^1, X^2, X^3, X^4, and L of formula (C-1) are as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0139] In some embodiments, provided herein is a compound of formula (A), formula (C), or formula (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of X^1 and X^2 is H and the other of X^1 and X^2 is chloro, X^3 is H, and X^4 is H, wherein the compound is of formula (C-2):



(C-2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some variations, L of formula (C-2) is as defined for a compound of formula (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or any variation or embodiment thereof.

[0140] In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-5), (B-6), (C), (C-1), or (C-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

wherein L is  , or any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0141] In some embodiments, provided herein is a compound of formula (A'), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-5), (B-6), (C), (C-1), or (C-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

wherein L is  , or any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0142] In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-5), (B-6), (C), (C-1), or (C-2), or a stereoisomer or tatomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

wherein L is  , or any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2),

(I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0143] In some embodiments, provided herein is a compound of formula (A'), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-5), (B-6), (C), (C-1), or (C-2), or a stereoisomer or tatomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

wherein L is 

, or any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0144] In some embodiments, provided herein is a compound of formula (A), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-5), (B-6), (C), (C-1), or (C-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

wherein L is 

, or any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0145] In some embodiments, provided herein is a compound of formula (A'), such as a compound of formula (B), (B-1), (B-2), (B-3), (B-4), (B-5), (B-6), (C), (C-1), or (C-2), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

wherein L is  , or any embodiment or variation thereof, as described elsewhere herein, including, for example, as in a compound of formula (I), (I-A1), (I-A2), (I-A3), (I-B1), (I-B2), (I-B3), (I-C1), (I-C2), (I-C3), (I-D1), (I-D2), (I-D3), (I-E1), (I-E2), (I-E3), (I-F1), (I-F2), (I-F3), (I-G1), (I-G2), (I-G3), (I-H1), (I-H2), (I-H3), (II), (II-A1), (II-A2), (II-A3), (II-B1), (II-C1), (II-C2), (II-C3), (II-D1), (II-D2), (II-D3), (II-E1), (III), (III-A1), (III-A2), or (III-A3), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0146] In some embodiments, provided herein is a compound of formula (A), or formula (A'), or a pharmaceutically acceptable salt of any of the foregoing, wherein L is selected from the group consisting of, 



, and , wherein # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4.

[0147] In some embodiments, provided herein is a compound of formula (A), or formula (A'), or a pharmaceutically acceptable salt of any of the foregoing, wherein L and the phenyl ring bearing moieties X^1-X^4 together form a structure selected from the group consisting of






,

,

,

,

,

,

,

,

,

,

, and

.

[0148] In some embodiments, provided herein is a compound of formula (A), or formula (A'), or a pharmaceutically acceptable salt of any of the foregoing, wherein the phenyl ring bearing Q is selected from the group consisting of

,

,

,

,

,

,

,

,

, and

.

[0149] In some embodiments, provided herein is a compound of formula (A'), or a pharmaceutically acceptable salt of any of the foregoing, wherein L and the phenyl ring bearing moieties Q together form a structure selected from the group consisting of


,

,

,

,

,

,

,

,

,

,

,

,

,

,















,

,

,

,

,

,

,

,

,

,

,

,

,

,

,

,








, and








,

,

, and

.

[0150] It is to be understood that any variation or embodiment of X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^g, R^x, R^y, R^z, *n*, *p*, A, E, G, L, Q, and Y provided herein can be combined with every other variation or embodiment of X^1, X^2, X^3, X^4, R^1, R^2, R^3, R^4, R^5, R^6, R^7, R^8, R^9, R^{10}, R^{11}, R^{12}, R^{13}, R^{14}, R^a, R^b, R^c, R^g, R^x, R^y, R^z, *n*, *p*, A, E, G, L, Q, and Y, the same as if each and every combination had been individually and specifically described.

[0151] In some embodiments, provided herein is a compound of formula (A'), formula (A), or any variation of embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

Table 1

Compound No.	Structure	Chemical name
1		1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane
2		(*R*) or (*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane

3		(*S*) or (*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane
4		1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol
5		(*R*) or (*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol
6		(*S*) or (*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol
7		*N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
8		(*S*) or (*R*)-*N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
9		(*R*) or (S)-*N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
10		*N*-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-

		yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
11		(*R*) or (*S*)-*N*-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
12		(*S*) or (*R*)- *N*-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
13		(*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine
14		(*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine
15		(*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
16		(*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
17		1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)m

		ethyl)piperidin-1-yl)ethan-1-ol
18		(*R*) or (*S*)-1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol
19		(*S*) or (*R*)-1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol
20		1-(3-chlorophenyl)-2-((*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol
21		(*R*) or (*S*)-1-(3-chlorophenyl)-2-((R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol
22		(*S*) or (*R*)-1-(3-chlorophenyl)-2-((*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol
23		(*S*)-1-((*R*) or (*S*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
24		(*S*)-1-((*S*) or (*R*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-

		(methylsulfonyl)phenoxy)methyl)piperidine
25		(*R*)-1-((*R*) or (*S*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
26		(*R*)-1-((*S*) or (*R*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
27		*rac-trans or cis*-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol
28		*rac-cis or trans*-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol
29		(3*S*,4*R*) or (3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol
30		(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol

31		(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol
32		(3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) or (3*R*,4*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol
33		*rac-trans or cis*-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
34		*rac-cis or trans*-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
35		(3*S*,4*R*) or (3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine

36		(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
37		(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) -1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
38		(3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) or (3*R*,4*R*) -1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine
39		1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl) piperidine
40		(*S*) or (*R*)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl) piperidine
41		(*R*) or (*S*)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl) piperidine

42		1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine
43		(*S*) or (*R*)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine
44		(*R*) or (*S*)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
45		*rac-trans-N*-(4-((1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
46		*N*-(4-(((3*S*,4*S*) or (3*R*,4*R*) -1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
47		*N*-(4-(((3*R*,4*R*) or (3*S*,4*S*) -1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
48		*trans-N*-(4-(3-((3-chlorophenethyl)amino)cycl

		obutoxy)phenyl)-*N*-methylmethanesulfonamide
49		(*S*)-*N*-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
50		(*R*)-*N*-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide
51		(*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
52		*rac-trans*-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
53		*rac-trans or cis*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
54		*rac-cis or trans*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine

55		(2*R*,4*S*) or (2*R*,4*R*) or (2*S*,4*R*) or (2*S*,4*S*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
56		(2*R*,4*R*) or (2*S*,4*R*) or (2*S*,4*S*) or (2*R*,4*S*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
57		(2*S*,4*R*) or (2*S*,4*S*) or (2*R*,4*S*) or (2*R*,4*R*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
58		(2*S*,4*S*) or (2*R*,4*S*) or (2*R*,4*R*) or (2*S*,4*R*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine
59		(*S*)-*N*-(4-(3-((3-chlorophenethyl)(cyclopropylmethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
60		(*S*)-*N*-(4-(3-((3-chlorophenethyl)(ethyl)amino)-2-

		hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
61		(*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide
62		(2*S*)-1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol
63		(*S*)-1-((*S*) or (*R*)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol
64		(*S*)-1-((*R*) or (*S*)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2- ol
65		*N*-(4-((*S*)-3-((*trans*-3-(3-chlorophenyl)cyclobutyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
66		(*S*)-1-((*trans*-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol

67		(*R*)-1-((*trans*-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol
68		*N*-(4-((2*S*)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
69		*N*-(4-((*S*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
70		*N*-(4-((*S*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
71		*N*-(4-((2*R*)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
72		*N*-(4-((*R*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide

73		*N*-(4-((*R*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
74		*N*-(4-((2*S*)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
75		*N*-(4-((*S*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
76		*N*-(4-((*S*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
77		*N*-(4-((2*R*)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
78		*N*-(4-((*R*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide

79		*N*-(4-((*R*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
80		*N*-(4-((2*S*)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
81		*N*-(4-((*S*)-3-((*S*) or (*R*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
82		*N*-(4-((*S*)-3-((*R*) or (*S*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
83		*N*-(4-((2*R*)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
84		*N*-(4-((*R*)-3-((*R*) or (*S*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide

85		*N*-(4-((*R*)-3-((*S*) or (*R*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
86		(*S*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
87		(*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
88		*N*-(4-((*R*)-3-(((*S*) or (*R*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
89		*N*-(4-((*R*)-3-(((*R*) or (*S*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
90		(*S*)-*N*-(4-(3-((2,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
91		(*S*)-*N*-(4-(3-((3,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-

		N-methylmethanesulfonamide
92		*N*-(4-((2*R*)-3-((3-(3-chlorobenzyl)tetrahydrofuran-3-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
93		(*S*)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol
94		(*R*)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol
95		*N*-(4-((*S*)-3-(((*S*) or (*R*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
96		*N*-(4-((*S*)-3-(((*R*) or (*S*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
97		(*R*)-1-((1-(3-chlorophenyl)-2-methylpropan-2-yl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol

98		(*S*)-*N*-(4-(2-hydroxy-3-((2-methoxyphenethyl)amino)propoxy)phenyl)-*N*-methylmethanesulfonamide
99		(*S*)-*N*-(4-(3-((3-cyanophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
100		(*S*)-*N*-(4-(3-((2-ethylphenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
101		(*S*)-*N*-(4-(3-((2-(difluoromethoxy)phenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide
102		(2*R*)-1-((2-(3-chlorophenyl)-1-cyclopropylethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol
103		(*R*) or (*S*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide
104		(*S*) or (*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-

		methylpropoxy)phenyl)-*N*-methylmethanesulfonamide
105		*N*-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-*N*-methylmethanesulfonamide
106		(*R*) or (*S*)-*N*-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-*N*-methylmethanesulfonamide
107		(3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine
108		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
109		*rac-trans*-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine

110		(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine
111		(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine
112		2-(4-{[(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethan-1-ol
113		2-(4-{[(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethan-1-ol
114		3-chloro-5-[(1*S* or 1*R*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile

115		3-chloro-5-[(1*R* or 1*S*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile
116		3-[(1*R* or 1*S*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile
117		3-[(1*S* or 1*R*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile
118		5-[(1*R* or 1*S*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile
119		5-[(1*S* or 1*R*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile
120		3-chloro-5-{1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile

121		3-chloro-5-[(1*S* or 1*R*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile
122		3-chloro-5-[(1*R* or 1*S*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile
123		1-(3-chlorophenyl)-2-((3*S*,4*S*)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethan-1-ol
124		(1*R* or 1*S*)-1-(3-chlorophenyl)-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethan-1-ol
125		(1*S* or 1*R*)-1-(3-chlorophenyl)-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethan-1-ol
126		3-[1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile

127		3-[(1*S* or 1*R*)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile
128		3-[(1*R* or 1*S*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile
129		5-{1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile
130		5-[(1*R* or 1*S*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile
131		5-[(1*S* or 1*R*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile

132		5-{2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile
133		(3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine
134		(2*S*,5*S*)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine
135		r*ac-cis* or t*rans*-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
136		*rac-trans* or *cis*-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
137		3-{2-[(2*S*,4*R* or 2*R*,4*S* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
138		3-{2-[(2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)m

		ethyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
139		3-{2-[(2*S*,4*S* or 2*S*,4*R* or 2*R*,4*S* or 2*R*,4*R*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
140		3-{2-[(2*R*,4*R* or 2*S*,4*S* or 2*S*,4*R* or 2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
141		5-chloro-3-{2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}-2-methylbenzonitrile
142		3-chloro-5-[(2*R* or 2*S*)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile
143		3-chloro-5-[(2*S* or 2*R*)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile
144		5-chloro-3-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-

		yl]ethyl}-2-methylbenzonitrile
145		5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile
146		3-chloro-5-[1-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile
147		3-chloro-5-[(2*R* or 2*S*)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile
148		3-chloro-5-[(2*S* or 2*R*)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile
149		3-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
150		*rac-cis*-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine

151		(3*R*,4*S* or 3*S*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine
152		(3*S*,4*R* or 3*R*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine
153		(2*R*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidine
154		(3*R*,4*R* or *3S,4S*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine
155		(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine
156		3-{2-[(2*R*,4*S*)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
157		3-{2-[(2*R*,4*S*)-2-methyl-4-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile

158		3-{2-[(2*R*,4*S*)-2-methyl-4-({4-[(*R* or *S*)methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile
159		3-{2-[(2*R*,4*S*)-2-methyl-4-({4-[(*S* or *R*)methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile
160		(2*R*,5*S*)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine
161		3-{2-[(2*R*,4*S*)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}-5-chlorobenzonitrile
162		3-{2-[(2*R*,4*S*)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile

163		(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methyl-1-{2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethyl}pyrrolidine
164		3-chloro-5-{2-[(2*R*,4*S*)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
165		3-chloro-5-{2-[(2*R*,4*S*)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
166		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
167		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile

168		3-{2-[(3*S*,4*S*)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
169		3-{2-[(3*S*,4*S*)-3-methyl-4-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile
170		3-{2-[(3*S*,4*S*)-3-methyl-4-({4-[(*R* or *S*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile
171		3-{2-[(3*S*,4*S*)-3-methyl-4-({4-[(*S* or *R*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile

172		3-{2-[(3*S*,4*S*)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
173		3-{2-[(3*S*,4*S*)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}-5-chlorobenzonitrile
174		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
175		*rac-trans*-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine
176		(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine

177		(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine
181		(3*S*,4*S*)-1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine
182		3-chloro-5-{2-[(3*S*)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}piperazin-1-yl]ethyl}benzonitrile
183		3-chloro-5-{2-[(3*S*)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}piperazin-1-yl]ethyl}benzonitrile
184		(3*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine
185		(3*S*)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-1-[2-(3-chlorophenyl)ethyl]piperazine

186		3-chloro-5-{2-[(3*S*)-3-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile
187		3-chloro-5-{2-[(3*S*)-3-({4-[(*S* or *R*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile
188		3-chloro-5-{2-[(3*S*)-3-({4-[(*R* or *S*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile
189		3-chloro-5-{2-[(3*S*)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}benzonitrile
190		(3*S*)-1-[2-(3,5-dichlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine
191		(3*S*)-1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-

		methanesulfonylphenoxy)methyl]piperazine
192		(3*S*)-1-{2-[5-chloro-2-(difluoromethoxy)phenyl]ethyl}-3-[(4-methanesulfonylphenoxy)methyl]piperazine
193		3-{2-[(3*S*)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}-5-(trifluoromethyl)benzonitrile
194		3-chloro-5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
195		3-fluoro-5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
196		3-bromo-5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile
197		(3*S*)-1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine

198		3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}-5-methylbenzonitrile
199		*rac-cis* or *trans*-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
200		3-chloro-5-{2-[(2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
201		3-chloro-5-{2-[(2*S*,4*R* or 2*R*,4*S* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
202		*rac-trans* or *cis*-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile
203		3-chloro-5-(2-((2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)m

		ethyl)pyrrolidin-1-yl)ethyl)benzonitrile
204		3-chloro-5-(2-((2*R*,4*S* or 2*S*,4*R* or 2*S*,4*S* or 2*R*.4*R*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile
205	 Cis	*rac-cis*-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol
206		(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol
207		(3*S*,4*S* or 3*R*,4*R*)-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol
208	 Trans	*rac-trans*-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol
209		(3*R*,4*S* or 3*S*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)m

		ethyl]-3-methylpyrrolidin-3-ol
210		(3*S*,4*R* or 3*R*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol
211		1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine
212		*rac-cis* or *trans*-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine
213		*rac-trans* or *cis*-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine
214		(1*R*) or (1*S*)-1-(3-chlorophenyl)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethan-1-ol
215		(1*S*) or (1*R*)-1-(3-chlorophenyl)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethan-1-ol

[0152] In some embodiments, a compound of formula (A) or (A') is selected from the group consisting of:

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane;

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol;

N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide;

N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide;

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine;

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;

1-(3-chlorophenyl)-2-(3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol;

1-(3-chlorophenyl)-2-(3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol;

1-(2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol;

1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine;

1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine;

1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;

N-(4-(1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide;

N-(4-(3-((3-chlorophenethyl)amino)cyclobutoxy)phenyl)-*N*-methylmethanesulfonamide;

N-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide;

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;

1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;

1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;

N-(4-(3-((3-chlorophenethyl)(cyclopropylmethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;

N-(4-(3-((3-chlorophenethyl)(ethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;

N-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide;

1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;

N-(4-(3-(3-(3-chlorophenyl)cyclobutyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;

1-(3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
N-(4-((2)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-((2)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((2,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((3,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((3-(3-chlorobenzyl)tetrahydrofuran-3-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
1-((1-(3-chlorophenyl)-2-methylpropan-2-yl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
N-(4-(2-hydroxy-3-((2-methoxyphenethyl)amino)propoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((3-cyanophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((2-ethylphenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-(3-((2-(difluoromethoxy)phenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide;
1-((2-(3-chlorophenyl)-1-cyclopropylethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide;
N-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-*N*-methylmethanesulfonamide;

1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine;
1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
2-[4-({1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl}methoxy)benzenesulfonyl]ethan-1-ol;
1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
2-[4-({1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl}methoxy)benzenesulfonyl]ethan-1-ol;
1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine;
1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine;
1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine;
1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidine;
1-[2-(3,5-dichlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine;
3-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine;

3-chloro-5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
1-(3-chlorophenyl)-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethan-1-ol;
1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
3-chloro-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl}ethyl)benzonitrile;
3-chloro-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
3-chloro-5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-chloro-5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
1-(3-chlorophenyl)-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethan-1-ol;
1-(3-chlorophenyl)-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethan-1-ol;
3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-chloro-5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-chloro-5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-1-[2-(3-chlorophenyl)ethyl]piperazine;
3-chloro-5-[2-(4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-chloro-5-[2-(4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-chloro-5-[2-(3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-fluoro-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-[(4-methanesulfonylphenoxy)methyl]-4-methyl-1-{2-[3-(pentafluoro-lambda6-sulfanyl)phenyl]ethyl}pyrrolidine;
3-chloro-5-[2-(3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;

3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-chloro-5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
1-{2-[5-chloro-2-(difluoromethoxy)phenyl]ethyl}-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
1-(3-chlorophenyl)-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethan-1-ol;
1-(3-chlorophenyl)-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethan-1-ol;
3-chloro-5-[2-(3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]benzonitrile;
1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
3-[2-(4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-chloro-5-(1-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}propan-2-yl)benzonitrile;
3-[2-(3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-chloro-5-[2-(3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-chloro-5-(1-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}propan-2-yl)benzonitrile;
3-chloro-5-(1-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}propan-2-yl)benzonitrile;
1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
3-chloro-5-(1-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}propan-2-yl)benzonitrile;
5-chloro-3-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)-2-methylbenzonitrile;
5-chloro-3-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)-2-methylbenzonitrile;
3-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-chloro-5-(1-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}propan-2-yl)benzonitrile;

3-chloro-5-[2-(3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}piperazin-1-yl)ethyl]benzonitrile;
3-(2-{3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl}ethyl)-5-(trifluoromethyl)benzonitrile;
3-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)-5-methylbenzonitrile;
3-[2-(3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-chloro-5-[2-(3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}piperazin-1-yl)ethyl]benzonitrile;
5-(2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzene-1,3-dicarbonitrile;
5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzene-1,3-dicarbonitrile;
3-[2-(4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl)ethyl]-5-chlorobenzonitrile;
3-[2-(3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl)ethyl]-5-chlorobenzonitrile;
3-bromo-5-(2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-[2-(4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl)ethyl]benzonitrile;
3-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-{2-[3-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzonitrile;
3-{2-[3-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[3-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[2-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzene-1,3-dicarbonitrile;
5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzene-1,3-dicarbonitrile;
5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzene-1,3-dicarbonitrile;

5-(1-hydroxy-2-{4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl}ethyl)benzene-1,3-dicarbonitrile;
3-{2-[2-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[2-methyl-4-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
5-(1-hydroxy-2-{3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl}ethyl)benzene-1,3-dicarbonitrile;
3-chloro-5-{2-[3-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[3-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile; and
3-chloro-5-{2-[3-({4-[methyl(methylimino)oxo-lambda6-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile,

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.

[0153] In some embodiments, a compound of formula (A) or (A') is selected from the group consisting of:

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane;
(R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane;
(S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane;
1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol;
(R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol;
(S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol;
N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
(R)-N-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
(R)-N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-N-methylmethanesulfonamide;

(S)-N-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
(S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine;
(R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine;
(R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
(S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
1-(3-chlorophenyl)-2-((S)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol;
(R)-1-(3-chlorophenyl)-2-((S)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol;
(S)-1-(3-chlorophenyl)-2-((S)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol;
1-(3-chlorophenyl)-2-((R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol;
(R)-1-(3-chlorophenyl)-2-((R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol;
(S)-1-(3-chlorophenyl)-2-((R)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol;
(S)-1-((R)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
(S)-1-((S)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
(R)-1-((R)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
(R)-1-((S)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
rac-trans or cis-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol;
rac-cis or trans-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol;
(3S,4R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol;
(3R,4R)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol;
(3R,4S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol;
(3S,4S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol;
rac-trans-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine;
rac-cis-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine;
(3S,4R)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
(3R,4R)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
(3R,4S)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;
(3S,4S)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine;

1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine;
(S)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine;
(R)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine;
1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine;
(S)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine;
(R)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
rac-trans-N-(4-((1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-(((3S,4S)-1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-(((3R,4R)-1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
trans-N-(4-(3-((3-chlorophenethyl)amino)cyclobutoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
(R)-N-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide;
(S)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
rac-trans-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
rac-trans-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
rac-cis-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
(2R,4S)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
(2R,4R)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
(2S,4R)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
(2S,4S)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine;
(S)-N-(4-(3-((3-chlorophenethyl)(cyclopropylmethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((3-chlorophenethyl)(ethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(R)-N-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-N-methylmethanesulfonamide;
(2S)-1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;

(S)-1-((S)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
(S)-1-((R)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
N-(4-((S)-3-((trans-3-(3-chlorophenyl)cyclobutyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-1-((trans-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
(R)-1-((trans-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
N-(4-((2S)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((S)-3-((S)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((S)-3-((R)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((2R)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-((S)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-((R)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((2S)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((S)-3-((S)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((S)-3-((R)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((2R)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-((S)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-((R)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((2S)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;

N-(4-((S)-3-((S)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((S)-3-((R)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((2R)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-((R)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-((S)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(R)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-(((S)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((R)-3-(((R)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((2,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((3,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((2R)-3-((3-(3-chlorobenzyl)tetrahydrofuran-3-yl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
(R)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
N-(4-((S)-3-(((S)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((S)-3-(((R)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(R)-1-((1-(3-chlorophenyl)-2-methylpropan-2-yl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;

(S)-N-(4-(2-hydroxy-3-((2-methoxyphenethyl)amino)propoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((3-cyanophenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((2-ethylphenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((2-(difluoromethoxy)phenethyl)amino)-2-hydroxypropoxy)phenyl)-N-methylmethanesulfonamide;
(2R)-1-((2-(3-chlorophenyl)-1-cyclopropylethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol;
(R)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-N-methylmethanesulfonamide;
(S)-N-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-N-methylmethanesulfonamide;
N-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-N-methylmethanesulfonamide;
(R)-N-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-N-methylmethanesulfonamide;
(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
3-chloro-5-{2-[(3S,4S)-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
rac-trans-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
(3R,4R)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
2-(4-{[(3R,4R)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethan-1-ol;
2-(4-{[(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethan-1-ol;

3-chloro-5-[(1S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile;
3-chloro-5-[(1R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile;
3-[(1R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile;
3-[(1S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile;
5-[(1R)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile;
5-[(1S)-1-hydroxy-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile;
3-chloro-5-{1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-chloro-5-[(1S)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile;
3-chloro-5-[(1R)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile;
1-(3-chlorophenyl)-2-((3S,4S)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethan-1-ol;
(1R)-1-(3-chlorophenyl)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethan-1-ol;
(1S)-1-(3-chlorophenyl)-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethan-1-ol;
3-[1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile;
3-[(1S)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile;
3-[(1R)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile;
5-{1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile;

5-[(1R)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile;
5-[(1S)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile;
5-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile;
(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
(2S,5S)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine;
rac-cis-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
rac-trans-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(2S,4R)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(2S,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(2R,4R)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
5-chloro-3-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}-2-methylbenzonitrile;
3-chloro-5-[(2R)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile;
3-chloro-5-[(2S)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile;
5-chloro-3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}-2-methylbenzonitrile;
5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile;

3-chloro-5-[1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile;
3-chloro-5-[(2R)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile;
3-chloro-5-[(2S)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile;
3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
rac-cis-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
(3R,4S)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
(3S,4R)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
(2R,4S)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidine;
(3R,4R)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
3-{2-[(2R,4S)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(2R,4S)-2-methyl-4-({4-[methyl(methylimino)oxo-λ^6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(2R,4S)-2-methyl-4-({4-[(R)methyl(methylimino)oxo-λ^6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(2R,4S)-2-methyl-4-({4-[(S)methyl(methylimino)oxo-λ^6-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
(2R,5S)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine;
3-{2-[(2R,4S)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}-5-chlorobenzonitrile;

3-{2-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methyl-1-{2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethyl}pyrrolidine;
3-chloro-5-{2-[(2R,4S)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[(2R,4S)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[(3S,4S)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[(3S,4S)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(3S,4S)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(3S,4S)-3-methyl-4-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(3S,4S)-3-methyl-4-({4-[(R)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(3S,4S)-3-methyl-4-({4-[(S)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(3S,4S)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-{2-[(3S,4S)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}-5-chlorobenzonitrile;
3-chloro-5-{2-[(3S,4S)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
rac-trans-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
(3R,4R)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;
(3S,4S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine;

(3S,4S)-1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine;
3-chloro-5-{2-[(3S)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}piperazin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[(3S)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}piperazin-1-yl]ethyl}benzonitrile;
(3S)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine;
(3S)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-1-[2-(3-chlorophenyl)ethyl]piperazine;
3-chloro-5-{2-[(3S)-3-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[(3S)-3-({4-[(S)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile ;
3-chloro-5-{2-[(3S)-3-({4-[(R)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile ;
3-chloro-5-{2-[(3S)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}benzonitrile;
(3S)-1-[2-(3,5-dichlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
(3S)-1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
(3S)-1-{2-[5-chloro-2-(difluoromethoxy)phenyl]ethyl}-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
3-{2-[(3S)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}-5-(trifluoromethyl)benzonitrile;
3-chloro-5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-fluoro-5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-bromo-5-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile;
(3S)-1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine;
3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}-5-methylbenzonitrile;

rac-cis-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-chloro-5-{2-[(2S,4R)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
rac-trans-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile;
3-chloro-5-(2-((2R,4R)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile;
3-chloro-5-(2-((2S,4S)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile;
rac-cis-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
(3R,4R)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
(3S,4S)-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol;
rac-trans-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
(3R,4S)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
(3S,4R)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol;
1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine;
rac-cis-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine;
rac-trans-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine;
(1R)-1-(3-chlorophenyl)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethan-1-ol; and
(1S)-1-(3-chlorophenyl)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethan-1-ol,

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Isotopically labeled forms of any of the foregoing are also embraced, such as deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein. Mixtures of any of the foregoing are also embraced and described. Prodrugs of any of the foregoing are also embraced herein.

[0154] Compound Names included in Table 1 and in the lists in the paragraphs above were generated using ChemDraw® software version 18.1.0.458 or Collaborative Drug Discovery Inc. (CDD) CDD Vault update #3.

COMPOSITIONS

[0155] Provided herein are pharmaceutical compositions comprising one or more compounds of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, provided herein is a pharmaceutical composition comprising (i) of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) one or more pharmaceutically acceptable excipients.

[0156] Suitable pharmaceutically acceptable excipients may include, for example, fillers, diluents, sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers, and adjuvants. Various substances may be embraced by the term excipient, including without limitation any substance used as a binder, disintegrant, coating, compression/encapsulation aid, cream or lotion, lubricant, solutions for parenteral administration, materials for chewable tablets, sweetener or flavoring, suspending/gelling agent, or wet granulation agent. Examples of suitable excipients are well-known to those skilled in the art. Such compositions are prepared in a manner well known in the pharmaceutical art. *See*, *e.g.*, *Remington's Pharmaceutical Sciences*, Academic Press, 23rd ed. (2020), which is incorporated herein by reference.

[0157] The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, oral, rectal, buccal, intranasal, and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered by intra-arterial injection,

intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant.

[0158] Compounds as described herein may be administered to individuals in a form of generally accepted oral compositions, such as tablets, coated tablets, gel capsules in a hard or in soft shell, emulsions or suspensions. Examples of carriers, which may be used for the preparation of such compositions, are lactose, corn starch or its derivatives, talc, stearate or its salts, *etc*. Acceptable carriers for gel capsules with soft shell are, for instance, plant oils, wax, fats, semisolid and liquid poly-ols, and so on. In addition, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulgators, sweeteners, dyes, adjusters, salts for the adjustment of osmotic pressure, buffers, coating agents or antioxidants.

[0159] The specific dose level of a compound as described herein will depend upon a variety of factors such as the age, body weight and sex of the individual as well as the route of administration and other factors. In some embodiments, a dosage is expressed as a number of milligrams of a compound described herein per kilogram of the individual's body weight (mg/kg). Dosages of between about 0.1 mg/kg and 100-150 mg/kg may be appropriate.

[0160] The compound may be administered to an individual in accordance with an effective dosing regimen for a desired period of time or duration, such as at least about one month, at least about 2 months, at least about 3 months, at least about 6 months, or at least about 12 months or longer, which in some variations may be for the duration of the individual's life.

METHODS OF TREATMENT

[0161] Provided herein is a method of modulating APOL1 in a cell, comprising exposing the cell to an effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein is a method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients. Isotopically labeled forms of any of the foregoing are also embraced, including, but not limited to, deuterated or tritiated forms (wherein at least one hydrogen is replaced by at least one deuterium or tritium) of any of the specific compounds detailed herein.

[0162] Provided herein is a method of inhibiting APOL1 in a cell, comprising exposing the cell to an effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein is a method of inhibiting APOL1 in a cell, comprising exposing the cell to a pharmaceutical composition comprising an effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0163] Provided herein is a method of inhibiting APOL1 in an individual, comprising administering to the individual an effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein is a method of inhibiting APOL1 in an individual, comprising administering to the individual a pharmaceutical composition comprising an effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0164] In some embodiments, the compounds provided herein inhibit APOL1 at a concentration of less than 10 μM, less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein inhibit APOL1 at a concentration of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM.

[0165] In some embodiments, the compounds provided herein reduce cell death caused by overexpression of APOL1. In some embodiments, the compounds provided herein reduce cell death caused by overexpression APOL1 at a concentration of less than 10 μM, less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein reduce cell death caused by APOL1 overexpression at a concentration of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM.

[0166] In some embodiments, compounds provided herein have an EC_{50} of less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein have an EC_{50} of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM.

[0167] In some embodiments, compounds provided herein have an AC_{50} of less than 1 μM, less than 0.5 μM, or less than 0.1 μM. In some embodiments, the compounds provided herein have an AC_{50} of 1 to 10 μM, 0.01 to 1 μM, or 0.01 to 10 μM. In some embodiments, the AC_{50} value reflects the compound's ability to prevent calcium influx by inhibiting APOL1.

[0168] In some embodiments, the compounds provided herein inhibit a cation channel. In some embodiments, the compounds of the present disclosure inhibit a calcium channel. In some embodiments, the compounds of the present disclosure reduce calcium transport.

[0169] Provided herein is a method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein is a method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0170] Provided herein is a method of treating a kidney disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein is a method of treating a kidney disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients.

[0171] In some embodiments, the individual has a chronic kidney disease. In some embodiments, the individual has hypertension-attributed kidney disease. In some embodiments,

the kidney disease, disorder, or condition is an APOL1-mediated kidney disease, disorder, or condition. In some embodiments, the kidney disease, disorder, or condition is selected from the group consisting of focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, viral nephropathy, COVID-19 associated nephropathy, human immunodeficiency virus-associated nephropathy (HIVAN), sickle-cell nephropathy, lupus nephritis, and diabetic kidney disease.

[0172] Also provided herein is a method of treating an APOL1-mediated disorder, such as preeclampsia and sepsis, comprising administering to an individual in need thereof a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the individual is genetically predisposed to developing the APOL1-mediated disorder.

[0173] Also provided herein is a method of delaying development of progressive renal allograft loss in a kidney transplant recipient comprising administering to the kidney transplant recipient a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In some embodiments, the kidney transplant recipient receives a kidney from a high-risk APOL1 genotype donor. In some embodiments, the kidney transplant recipient is administered a therapeutically effective amount of the compound for a period of time before receiving the kidney transplant. In some embodiments, the kidney transplant recipient is administered a therapeutically effective amount of the compound subsequent to receiving the kidney transplant.

[0174] Provided herein is a method of treating a kidney disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the individual has an APOL1 mutation. Also provided herein is a method of treating a kidney disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing,

and one or more pharmaceutically acceptable excipients, wherein the individual has an APOL1 mutation.

[0175] The compounds provided herein may also be used in a method of delaying the development of an APOL1-mediated disease, disorder, or condition, comprising administering a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to an individual who is at risk of developing an APOL1-mediated disease, disorder, or condition. In some embodiments, the APOL1-mediated disease, disorder, or condition is preeclampsia or sepsis and the individual has two APOL1 risk alleles. In some embodiments, the APOL1-mediated disease, disorder, or condition is a chronic kidney disease and the individual has any binary combination of G1 and G2 APOL1 risk alleles. In some embodiments, the chronic kidney disease is focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN), hypertension-attributed kidney disease, sickle cell nephropathy, viral nephropathy, COVID-19 associated nephropathy, lupus nephritis, diabetic kidney disease, or APOL1-associated nephropathy. The compounds as provided herein may also be used in a method of delaying the development of progressive renal allograft loss in an individual who has received a kidney transplantation from a high-risk APOL1 genotype donor.

[0176] In some embodiments, the individual has a gain-of-function mutation in APOL1. In some embodiments, the individual has an APOL1 risk allele. In some embodiments, the APOL1 risk allele is a missense variant. In some embodiments, the APOL1 risk allele is a G1 variant. In some embodiments, the G1 variant is $G1^{G}$ (p.S342 G) or $G1^{M}$ (p.I384 M). In some embodiments, the APOL1 risk allele is the G2 variant. In some embodiments, the G2 variant is NYK388–389K. In some embodiments, the APOL1 risk variant is a mutation in the serum resistance-associated (SRA) binding domain of the APOL1 protein.

[0177] Also provided herein is a method of inhibiting APOL1 in an individual comprising administering to the individual a therapeutically effective amount of a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0178] Also provided herein is method of preventing kidney failure in an individual comprising administering a therapeutically effective amount of a compound of Formula (A), or

formula (A') or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing to the individual. In some embodiments, the compound prevents tissue necrosis. In some embodiments, the compound prevents apoptosis. In some embodiments, the compound reduces inflammation.

[0179] In some embodiments, the compounds provided herein reduce or eliminate one or more symptoms of a kidney disease. In some embodiments, the compounds reduce nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, urinary frequency issues, muscle twinges and cramps, swelling, itching, chest pain, shortness of breath, and/or high blood pressure.

[0180] In some embodiments, the compounds provided herein reduce the rate of kidney damage and/or progression of kidney damage. In some embodiments, the compounds provided herein reduce the rate of kidney failure. In some embodiments, the compounds provided herein reverse kidney damage. In some embodiments, the compounds reduce the need for dialysis. In some embodiments, the compounds provided herein delay the need for dialysis at least one month, at least two months, at least three months, or at least one year.

[0181] In some embodiments, the compounds reduce the rate of or delay the need for a kidney transplant. For example, in some embodiments, the compounds provided herein delay the need for a kidney transplant at least one month, at least two months, at least three months, at least six months, or at least one year. In some embodiments, the compounds provided herein eliminate the need for a kidney transplant.

[0182] In some embodiments, the individual has stage 1, stage 2, stage 3A, stage 3B, stage 4, or stage 5 chronic kidney disease. In some embodiments, kidney function is evaluated using an estimated glomerular filtration rate (eGFR) kidney function test.

[0183] In some embodiments, the administration is oral administration.

KITS

[0184] The present disclosure further provides kits for carrying out the methods of the invention. The kits may comprise a compound or pharmaceutically acceptable salt thereof as described herein and suitable packaging. The kits may comprise one or more containers comprising any compound described herein. In one aspect, a kit includes a compound of the disclosure or a pharmaceutically acceptable salt thereof, and a label and/or instructions for use of

the compound in the treatment of a disease or disorder described herein. The kits may comprise a unit dosage form of the compound.

[0185] Provided herein are kits, comprising (i) a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof. Also provided herein are kits, comprising (i) a pharmaceutical composition comprising a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, and one or more pharmaceutically acceptable excipients; and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof.

Articles of manufacture are also provided, wherein the article of manufacture comprises a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in a suitable container. Also provided herein are articles of manufacture, comprising a pharmaceutical composition comprising a compound of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, or intravenous bag.

METHODS OF ASSAYING APOL1 ACTIVITY

[0186] Provided herein is a method of assessing APOL1 inhibition in a cell, comprising inducing APOL1 expression in a cell, contacting the cell with an APOL1 inhibitor, and measuring inhibition of calcium transport. In some embodiments, inducing APOL1 expression comprises contacting the cell with doxycycline. In some embodiments, the cell stably expresses a genetically encoded calcium indicator. In some embodiments, the genetically encoded calcium indicator comprises GCaMP6f. In some embodiments, the cell inducibly expresses APOL1 G2. In some embodiments, the cell stably expresses a genetically encoded calcium indicator and inducibly expresses APOL1 G2. In some embodiments, the APOL1 inhibitor is a compound of formula (A'), or any variation or embodiment thereof, as described

elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing

[0187] Provided herein is a method of assessing rescue of HEK cell death caused by overexpression of APOL1, inducing APOL1 expression in a cell, contacting the cell with an APOL1 inhibitor, exposing the cell to a luminescence reagent, and measuring luminescence. In some embodiments, inducing APOL1 expression comprises contacting the cell with doxycycline. In some embodiments, the cell overexpresses APOL1G2. In some embodiments, the APOL1 inhibitor is a compound of formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

METHODS OF PREPARING

[0188] The present disclosure further provides methods for preparing the compounds of present invention. In some aspect, provided herein are methods of preparing a compound of formula (A), or formula (A'), or any embodiment or variation thereof, such as a compound of formula (I), (II), (III), (B-2), (B-5), or (C-1), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0189] In some embodiments, a method for preparing a compound of formula (A) or (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprises a step of reacting a compound of formula (A-I1):



(A-I1)

wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl; and

V^1 is selected from the group consisting of:

(i) 

, wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^x is H,

or R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^1 and R^2 are independently H, halo, or -OH,

or one of R^1 and R^2 is taken together with R^x, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH;

R^4 and R^5 are independently H,

or R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that either:

(1) R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, or

(2) R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(ii) 

, wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^6 is H or -OH; and

R^y is H; and

(iii) 

, wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^z is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl; and

R^{11} and R^{12} are independently H, -OH, halo, or C_{1-6}alkyl;

with:

a compound of formula (A-I2):



(A-I2)

wherein:

the dashed line represents a single or double bond;

W^1 is oxo, halo, or sulfonate ester;

V^2 is selected from the group consisting of:

(i) 

, wherein

R^3 is H, -OH, halo, or $C_{1\text{-}6}$alkoxy;

(ii) 

, wherein

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^7 is H;

one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a $C_{3\text{-}8}$cycloalkyl, and the other of R^8 and R^9 is H or $C_{1\text{-}6}$alkyl; and

R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl; and

(iii)  , wherein

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

wherein, for each of (i)-(iii), # denotes the point of attachment to W^1, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo;

to give a compound of formula (A) or (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0190] In some embodiments, the compound of formula (A) or (A') is prepared by a step comprising:

a) alkylation of an amine of formula (A-I1) with an alkyl halide, or sulfonate ester compound of formula (A-I2) in the presence of an inorganic or organic base; or

b) reductive amination of an aldehyde or ketone of formula (A-I2) with an amine of formula (A-I1) in the presence of a reducing agent.

[0191] In some embodiments, the compound of formula (A) or (A') is prepared by a step comprising alkylation of an amine of formula (A-I1) with an alkyl halide, or sulfonate ester compound of formula (A-I2) in the presence of an inorganic or organic base. In some embodiments, the inorganic base is selected from the group consisting of potassium carbonate, sodium carbonate, and sodium bicarbonate. In some embodiments, the organic base is a tertiary

amine. In some embodiments, the organic base is selected from the group consisting of trimethylamine, triethylamine, and diisopropylethyamine.

[0192] In some embodiments, the sulfonate ester compound of formula (A-I2) is a mesylate or a tosylate. In some embodiments, the sulfonate ester compound of formula (A-I2) is a mesylate. In some embodiments, the sulfonate ester compound of formula (A-I2) is a tosylate.

[0193] In some embodiments, the compound of formula (A) or (A') is prepared by a step comprising reductive amination of an aldehyde or ketone of formula (A-I2) with an amine of formula (I-I1). In some embodiments, the reductive amination proceeds under the action of a reducing agent. In some embodiments, the reducing agent is sodium triacetoxyborohydride, or sodium cyanoborohidride.

[0194] In some embodiments, a method for preparing a compound of formula (A) or (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprises a step of reacting a compound of formula (A-I3):



(A-I3)

wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-}

$_{6}$alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl; and

V^2 is halo or OH,

with:

a compound of formula (A-I4):



(A-I4)

wherein:

W^2 is H, or sulfamate;

L is selected from the group consisting of:

(i) 

, wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^x is H,

or R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^1 and R^2 are independently H, halo, or -OH,

or one of R^1 and R^2 is taken together with R^x, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH;

R^3 is H, -OH, halo, or C_{1-6}alkoxy; and

R^4 and R^5 are independently H,

or R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that either:

(1) R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, or

(2) R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(ii) 

, wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^6 is H or -OH;

R^y is H,

or R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

or R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^7 is H,

or R^7 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^8 and R^9 are independently H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl,
or one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl; and

R^{10} is H,

or R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that:

(1) R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(2) R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(3) one of R^8 and R^9 is taken together with R^{10} and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and

(iii)  , wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^z is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl;

R^{11} and R^{12} are independently H, -OH, halo, or C_{1-6}alkyl; and

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo;

to give a compound of formula (A) or (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0195] In some embodiments, the compound of formula (A) or (A') is prepared by a step comprising alkylation of an alcohol or amine of formula (A-I4) with an alkyl halide

compound of formula (A-I3) in the presence of an inorganic or organic base. In some embodiments, the inorganic base is selected from the group consisting of potassium carbonate, sodium carbonate, and sodium bicarbonate. In some embodiments, the organic base is a tertiary amine. In some embodiments, the organic base is selected from the group consisting of trimethylamine, triethylamine, and diisopropylethyamine.

[0196] In some embodiments, the compound of formula (A) or (A') is prepared by a step comprising alkylation of an alcohol of formula (A-I3) with a sulfamate compound of formula (A-I4) in the presence of an inorganic or organic base. In some embodiments, the inorganic base is selected from the group consisting of potassium carbonate, sodium carbonate, and sodium bicarbonate. In some embodiments, the organic base is a tertiary amine. In some embodiments, the organic base is selected from the group consisting of trimethylamine, triethylamine and diisopropylethyamine.

[0197] In some embodiments, a method for preparing a compound of formula (A) or (A'), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, comprises a step of reacting a compound of formula (A-I5):



(A-I5)

wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl; and

V^3 is selected from the group consisting of:

(iv)  , wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^1 is H, halo, or -OH,

R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(v)  , wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^6 is H or -OH; and

(vi)  , wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^{11} is H, -OH, halo, or C_{1-6}alkyl;

with:

a compound of formula (A-I6):



(A-I6)

wherein:

V^4 is selected from the group consisting of:

(iv)  , wherein

R^x is H, and

R^3 is H, -OH, halo, or $C_{1\text{-}6}$alkoxy;

(v)  , wherein

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^y is H,

or R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

or R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^7 is H,

or R^7 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^8 and R^9 are independently H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl,
or one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl; and

R^{10} is H,

or R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that:

(1) R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(2) R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(3) one of R^8 and R^9 is taken together with R^{10} and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and

(vi)  , wherein

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo;

to give a compound of formula (A) or (A') or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0198] In some embodiments, the compound of formula (A) or (A') is prepared by a step comprising alkylation of an epoxide compound of formula (A-I5) with an amine compound of formula (A-I6) in the presence of an organic base. In some embodiments, the organic base is a tertiary amine. In some embodiments, the organic base is selected from the group consisting of trimethylamine, triethylamine and diisopropylethyamine.

EXAMPLES

[0199] The following synthetic reaction schemes, which are detailed in the Schemes, General Procedures, and Examples, are merely illustrative of some of the methods by which the compounds of the present disclosure, or an embodiment or aspect thereof, can be synthesized. Various modifications to these synthetic reaction schemes can be made, as will be apparent to those of ordinary skill in the art.

[0200] The starting materials and the intermediates of the synthetic reaction schemes can be isolated and purified if desired using conventional techniques, including but not limited to, filtration, distillation, crystallization, chromatography, and the like. Such materials can be characterized using conventional means, including physical constants and spectral data.

[0201] Although certain exemplary embodiments are depicted and described herein, the compounds of the present disclosure, or any variation or embodiment thereof, may be prepared using appropriate starting materials according to the methods described generally herein and/or by methods available to one of ordinary skill in the art.

Synthetic Examples

[0202] As depicted in the Schemes, General Procedures, and Examples below, in certain exemplary embodiments, compounds of formula (A), or formula (A'), or any variation or embodiment thereof, as described elsewhere herein, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, are prepared according to the general procedures. The general methods below, and other methods known to synthetic chemists of ordinary skill in the art, can be applied to all formulae, variations, embodiments, and species described herein.

Scheme 1



[0203] Compounds of formulae **S7**–**S9** may be prepared by the general synthetic method shown in **Scheme 1.** It is to be understood that, where applicable, the moieties and variables depicted in **Scheme 1** are as defined elsewhere herein for a compound of formula (A), or formula (A'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In addition, with reference to **Scheme 1**, m is an integer from 0-5 and q is an integer from 0-5, provided that $1 \leq (m + q) \leq 6$.

[0204] C–O bond formation may be accomplished through either a Mitsunobu reaction with phenols of formula **S2** or an S_NAr with aryl fluorides of formula **S3** to provide compounds of formula **S4**. Deprotection of the *N-tert*-butyloxycarbonyl (Boc) group may proceed using a protic acid such as hydrochloric acid to give compounds of formula **S5**.

Compounds of formula **S7** can be prepared through reductive amination using an aldehyde of formula **S6** and a hydride source such as $NaBH_3CN$. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formulas **S8** and **S9**.

Scheme 2



[0205] Compounds of formulas **S7**–**S9** may be prepared by the alternative general synthetic method shown in **Scheme 2.** It is to be understood that, where applicable, the moieties and variables depicted in **Scheme 2** are as defined elsewhere herein for a compound of formula (A), or formula (A'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In addition, with reference to **Scheme 2**: m is an integer from 0-5 and q is an integer from 0-5, provided that $1 \leq (m + q) \leq 6$; and Z^1 is halo (for example: chloro or bromo) or a sulfonate ester (for example: mesylate).

[0206] C–O coupling of an aryl halide of formula **S10** with an alcohol of formula **S1** may be performed using conditions such as copper(I) iodide, Cs_2CO_3, and 3,4,7,8-tetramethyl-1,10-phenanthroline in toluene at an elevated temperature to afford compounds of formula **S4**.

Deprotection of the *N-tert*-butyloxycarbonyl (Boc) group may proceed using a protic acid such as trifluoroacetic acid to give compounds of formula **S5**. Compounds of formula **S7** can be prepared using a base such as K_2CO_3, an alkyl halide or alkyl sulfonate ester such as alkyl bromide of formula **S11**, and an organic solvent such as MeCN at elevated temperature. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formulas **S8** and **S9**.

Scheme 3



[0207] Compounds of formulas **S7**–**S9** may be prepared by the alternative general synthetic method shown in **Scheme 3.** It is to be understood that, where applicable, the moieties and variables depicted in **Scheme 3** are as defined elsewhere herein for a compound of formula (A), or formula (A'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. In addition, with reference to **Scheme 3**: m is an integer from 0-5 and q is an integer from 0-5, provided that $1 \leq (m + q) \leq 6$; and Z^2 is halo (for example: chloro or bromo) or a sulfonate ester (for example: mesylate).

[0208] C–O bond formation may be accomplished through an S_N2 reaction with alkyl halide or alkyl sulfonate ester such as alkyl bromide of formula **S12** with phenols of formula **S2** in the presence of bases such as K_2CO_3 to give compounds of formula **S4**. Deprotection of the *N*-*tert*-butyloxycarbonyl (Boc) group may proceed using a protic acid such as HCl to give

compounds of formula **S5**. Compounds of formula **S7** can be prepared through reductive amination using an aldehyde of formula **S6** and a hydride source such as $NaBH_3CN$. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula **S8** and **S9**.

Scheme 4



[0209] Compounds of formula **S17** may be prepared by the alternative general synthetic method shown in **Scheme 4.** It is to be understood that, where applicable, the moieties and variables depicted in **Scheme 4** are as defined elsewhere herein for a compound of formula (A), or formula (A'), or any variation or embodiment thereof, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

[0210] Compounds of formula S17 with (S)-stereochemistry may be accessed by treating phenols of formula S2 with (R)-2-(chloromethyl)oxirane (S13) in the presence of a phase transfer catalyst such as TBAB and a base such as NaOH. Alternately, treatment of phenol **S2** with (*R*)-oxiran-2-ylmethanol **S14** and Mitsunobu conditions such as PPh_3 and DIAD may also provide **(*S*)-S15**. Epoxide opening to provide compounds of formula **S17** proceeds in the presence of amines of formula **S16**, triethylamine in cases where the salt form of amine **S16** is used, as a solution in ethanol at elevated temperatures. In cases where epimeric –OH stereochemistry of compounds of formula **S17** is desired, the above synthetic scheme may be modified to utilize (*S*)-2-(chloromethyl)oxirane or (*S*)-oxiran-2-ylmethanol.

Scheme 5.



[0211] Compounds of formula **S24** may be prepared according to **Scheme 5**. Reductive amination of a mono-protected piperazine such as **S18** with an aldehyde such as **S6** gives compound **S19**. Removal of the the N-*tert*-butyloxycarbonyl (Boc) group upon treatment with a protic acid such as HCl in a solvent such as MeOH gives **S20**. Treatment with thionyl chloride, triethylamine, and imidazole gives rise to **S21**. Oxidation to the oxathiazolidine-2,2-dioxide occurs on treatment with ruthenium (III) chloride and sodium periodate in a mixed solvent system of acetonitrile and water to give **S22**. Heating **S22** with a phenol such as **S23** and potassium carbonate in DMF, followed by treatment with aqueous HCl, gives compounds of formula **S24**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula **S24.**

Scheme 6.



[0212] An alternative synthetic approach to compounds of formula **S24** is depicted in **Scheme 6**. Reaction of piperazine **S18** with benzyl chloroformate in the presence of a base such as sodium bicarbonate generates the bis-carbamate **S25**. Mitsunobu coupling of phenol **S23** with triphenylphosphine and DIAD in THF generates **S26**. Selective cleavage of the benzyl carbamate may be achieved by treatment with thionyl chloride, triethylamine, and imidazole in DCM to give **S27**, which may then undergo reductive amination using sodium triacetoxyborohydride provides compounds of formula **S28**. Cleavage of the the N-*tert*-butyloxycarbonyl (Boc) group provides **S24**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula **S24.**

Scheme 7.



[0213] **Scheme 7** outlines an approach to compounds of formula **S32**. Addition of an alkylzinc reagent generated in situ from benzyl bromide **S29** to an iminium ion formed by reaction of piperazine **S27** and aldehyde **S30** gives **S31**. Removal of the *N-tert*-butyloxycarbonyl (Boc) group using a protic acid such as HCl in a solvent such as MeOH gives **S32**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula **S32.**

Scheme 8.



[0214] A synthetic approach to compounds of formula **S28** is depicted in Scheme **8**. Selective removal of the benzyl carbamate of **S26** via hydrogenation gives piperazine **S27**. Reductive amination under the action of sodium triacetoxyborohydride generates **S34**. Further manipulation may be accomplished by Suzuki coupling with a boronic acid ($X^1B(OH_2)$), $Pd(dppf)Cl_2$ catalyst, and potassium carbonate to give **S24**. Removal of the *N-tert*-butyloxycarbonyl (Boc) group upon reaction with HCl in EtOAc gives compounds of formula **S28**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula **S28.**

Scheme 9.



[0215] **Scheme 9** depicts an alternate application of the three-component coupling described in **Scheme 7.** Coupling of pyrrolidine **S35**, benzyl bromide **S29**, and formaldehyde provides compounds of formula **S36**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula **S37**.

Scheme 10.



[0216] **Scheme 10** depicts an alternative approach to pyrrolidine analogs of formula **S48**. $NaBH_4$ reduction of β-keto ester **S40** gives diol **S41**, which can undergo S_NAr reaction with fluorobenzene **S42** upon heating in DMF with potassium carbonate as base. Oxidation to ketone **S44** may be achieved with the Dess-Martin periodinane. Reaction with an alkyl metal reagent such as methylmagnesium bromide gives tertiary alcohol **S45**, as a mixture of isomers. Removal of the *N-tert*-butyloxycarbonyl (Boc) group with a protic acid such as TFA, followed by reductive amination with aldehyde **S6**, gives pyrrolidine **S47**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula **S48.**

Scheme 11.



[0217] **Scheme 11** depicts a route to analogs bearing substituted piperazine cores. Reductive amination of piperazine **S49** and aldehyde **S6** with 2-methyl pyridine borane complex gives **S50**. Reduction of the carboxylic acid **S50** with borane-dimethylsulfide gives alcohol **S51**, which may undergo S_NAr reaction with fluorobenzene **S42** to give **S52**. Removal of the *N-tert*-butyloxycarbonyl (Boc) group with a protic acid such as HCl in a solvent such as MeOH gives piperazine **S53**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of formula **S54.**

Scheme 12.



[0218] **Scheme 11** depicts an approach to compounds of formula **S57**. Amide bond formation between an amine such as pyrrolidine **S55** and carboxylic acid **S6** using EDC and HOBt with a tertiary amine base such as DIEA to provide **S56**. Amide reduction can be achieved upon treatment with lithium aluminum hydride to give compounds of formula **S57**. Chiral preparative SFC or HPLC separation may be utilized to provide two or more single stereoisomers of compounds derived from formula **S57.**

General Procedure for Intermediate A



Step 1: *N*-(4-methoxyphenyl)-*N*-methylmethanesulfonamide



[0219] To a solution of 4-methoxy-*N*-methyl-aniline (**G1**, 7.00 g, 51.0 mmol) in DCM (60 mL) was added TEA (14.2 mL, 102 mmol). After cooling the reaction to 0 °C, MsCl (5.13 mL, 66.3 mmol) was added dropwise. The mixture was stirred at room temperature for 1 h. The reaction mixture was cooled to 0 °C and quenched by the addition of water (40 mL). The biphasic mixture was extracted with DCM (60 mL x 2). The combined organic layers were washed with brine (40 mL), dried over Na_2SO_4, filtered and concentrated in vacuo to give *N*-(4-methoxyphenyl)-*N*-methylmethanesulfonamide (**G2**), which was used in the next step without further purification. MS = 216.1 $[M+H]^+$.

Step 2: *N*-(4-hydroxyphenyl)-*N*-methylmethanesulfonamide



[0220] To a –78 °C solution of *N*-(4-methoxyphenyl)-*N*-methylmethanesulfonamide (**G2**, 11.4 g, 53.0 mmol) in DCM (100 mL) was added BBr_3 (10.2 mL, 106 mmol) dropwise. The mixture was warmed to 0 °C and stirred for 2 h. The reaction mixture was quenched by the dropwise addition of water (70 mL), and the mixture was stirred at room temperature for 20 min. Then the mixture was extracted with DCM (100 mL x 3). The combined organic layers were washed with brine (80 mL), dried over Na_2SO_4, filtered and concentrated under in vacuo to give *N*-(4-hydroxyphenyl)-*N*-methyl-methanesulfonamide (**G3**). MS = 202.2 $[M+H]^+$.

Step 3: (*S*)-*N*-methyl-*N*-(4-(oxiran-2-ylmethoxy)phenyl)methanesulfonamide (Intermediate A)



[0221] To a solution of *N*-(4-hydroxyphenyl)-*N*-methyl-methanesulfonamide (**G3**, 4.00 g, 19.9 mmol) and (*R*)-2-(chloromethyl)oxirane (**G4**, 3.12 mL, 39.8 mmol) in water (10 mL) and THF (20 mL) was added TBAB (897 mg, 2.78 mmol). Next, a solution of NaOH (1.19 g, 29.8 mmol) in water (10 mL) was added dropwise. The mixture was stirred at room temperature for 12 h. The reaction mixture was diluted by the dropwise addition of water (20 mL), and then extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (15 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 40 g cartridge, 0–55% EtOAc in petroleum ether). The resulting residue was further purified by re-crystallization (50 mL of 1:10 EtOAc in petroleum ether) to give (*S*)-*N*-methyl-*N*-(4-(oxiran-2-ylmethoxy)phenyl)methanesulfonamide (**Intermediate A**). MS = 280.0 $[M+Na]^+$.

[0222] The following intermediates in Table 2 were prepared according to procedures similar to those described for **Intermediate A** using the appropriate starting materials.

Table 2

Intermediate	Structure	IUPAC Name	Exact Mass $[M+H]^+$
B		(*R*)-*N*-methyl-*N*-(4-(oxiran-2-ylmethoxy)phenyl)methane sulfonamide	Calc'd 280.1 Found 280.0 $[M+Na]^+$
C		(*S*)-2-((4-(methylsulfonyl)phenoxy) methyl)oxirane	Calc'd 229.1 Found 229.0
D		(*R*)-2-((4-(methylsulfonyl)phenoxy) methyl)oxirane	Calc'd 229.1 Found 229.2
E		*N*-methyl-*N*-(4-((2-methyloxiran-2-	Calc'd 193.1 Found 193.1

		yl)methoxy)phenyl)methanesulfonamide	[M–CH_3O_2S+H]$^+$
F		*N*-methyl-*N*-(4-((oxiran-2-ylmethyl)amino)phenyl)methanesulfonamide	Calc'd 279.1 Found 279.0 [M+Na]$^+$

General Procedure for Intermediate G



Step 1: (*tert*-butyl (*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate



[0223] To a solution of *tert*-butyl (*R*)-3-(hydroxymethyl)piperidine-1-carboxylate (**G6**, 1.00 g, 4.64 mmol) and 4-methylsulfonylphenol (**G5**, 800 mg, 4.64 mmol) in THF (20 mL) was added PPh_3 (2.44 g, 9.29 mmol). The mixture was cooled to 0 °C and DIAD (1.88 g, 9.29 mmol, 1.81 mL, 2.00 eq) was added dropwise. After stirring at room temperature for 12 h, the reaction mixture was concentrated in vacuo. The residue was purified by normal phase silica gel chromatography (Biotage 12 g cartridge, 1–25% EtOAc in petroleum ether) to give (*tert*-butyl (*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate (**G7**). MS = 387.2 [M+NH_4]$^+$.

Step 2: (*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine



[0224] To a solution of (*tert*-butyl (*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate (**7**, 780 mg, 2.11 mmol, 1.00 eq) in EtOAc (5 mL) was added HCl/EtOAc (4 M, 10 mL). The mixture was stirred at room temperature for 2 h. The suspension was triturated with MTBE (100 mL) and the resulting solid was isolated through filtration to give (*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (Intermediate **G**) which was used in the next step without further purification. MS = 270.1 $[M+H]^+$.

[0225] The following intermediate in Table 3 was prepared according to procedures similar to those described for **Intermediate G** using the appropriate starting materials.

Table 3

Intermediate	Structure	IUPAC Name	Exact Mass $[M+H]^+$
H		(*S*)-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine	Calc'd 270.1 Found 270.1

General Procedure for Intermediate I



Step 1: 3-bromo-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile



[0226] To a solution of 3-bromo-2-methyl-benzonitrile (**G8**, 5.00 g, 25.5 mmol) and 4,4,5,5-tetramethyl-1,3,2-dioxaborolane (32.6 g, 255 mmol) in THF (80 mL) under N_2 was added 4-*tert*-butyl-2-(4-*tert*-butyl-2-pyridyl)pyridine (685 mg, 2.55 mmol) and $[Ir(cod)(OMe)]_2$ (845 mg, 1.28 mmol). Then the mixture was stirred at 80 °C for 8 h under N_2. The reaction mixture was diluted with H_2O (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (ISCO 80 g cartridge, 0–20% EtOAc:Hexane) to give 3-bromo-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (**G9**). ^1H NMR (400 MHz, $CDCl_3$): δ 8.15 (s, 1H), 7.98 (s, 1H), 2.65 (s, 3H), 1.35 (s, 12H).

Step 2: 3-bromo-5-chloro-2-methylbenzonitrile



[0227] To solution of 3-bromo-2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile (**G9**, 3.10 g, 9.63 mmol) in MeOH (30 mL) and H_2O (10 mL) was added $CuCl_2$ (3.88 g, 28.9 mmol) at room temperature, then the mixture was stirred at 90 °C for 16 h. After cooling to room temperature, the reaction mixture was diluted with H_2O (50 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–5% EtOAc:Hexane) to give 3-bromo-5-chloro-2-methyl-benzonitrile (**G10**). ^1H NMR (400 MHz, $CDCl_3$): δ 7.78 (s, 1H), 7.57 (s, 1H), 2.61 (s, 3H).

Step 3: (*E*)-5-chloro-3-(2-ethoxyvinyl)-2-methylbenzonitrile



[0228] To a solution of 3-bromo-5-chloro-2-methyl-benzonitrile (**G10**, 300 mg, 1.30 mmol) and 2-[(*E*)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (296 mg, 1.50 mmol) in 1,4-dioxane (5 mL) under N_2 were added K_2CO_3 (360 mg, 2.60 mmol) and $Pd(dppf)Cl_2$ (95.2 mg, 130 μmol). Then the mixture was stirred at 80 °C for 16 h. The reaction mixture was allowed to cool to room temperature, diluted with H_2O (10 mL), and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4 g cartridge, 0–5% EtOAc:Hexane) to give 5-chloro-3-[(*E*)-2-ethoxyvinyl]-2-methyl-benzonitrile (**G11**). MS = 222.1 $[M+H]^+$.

Step 4: 5-chloro-2-methyl-3-(2-oxoethyl)benzonitrile (Intermediate I)



[0229] To a solution of 5-chloro-3-[(*E*)-2-ethoxyvinyl]-2-methyl-benzonitrile (**G11**, 1.50 g, 6.77 mmol) in THF (12 mL) was added aqueous HCl (4 M, 12 mL), and then the mixture was stirred at 50 °C for 5 h. The reaction mixture was diluted with H_2O (30 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–50% EtOAc:Hexane) to give 5-chloro-2-methyl-3-(2-oxoethyl)benzonitrile (**Intermediate I**). MS = 194.0 $[M+H]^+$.

General Procedure for Intermediate J



Step 1: 4-((2-(methylsulfonyl)ethyl)thio)phenol



[0230] To a solution of 4-sulfanylphenol (**G12**, 4.75 g, 37.7 mmol) and 1-methylsulfonylethylene (4 g, 37.7 mmol) in DMF (40 mL) was added K_2CO_3 (7.81 g, 56.5 mmol). The mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with H_2O (100 mL) and then extracted with EtOAc (100 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 40 g cartridge, 0–40% EtOAc:Hexane) to give 4-((2-(methylsulfonyl) ethyl) thio) phenol (**G13**). MS = 231.1 $[M–H]^-$.

Step 2: 4-((2-(methylsulfonyl)ethyl)sulfonyl)phenol (Intermediate J)



[0231] To a solution of 4-(2-methylsulfonylethylsulfanyl) phenol (**G13**, 3.00 g, 12.9 mmol) in THF (40 mL) at room temperature was added a mixture of $NaIO_4$ (5.50 g, 25.8 mmol) in H_2O (10 mL). The mixture was then stirred at 40 °C for 16 h. The reaction mixture was diluted with saturated aqueous Na_2SO_3 (20 mL), extracted with EtOAc (20 mL x 3), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 40 g cartridge, 0–100% EtOAc:Hexane) to give 4-(2-methylsulfonylethylsulfonyl) phenol (**Intermediate J**). MS = 263.1 $[M–H]^-$.

General Procedure for Intermediate K



Step 1: 3-(oxiran-2-yl)benzonitrile (Intermediate K)



[0232] To a suspension of NaH (73 mg, 1.83 mmol, 60% by weight in mineral oil) in THF (5 mL) was added a solution of trimethylsulfonium iodide (374 mg, 1.83 mmol) in DMSO (3 mL) under N_2. After 10 min, a solution of 3-formylbenzonitrile (**G14**, 200 mg, 1.53 mmol) in THF (2 mL) was slowly added. The reaction mixture was degassed and purged with N_2 for 3 times, and then the mixture was stirred at room temperature for 12 h under N_2. The reaction mixture was quenched by addition of H_2O (10 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL x 3), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 4 g cartridge, 0–50% EtOAc:Hexane) to give 3-(oxiran-2-yl)benzonitrile (**Intermediate K**). MS = 146.1 $[M+H]^+$.

General Procedure for Intermediate M



Step 1: 4-((2-methoxyethyl)thio)phenol



[0233] A mixture of 4-sulfanylphenol (**G12**, 1 g, 7.93 mmol,), 1-bromo-2-methoxy-ethane (1.10 g, 7.93 mmol) and Cs_2CO_3 (2.58 g, 7.93 mmol) in DMF (12 mL) was stirred at

60°C for 3 h. The reaction mixture was poured into ice water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 20 g cartridge, 0–20% EtOAc:Hexane) to give 4-(2-methoxyethylsulfanyl)phenol (**G18**). MS = 183.1 $[M–H]^-$.

Step 2: 4-((2-methoxyethyl)sulfonyl)phenol (Intermediate M)



[0234] A mixture of 4-(2-methoxyethylsulfanyl)phenol (**G18**, 700 mg, 3.80 mmol) and $NaIO_4$ (2.44 g, 11.4 mmol) in THF (6 mL) and H_2O (6 mL) was stirred at 70 °C for 16 h. The mixture was filtered, quenched with saturated aqueous $Na_2S_2O_3$ (15 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (40 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 20 g cartridge, 0–70% EtOAc:Hexane) to give 4-(2-methoxyethylsulfonyl)phenol (**Intermediate M**). MS = 217.1 $[M+H]^+$.

[0235] The following intermediate in Table 4 was prepared according to procedures similar to those described for **Intermediate M** using the appropriate starting materials.

Table 4

Intermediate	Structure	IUPAC Name	Exact Mass $[M–H]^-$
N		4-(2-hydroxy ethylsulfonyl)phenol	Calc'd 201.1 Found 201.1

General Procedure for Intermediate O and Intermediate P



Step 1: *tert*-butyl 3-((4-hydroxyphenyl)thio)azetidine-1-carboxylate



[0236] To a solution of *tert*-butyl 3-bromoazetidine-1-carboxylate (1.87 g, 7.93 mmol) in DMF (30 mL) at room temperature were added Cs_2CO_3 (5.16 g, 15.85 mmol) and 4-sulfanylphenol (**G12**, 1.00 g, 7.93 mmol), and the resulting mixture was stirred at 90 °C for 16 h. The reaction mixture was poured into water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0-100% EtOAc:hexane) to give *tert*-butyl 3-(4-hydroxyphenyl)sulfanylazetidine-1-carboxylate (**G19**). MS = 282.1 $[M+H]^+$.

Step 2: *tert*-butyl 3-((4-hydroxyphenyl)sulfonyl)azetidine-1-carboxylate (Intermediate O)



[0237] To a solution of *tert*-butyl 3-(4-hydroxyphenyl)sulfanylazetidine-1-carboxylate (**G19**, 50 mg, 178 µmol) in DCM (2 mL) at 0 °C was added m-CPBA (46 mg, 267 µmol, 77% purity) at 0 °C. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched by addition saturated aqueous Na_2SO_3 (5 mL), and then extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (5 mL x 3), dried over

Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by by flash silica gel chromatography (Biotage 4 g cartridge, 0–50% EtOAc:Hexane) to give *tert*-butyl 3-(4-hydroxyphenyl)sulfonylazetidine-1-carboxylate (**Intermediate O**). MS = 258.0 $[M–C_4H_8+H]^+$.

Step 3: 4-(azetidin-3-ylsulfonyl)phenol



[0238] To a solution of *tert*-butyl 3-(4-hydroxyphenyl)sulfonylazetidine-1-carboxylate (**Intermediate O**, 0.5 g, 1.91 mmol) in MeOH (3 mL) was added HCl/MeOH (4 M, 3 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then concentrated under reduced pressure to give 4-(azetidin-3-ylsulfonyl)phenol HCl salt (**G20**), which was taken to the next step without further purification. MS = 214.1 $[M+H]^+$.

Step 4: 4-((1-methylazetidin-3-yl)sulfonyl)phenol (Intermediate P)



[0239] To a solution of 4-(187zetidine-3-ylsulfonyl)phenol (**G20**, 400 mg, 1.60 mmol, HCl salt) in MeOH (5 mL) and AcOH (0.05 mL) were added HCHO (120 mg, 4.00 mmol) and borane-2-methylpyridine complex (205 mg, 1.90 mmol). The mixture was stirred at 40 °C for 16 h. The reaction mixture was quenched by addition of saturated aqueous $NaHCO_3$ (10 mL), and then extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0–100% EtOAc:Hexane) to give 4-(1-methylazetidin-3-yl)sulfonylphenol (**Intermediate P**). MS = 228.0 $[M+H]^+$.

General Procedure for Intermediate Q



Step 1: methyl 5-chloro-2-methoxybenzoate



[0240] To a solution of methyl 5-chloro-2-hydroxy-benzoate (**G21**, 2.00 g, 10.7 mmol) in DMF (20 mL) were added K_2CO_3 (2.96 g, 21.4 mmol) and CH_3I (7.61 g, 53.6 mmol). The mixture was stirred at 40 °C for 16 h. The reaction mixture was then cooled to room temperature, poured into water (100 mL), and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (80 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give the residue, which was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–10% EtOAc:Hexane) to give methyl 5-chloro-2-methoxy-benzoate (**G22**). MS = 201.0 $[M+H]^+$.

Step 2: (5-chloro-2-methoxyphenyl)methanol



[0241] To a solution of methyl 5-chloro-2-methoxy-benzoate (**G22**, 1.50 g, 7.48 mmol) in THF (15 mL) was added $LiBH_4$ (2 M in THF, 7.5 mL, 15.0 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with water

(20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na_2SO_4, filtered and concentrated to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–50% EtOAc:Hexane) to give (5-chloro-2-methoxy-phenyl)methanol (**G23**). ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.30 (d, J = 2.8 Hz, 1H), 7.25 – 7.21 (m, 1H), 6.81 (d, J = 8.8 Hz, 1H), 4.66 (s, 2H), 3.86 (s, 3H).

Step 3: 2-(bromomethyl)-4-chloro-1-methoxybenzene (Intermediate Q)



[0242] To a solution of (5-chloro-2-methoxy-phenyl)methanol (**G23**, 1.10 g, 6.37 mmol) in DCM (50 mL) at 0 °C was added PBr_3 (1.73 g, 6.37 mmol). The reaction mixture was then stirred at room temperature for 16 h. The mixture was concentrated, diluted with water (50 mL) and neutralized by addition of saturated aqueous $NaHCO_3$ to pH=7-8, then extracted with DCM (50 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated to give 2-(bromomethyl)-4-chloro-1-methoxy-benzene (**Intermediate Q**). ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.27 (d, J = 2.8 Hz, 1H), 7.21 (dd, J = 5.6 Hz, 2.8 Hz, 1H), 6.77 (d, J = 8.8 Hz, 1H), 4.45 (s, 2H), 3.85 (s, 3H).

General Procedure for Intermediate R



Step 1: methyl 5-chloro-2-(difluoromethoxy)benzoate



[0243] To a mixture of methyl 5-chloro-2-hydroxy-benzoate (**G24**, 1.50 g, 8.04 mmol,) in MeCN (75 mL) and H_2O (37.5 mL) were added KOH (2.71 g, 48.2 mmol) and [bromo(difluoro)methyl]-trimethylsilane (3.27 g, 16.1 mmol) at 0 °C. The mixture was then stirred at room temperature for 16 h. The reaction mixture was poured into water (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (25 mL), dried over Na_2SO_4, filtered and concentrated under reduced presure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–20% EtOAc:Hexane) to give methyl 5-chloro-2-(difluoromethoxy)benzoate (**G25**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.86 (d, J = 2.8 Hz, 1H), 7.75 (dd, J = 8.8 Hz, 2.8 Hz, 1H), 7.37 (d, J = 9.2 Hz, 1H), 7.20 (t, J = 73.6 Hz, 1H), 7.21 – 7.03 (m, 1H), 3.85 (s, 3H).

Step 2: (5-chloro-2-(difluoromethoxy)phenyl)methanol



[0244] To a mixture of methyl 5-chloro-2-(difluoromethoxy)benzoate (**G25**, 200 mg, 845 µmol) in THF (5 mL) at 0 °C was added $LiBH_4$ (4 M in THF, 634 µL, 2.54 mmol) dropwise under N_2, the mixture was then stirred at room temperature for 16 h under N_2. The reaction mixture was poured into saturated aqueous NH_4Cl (5 mL), then extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure to give [5-chloro-2-(difluoromethoxy)phenyl]methanol (**G26**), which was used without further purification. MS = 190.9 **[**M–H_2O+H]$^+$.

Step 3: 2-(bromomethyl)-4-chloro-1-(difluoromethoxy) benzene (Intermediate R)



[0245] To a solution of [5-chloro-2-(difluoromethoxy)phenyl]methanol (**G26**, 170 mg, 815 µmol) in DCM (3 mL) was added PBr_3 (221 mg, 815 µmol) at 0 °C. The mixture was stirred at room temperature for 1 h. The reaction mixture was then poured into water (15 mL) and extracted with DCM (10 mL x 3). The combined organic layers were washed with brine (5 mL), dried over anhydrous Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4g cartridge, 0–10% EtOAc:Hexane) to give 2-(bromomethyl)-4-chloro-1-(difluoromethoxy)benzene (**Intermediate R**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.69 (d, J = 2.4 Hz, 1H), 7.50 (dd, J = 8.0 Hz, 2.8 Hz, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.31 (t, J = 73.2 Hz, 1H), 4.63 (s, 2H).

General Procedure for Intermediate S



G27 step 1 Intermediate S

Step 1: 2-(3, 5-dichlorophenyl) acetaldehyde (Intermediate S)



[0246] To a mixture of 2-(3,5-dichlorophenyl)ethanol (**G27**, 1.00 g, 5.23 mmol) in DCM (10 mL) was added DMP (2.66 g, 6.28 mmol). The mixture was then stirred at room temperature for 3 h under N_2. The reaction mixture was diluted with H_2O (5 mL) and extracted with EtOAc (8 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0–20% EtOAc:Hexane) to

give 2-(3, 5-dichlorophenyl) acetaldehyde (**Intermediate S**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 9.68 (s, 1H), 7.53 (s, 1H), 7.47 (s, 1H), 7.46 (s, 1H), 3.86 (s, 2H).

[0247] The following intermediate in Table 5 was prepared according to procedures similar to those described for **Intermediate S** using the appropriate starting materials.

Table 5

Intermediate	Structure	IUPAC Name	^{1}H NMR (400 MHz, DMSO-d_6):
T		2-(2-bromo-5-chloro-phenyl)acetaldehyde	δ 9.70 (s, 1H), 7.66 (d, *J* = 8.8 Hz, 1H), 7.51 (d, *J* = 2.4 Hz, 1H), 7.32 (d, *J* = 8.4 Hz, 2.4 Hz, 1H), 3.98 (s, 2H).
U		3-(2-oxoethyl)benzonitrile	δ 9.80 (t, *J* = 2.0 Hz, 1H), 7.63 – 7.52 (m, 4H), 3.92 – 3.88 (m, 2H).

General Procedure for Intermediate V



Step 1: (E)-3-chloro-5-(2-ethoxyvinyl) benzonitrile



[0248] To a solution of 2-[(E)-2-ethoxyvinyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (503 mg, 2.54 mmol) and 3-bromo-5-chloro-benzonitrile (**G28**, 500 mg, 2.31 mmol) in dioxane (10 mL) were added K_2CO_3 (958 mg, 6.93 mmol) and $Pd(dppf)Cl_2$ (169 mg,

231 µmol) under N_2. The reaction mixture was then stirred at 100 °C for 16 h under N_2. The reaction mixture was diluted with H_2O (10 mL) and extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give (E)-3-chloro-5-(2-ethoxyvinyl)benzonitrile (**G29**), which was taken to the next step without further purification.^{1}H NMR (400 MHz, $CDCl_3$): δ 7.40 (s, 1H), 7.36 (s, 1H), 7.35 (s, 1H), 7.05 (d, *J* = 13.2 Hz, 1H), 5.73 (d, *J* = 12.8 Hz, 1H), 3.94 (q, *J* = 7.2 Hz, 2H), 1.37 (t, *J* = 7.2 Hz, 3H).

Step 2: 3-chloro-5-(2-oxoethyl) benzonitrile (Intermediate V)



[0249] To a solution of (E)-3-chloro-5-(2-ethoxyvinyl)benzonitrile (**G29**, 750 mg, 3.61 mmol) in THF (4 mL) was added HCl (3 M in H_2O, 4 mL). The reaction mixture was then stirred at 50 °C for 16 h. The reaction mixture was diluted with H_2O (10 mL) and extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 4 g cartridge, 0–30% EtOAc:Hexane) to give 3-chloro-5-(2-oxoethyl)benzonitrile (**Intermediate V**). ^{1}H NMR (400 MHz, $CDCl_3$): δ 9.81 (s, 1H), 7.60 (s, 1H), 7.46 (s, 1H), 7.42 (s, 1H), 3.80 (s, 2H).

[0250] The following intermediate in Table 6 was prepared according to procedures similar to those described for **Intermediate V** using the appropriate starting materials.

Table 6

Intermediate	Structure	IUPAC Name	^{1}H NMR (400 MHz, $CDCl_3$):
W		5-(2-oxoethyl) isophthalonitrile	δ 9.86 (s, 1H), 7.90 (s, 1H), 7.81 (s, 1H), 7.74 (s, 1H), 3.49 (s, 2H).

General Procedure for Intermediate X



Step 1: 3-chloro-5-vinylbenzonitrile



[0251] To a solution of 3-bromo-5-chloro-benzonitrile (**G28**, 2.50 g, 11.5 mmol), potassium vinyltrifluoroborate (3.09 g, 23.1 mmol) in dioxane (25 mL) and H_2O (2.5 mL) were added K_2CO_3 (3.19 g, 23.1 mmol) and $Pd(dppf)Cl_2$ (845 mg, 1.15 mmol). The mixture was purged with N_2 three times and then stirred at 80 °C for 16 h. The reaction mixture was poured into water (50 mL) and extracted with EtOAc (40 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (BIOTAGE 20 g cartridge, 0–10% EtOAc:Hexane) to give 3-chloro-5-vinyl-benzonitrile (**G30**). ^1H NMR (400 MHz, $CDCl_3$): δ 7.60 (s, 1H), 7.56 (s, 1H), 7.52 (s, 1H), 6.69 – 6.62 (m, 1H), 5.85 (d, J = 17.6 Hz, 1H), 5.47 (d, J = 10.8 Hz, 1H).

Step 2: 3-chloro-5-(oxiran-2-yl) benzonitrile (Intermediate X)



[0252] To a solution of 3-chloro-5-vinyl-benzonitrile (**G30**, 500 mg, 3.06 mmol) in DCM (5 mL) was added *m*CPBA (931 mg, 4.58 mmol, 85% purity) at 0 °C, the reaction was stirred at room temperature for 16 h. The reaction mixture was then poured into saturated aqueous Na_2SO_3 (20 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (120 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12

g cartridge, 0–100% EtOAc:Hexane) to give 3-chloro-5-(oxiran-2-yl)benzonitrile (**Intermediate X**).The following intermediate in Table 7 was prepared according to procedures similar to those described for **Intermediate X** using the appropriate starting materials.

Table 7

Intermediate	Structure	IUPAC Name	^{1}H NMR (400 MHz, $CDCl_3$):
Y		5-(oxiran-2-yl) benzene-1, 3-dicarbonitrile	δ 7.69 (s, 1H), 7.62 – 7.61 (m, 2H), 3.77 – 3.75 (m, 1H), 3.07 – 3.05 (m, 1H), 2.58 – 2.56 (m, 1H).

General Procedure for Intermediate Z



G31 step 1 Intermediate Z

Step 1: 3-(bromomethyl)-5-(trifluoromethyl) benzonitrile (Intermediate Z)



[0253] A mixture of 3-methyl-5-(trifluoromethyl) benzonitrile (**G31**, 750 mg, 4.05 mmol), NBS (865 mg, 4.86 mmol) and AIBN (67 mg, 405 µmol) in DCE (7.5 mL) was stirred at 90 °C for 6 h. The mixture was then diluted with DCM (20 mL) and washed with water (20 mL). The organic layer was concentrated under reduced presure. The residue was purified twice by flash silica gel chromatography (Biotage 12 g cartridge, 0–1% EtOAc:Hexane) to give 3-(bromomethyl)-5-(trifluoro methyl)benzonitrile (**Intermediate Z**). MS = 264.0/266.1 $[M+H]^+$.

General Procedure for Intermediate AA



Step 1: methyl 2-((4-hydroxyphenyl)thio)-2-methylpropanoate



[0254] To a mixture of 4-sulfanylphenol (**G12**, 2.00 g, 15.8 mmol) and methyl 2-bromo-2-methyl-propanoate (2.40 g, 13.3 mmol) in DMF (30 mL) was added Cs_2CO_3 (7.20 g, 22.1 mmol). The mixture was then stirred at 80 °C for 16 h. The reaction mixture was diluted with saturated aqueous NH_4Cl (30 mL), extracted with EtOAc (30 mL x 3), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–100% EtOAc:Hexane) to give methyl 2-(4-hydroxyphenyl) sulfanyl-2-methyl-propanoate (**G32**). MS = 225.2 $[M-H]^-$.

Step 2: methyl 2-((4-hydroxyphenyl) sulfonyl)-2-methylpropanoate



[0255] To a solution of methyl 2-(4-hydroxyphenyl) sulfanyl-2-methyl-propanoate (**G32**, 2.30 g, 10.2 mmol) in THF (30 mL) was added a solution of $NaIO_4$ (6.52 g, 30.5 mmol) in H_2O (6 mL). The mixture was stirred at 50 °C for 16 h. The reaction mixture was quenched with saturated aqueous Na_2SO_3 (15 mL), extracted with EtOAc (10 mL x 3), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–30% EtOAc:Hexane) to give methyl 2-(4-hydroxyphenyl) sulfonyl-2-methyl-propanoate (**G33**). MS = 257.1 $[M-H]^-$.

Step 3: 4-((1-hydroxy-2-methylpropan-2-yl) sulfonyl)phenol



[0256] To a solution of methyl 2-(4-hydroxyphenyl) sulfonyl-2-methyl-propanoate (**G33**, 2.30 g, 8.90 mmol) in THF (30 mL) at 0 °C was added $LiAlH_4$ (507 mg, 13.4 mmol). The mixture was stirred at room temperature for 2 h. The residue was diluted with aqueous NaOH (5 M, 2 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4 g cartridge, 0–100% EtOAc:Hexane to give 4-(2-hydroxy-1, 1-dimethyl-ethyl) sulfonylphenol (**Intermediate AA**). MS = 229.0 $[M–H]^-$.

General Procedure for Intermediate AB



Step 1: *tert*-butyl 3-((4-hydroxyphenyl) thio) azetidine-1-carboxylate



[0257] To a solution of 4-sulfanylphenol (**G12**, 10.0 g, 79.2 mmol) in DMF (100 mL) were added K_2CO_3 (10.9 g, 79.2 mmol) and *tert*-butyl 3-iodoazetidine-1-carboxylate (22.4 g, 79.2 mmol). The mixture was then stirred at 40 °C for 16 h. The reaction mixture was diluted with water (200 mL) and extracted with EtOAc (100 mL x 3). The combined organic layers were washed with H_2O (80 mL) and brine (80 mL), dried over (Na_2SO_4), filtered and concentrated under reduced pressure to give a residue. The crude product was triturated with MTBE (100 mL)

at room temperature for 5 h and filtered to give *tert*-butyl 3-(4-hydroxyphenyl)sulfanylazetidine-1-carboxylate (**G19**). MS = 226.1 $[M–C_4H_8+H]^+$.

Step 2: *tert*-butyl 3-((4-hydroxyphenyl) sulfonyl) azetidine-1-carboxylate



[0258] To a solution of *tert*-butyl 3-(4-hydroxyphenyl) sulfanylazetidine-1-carboxylate (**G19**, 6.50 g, 13.9 mmol) in THF (60 mL) and H_2O (20 mL) was added $NaIO_4$ (8.80 g, 41.6 mmol,). The mixture was stirred at 50 °C for 16 h. The reaction mixture was cooled to room temperature, quenched with saturated aqueous Na_2SO_3 (60 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 20 g cartridge, 0–100% EtOAc:Hexane) to give *tert*-butyl 3- (4- hydroxyphenyl) sulfonylazetidine-1-carboxylate (**Intermediate O**). MS = 312.2 $[M–H]^-$.

Step 3: 4-(azetidin-3-ylsulfonyl) phenol



[0259] To a solution of *tert*-butyl 3-(4-hydroxyphenyl) sulfonylazetidine-1-carboxylate (**Intermediate O**, 1.5 g, 4.79 mmol) in MeOH (4 mL) was added HCl/MeOH (4 M, 12 mL). The mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give 4-(azetidin-3-ylsulfonyl) phenol HCl salt (**G20**), which was used without further purification. MS = 214.1 $[M+H]^+$.

Step 4: allyl 3-((4-hydroxyphenyl) sulfonyl) azetidine-1-carboxylate (Intermediate AB)



[0260] To a solution of 4-(azetidin-3-ylsulfonyl)phenol (**G20**, 1.1 g, 4.41 mmol, HCl salt) in DCM (10 mL) were added TEA (1.11 g, 11.0 mmol, 1.53 mL) and allyl chloroformate (584 mg, 4.85 mmol) at 0 °C. The mixture was then stirred at room temperature for 3 h. The reaction mixture was diluted with H_2O (30 mL) and extracted with DCM (15 mL x 3). The combined organic layers were washed with brine (5 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–100% EtOAc:Hexane) to give allyl 3-(4-hydroxyphenyl)sulfonylazetidine-1-carboxylate (**Intermediate AB**). MS = 298.1 $[M+H]^+$.

General Procedure for Intermediate AC



G34 step 1 Intermediate AC

Step 1: 3-(bromomethyl)-5-chlorobenzonitrile (Intermediate AC)



[0261] To a solution of 3-chloro-5-(hydroxymethyl)benzonitrile (**G34**, 500 mg, 2.98 mmol) in DCM (10 mL) was added PBr_3 (807 mg, 2.98 mmol) at 0 °C. The reaction mixture was then stirred at room temperature for 10 h, then the reaction mixture was concentrated. The residue was diluted with water (10 mL) and neutralized by addition of saturated aqueous $NaHCO_3$ to pH = 7, then extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated to give 3-

(bromomethyl)-5-chloro-benzonitrile (**Intermediate AC**), which was taken to the next step without further purification. ^{1}H NMR (400 MHz, $CDCl_3$): δ 7.63 (s, 1H), 7.58 (s, 2H), 4.43 (s, 2H).

General Procedure for Intermediate AD



Step 1: 3-(methylsulfonyl)propyl methanesulfonate



[0262] To a solution of 3-methylsulfonylpropan-1-ol (**G35**, 500 mg, 3.62 mmol) in DCM (5 mL) at 0 °C were added Et_3N (732 mg, 7.24 mmol) and methylsulfonyl methanesulfonate (945 mg, 5.43 mmol). The mixture was stirred at 0 °C for 2 h. The reaction mixture was diluted with H_2O (20 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give crude 3-(methylsulfonyl)propyl methanesulfonate (**G36**), which was taken to the next step without further purification. ^{1}H NMR (400 MHz, DMSO-d_6): δ 4.30 (t, J = 6.4 Hz, 2H), 3.23 – 3.01 (m, 5H), 3.01 (s, 3H), 2.13 – 2.08 (m, 2H).

Step 2: 4-((3-(methylsulfonyl)propyl)thio)phenol



[0263] To a mixture of 3-(methylsulfonyl)propyl methanesulfonate (**G36**, 390 mg, 1.80 mmol) and 4-sulfanylphenol (**G12**, 318 mg, 2.52 mmol) in CH_3CN (5 mL) was added Cs_2CO_3 (705 mg, 2.16 mmol). The mixture was then stirred at room temperature for 2 h. The reaction mixture was then diluted with H_2O (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (40 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–50% EtOAc:Hexane) to give 4-(3-methylsulfonylpropylsulfanyl)phenol (**G37**). MS = 245.1 $[M–H]^-$.

Step 3: 4-((3-(methylsulfonyl)propyl)sulfonyl)phenol (Intermediate AD)



[0264] To a solution of 4-(3-methylsulfonylpropylsulfanyl)phenol (**G37**, 370 mg, 1.50 mmol) in THF (2 mL) and H_2O (2 mL) was added $NaIO_4$ (964 mg, 4.51 mmol) at 0 °C. The mixture was then stirred at 70 °C for 12 h. The reaction mixture was quenched by addition of saturated aqueous Na_2SO_3 (10 mL), and then diluted with H_2O (5 mL) and extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 12 g cartridge, 0–50% EtOAc:Hexane) to give 4-(3-methylsulfonylpropylsulfonyl)phenol (**Intermediate AD**). MS = 277.1 $[M–H]^-$.

General Procedure for Intermediate AE



G38 step 1 G39 step 2 Intermediate AE

Step 1: *tert*-butyl (3*S*,4*S*)-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate



[0265] To a solution of (3S,4S)-1-*tert*-butoxycarbonyl-4-methyl-pyrrolidine-3-carboxylic acid (**G38**, 5.00 g, 21.8 mmol) in THF (50 mL) was added BH_3 (10 M in Me_2S, 10.9 mL, 109 mmol) at 0 °C. Then the reaction was stirred at room temperature for 16 h. The reaction mixture was quenched by addition of MeOH (40 mL) and stirred 0.5 h. The mixture was then diluted with water (100 mL) and extracted with EtOAc (60 mL x 3). The combined organic layers were washed with brine (100 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated to give *tert*-butyl (3S,4S)-3-(hydroxymethyl)-4-methyl-pyrrolidine-1-carboxylate (**G39**). MS = 160.2 $[M–C_4H_8+H]^+$.

Step 2: *tert*-butyl (3*S*,4*S*)-3-methyl-4-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (Intermediate AE)



[0266] To a solution of *tert*-butyl (3*S*,4*S*)-3-(hydroxymethyl)-4-methyl-pyrrolidine-1-carboxylate (**G39**, 200 mg, 929 μmol) in DCM (3 mL) were added Et_3N (188 mg, 1.86 mmol) and methylsulfonyl methanesulfonate (161 mg, 929 μmol) at 0 °C. The mixture was stirred at room temperature for 2 h. The reaction mixture was then concentrated under reduced pressure. The residue was diluted with saturated aqueous NH_4Cl (5 mL), extracted with EtOAc (5 mL x 3), dried over $Na2_SO_4$, filtered and concentrated under reduced pressure to give *tert*-butyl (3*S*,4*S*)-3-methyl-4-(((methylsulfonyl)oxy)methyl)pyrrolidine-1-carboxylate (**Intermediate AE**). ^1H NMR (400 MHz, $CDCl_3$): δ 4.32 – 4.28 (m, 1H), 4.16 – 4.14 (m, 1H), 3.65 – 3.61 (m, 3H), 3.20 – 3.18 (m, 1H), 3.03 (s, 3H), 2.97 – 2.95 (m, 1H), 2.33 – 2.20 (m, 4H), 1.46 (s, 9H).

[0267] The following intermediate in Table 8 was prepared according to procedures similar to those described for **Intermediate AE** using the appropriate starting materials.

Table 8

Intermediate	Structure	IUPAC Name	^{1}H NMR (400 MHz, DMSO-d_6):
AF		*tert*-butyl (2*R*,4*S*)-2-methyl-4-(methylsulfonyloxymethyl) pyrrolidine-1-carboxylate	δ 4.24 – 4.14 (m, 2H), 3.73 – 3.71 (m, 1H), 3.63 – 3.58 (m, 1H), 3.18 (s, 3H), 2.96 – 2.92 (m, 1H), 2.25 – 2.23 (m, 1H), 2.21 – 2.18 (m, 1H), 1.39 (s, 9H), 1.32 – 1.27 (m, 1H), 1.86 (d, *J* = 3.2 Hz, 3H).

[0268] In the following Examples, the numbers in the column headed with "No." in each of Tables 9-25 refer to the corresponding compound numbers in Table 1.

Example 1

1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane

(Compound 1)

(*R*) or (*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane

(Compound 2)

(*S*) or (*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane

(Compound 3)



Step 1: *tert*-butyl 3-((4-(methylsulfonyl)phenoxy)methyl)azepane-1-carboxylate



[0269] To a mixture of *tert*-butyl-3-(hydroxymethyl)azepane-1-carboxylate (200 mg, 0.872 mmol), 4-(methylsulfonyl)phenol (195 mg, 1.13 mmol), and PPh_3 (297 mg, 1.13 mmol) in THF (5 mL) at 0 °C was added DIAD (509 µL, 2.62 mmol) dropwise. The mixture was stirred at room temperature for 12 h. The reaction mixture was cooled to 0 °C, quenched by the addition of water (20 mL), then extracted with EtOAc (25 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 10 g cartridge, 0–85% EtOAc in petroleum ether) to give *tert*-butyl 3-((4-(methylsulfonyl)phenoxy)methyl)azepane-1-carboxylate. MS = 384.2 $[M+H]^+$.

Step 2: 3-((4-(methylsulfonyl)phenoxy)methyl)azepane



[0270] To a solution of *tert*-butyl 3-((4-(methylsulfonyl)phenoxy)methyl)azepane-1-carboxylate (260 mg, 0.678 mmol) in EtOAc (2 mL) was added HCl/EtOAc (4 M, 2 mL), the mixture was stirred at room temperature for 1 h. The reaction mixture was concentrated in vacuo to give 3-((4-(methylsulfonyl)phenoxy)methyl)azepane (HCl salt), which was used in the next step without further purification. MS = 284.2 $[M+H]^+$.

Step 3: 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane (Compound 1)



[0271] A mixture of 3-((4-(methylsulfonyl)phenoxy)methyl)azepane (200 mg, 0.625 mmol, HCl salt), 2-(3-chlorophenyl)acetaldehyde (142 mg, 0.918 mmol) in MeOH (4 mL) was stirred at room temperature for 1 h, then $NaBH_3CN$ (66.5 mg, 1.06 mmol) was added. The resulting mixture was stirred at room temperature for 1 h. The reaction mixture was quenched by addition of water (1 mL) and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Waters Xbridge BEH C18 column, 45–80% MeCN/10 mM NH_4HCO_3 in water) to give 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane (Compound **1**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 8.8 Hz, 2H), 7.28 – 7.22 (m, 3H), 7.14 – 7.11 (m, 3H), 3.89 – 3.82 (m, 2H), 3.14 (s, 3H), 2.77 – 2.70 (m, 1H), 2.70 – 2.60 (m, 7H), 2.06 – 2.05 (m, 1H), 1.72 – 1.51 (m, 5H), 1.35 – 1.33 (m, 1H). MS = 422.3 $[M+H]^+$.

Step 4: (*R*) or (*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane (Compound 2); (*S*) or (*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane (Compound 3)



[0272] 1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)azepane (**Compound 1**, 200 mg, 0.475 mmol) was separated by preparative chiral SFC (Phenomenex-Cellulose-2, 55% (1:1 MeOH:MeCN) with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 2**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 8.8 Hz, 2H), 7.29 – 7.23 (m, 3H), 7.14 – 7.11 (m, 3H), 3.90 – 3.83 (m, 2H), 3.15 (s, 3H), 2.78 – 2.71 (m, 1H), 2.68 – 2.57 (m, 7H), 2.01 – 2.10 (m, 1H), 1.75 – 1.50 (m, 5H), 1.35 – 1.32 (m, 1H). MS = 422.3 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 3**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 8.8 Hz, 2H), 7.28 – 7.23 (m, 3H), 7.15 – 7.11 (m, 3H), 3.90 – 3.83 (m, 2H), 3.15 (s, 3H), 2.79 – 2.75 (m, 1H), 2.69 – 2.53 (m, 7H), 2.01 – 2.10 (m, 1H), 1.75 – 1.50 (m, 5H), 1.35 – 1.32 (m, 1H). MS = 422.3 $[M+H]^+$.

[0273] The following compounds in Table 9 were prepared according to procedures similar to those described for Example 1 using the appropriate starting materials.

Table 9

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$	Chiral Column	Chiral Elution Order
4		1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)p	Calc'd 424.1 Found 424.1	n/a	n/a

		henoxy)methyl)piperidin-3-ol			
5		(*R*) or (*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol	Calc'd 424.1 Found 424.2	Chiralpak AS-3	1st
6		(*S*) or (*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-3-ol	Calc'd 424.1 Found 424.2	Chiralpak AS-3	2nd
107		(3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine	Calc'd 500.1 Found 500.1	n/a	n/a
108		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(2-methanesulfonylethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 525.1 Found 525.2	n/a	n/a

109		*rac-trans*-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine	Calc'd 452.2 Found 452.1	n/a	n/a
110		(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine	Calc'd 452.2 Found 452.1	Chiralpak AD	1st
111		(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(2-methoxyethanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine	Calc'd 452.2 Found 452.1	Chiralpak AD	2nd
112		2-(4-{[(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethan-1-ol	Calc'd 438.2 Found 438.1	n/a	n/a

113		2-(4-{[(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-4-methylpyrrolidin-3-yl]methoxy}benzenesulfonyl)ethan-1-ol	Calc'd 438.2 Found 438.1	n/a	n/a

Example 2

***N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 7)**

(*S*) or (*R*) -*N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 8)

(*R*) or (*S*)-*N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 9)



Step 1: 3-((4-(*N*-methylmethylsulfonamido)phenoxy)methyl)piperidine-1- carboxylate



[0274] To a mixture of *tert*-butyl 3-(bromomethyl)piperidine-1-carboxylate (300 mg, 1.08 mmol) and *N*-(4-hydroxyphenyl)-*N*-methylmethanesulfonamide (260 mg, 1.29 mmol) in DMF (3 mL) was added K_2CO_3 (447 mg, 3.24 mmol). The mixture was stirred at 60 °C for 12 h. The reaction mixture was cooled to 0 °C and quenched by the addition of water (15 mL), then extracted with EtOAc (25 mL x 2). The combined organic layers were washed with brine (10 mL x 2), dried over Na_2SO_4, filtered and concentrated in vacuo. The residue was purified by normal phase silica gel chromatography (Biotage 10 g cartridge, 0–25% EtOAc in petroleum ether) to give *tert*-butyl 3-((4-(N-methylmethylsulfonamido)phenoxy)methyl)piperidine-1-carboxylate. MS = 343.2 $[M–C_4H_7+H]^+$.

Step 2: *N*-methyl-*N*-(4-(piperidin-3-ylmethoxy)phenyl)methanesulfonamide



[0275] To a solution of *tert*-butyl 3-((4-(*N*-methylmethylsulfonamido)phenoxy)methyl) piperidine-1-carboxylate (336 mg, 843.1 mmol) in EtOAc (3 mL) was added HCl/EtOAc (4 M, 3 mL). The mixture was stirred at room temperature for 3 h. The mixture was concentrated in vacuo to give *N*-methyl-*N*-(4-(piperidin-3-ylmethoxy)phenyl)methanesulfonamide (HCl salt), which was used in the next step without further purification. MS = 299.3 $[M+H]^+$.

Step 3: *N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide



[0276] A mixture of *N*-methyl-*N*-(4-(piperidin-3-ylmethoxy)phenyl)methanesulfonamide (181 mg, 0.543 mmol, HCl salt) and 2-(3-chlorophenyl)acetaldehyde (109 mg, 0.706 mmol) in MeOH (2 mL) was stirred at room temperature for 30 min, and then $NaBH_3CN$ (51.2 mg, 0.814 mmol) was added. The resulting mixture was stirred at room temperature for 3 h. The reaction mixture was quenched by the addition of water (0.5 mL) and purified by reverse phase preparative HPLC (Waters Xbridge BEH C18 column, 40–70% MeCN/10 mM NH_4HCO_3 in water) to give *N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (**Compound 7**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.32 – 7.19 (m, 6H), 6.94 (d, J = 8.8 Hz, 2H), 4.12 – 4.09 (m, 1H), 3.86 – 3.81 (m, 2H), 3.18 (m, 3H), 3.17 – 3.16 (m, 1H), 2.89 (s, 3H), 2.75 – 2.72 (m, 4H), 2.06 – 1.95 (m, 3H), 1.76 – 1.62 (m, 2H), 1.48 – 1.47 (m, 1H), 1.23 – 1.10 (m, 1H). MS = 437.2 $[M+H]^+$.

Step 4: (*S*) or (*R*)-*N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 8); (*R*) or (*S*)-*N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-N-methylmethanesulfonamide (Compound 9)



[0277] *N*-(4-((1-(3-chlorophenethyl)piperidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (**Compound 7**, 96 mg, 0.220 mmol) was separated by preparative chiral SFC (Chiralcel OD-3 column, 35% ethanol with 0.1% NH_4OH in CO_2). The first eluting

enantiomer of the title compound, **Compound 8**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.33 – 7.19 (m, 6H), 6.94 (d, J = 9.2 Hz, 2H), 3.86 – 3.81 (m, 2H), 3.18 (s, 3H), 2.90 (s, 4H), 2.77 – 2.67 (m, 4H), 2.09 – 1.92 (m, 4H), 1.75 – 1.61 (m, 2H), 1.52 – 1.42 (m, 1H), 1.12 –1.09 (m, 1H). MS = 437.2 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 9**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.33 – 7.17 (m, 6H), 6.95 (d, J = 9.2 Hz, 2H), 3.89 – 3.84 (m, 2H), 3.18 (s, 3H), 2.90 (s, 4H), 2.78 – 2.72 (m, 4H), 2.08 – 1.96 (m, 4H), 1.74 – 1.65 (m, 2H), 1.50 – 1.49 (m, 1H), 1.14 – 1.04 (m, 1H). MS = 437.2 $[M+H]^+$.

[0278] The following compounds in Table 10 were prepared according to procedures similar to those described for **Compounds 7-9** using the appropriate starting materials.

Table 10

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$	Chiral Column	Chiral Elution Order
10		*N*-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 453.2 Found 453.2	n/a	n/a
11		(*R*) or (*S*)-*N*-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 453.2 Found 453.2	Chiralpak AD-3	1st

12		(*S*) or (*R*)- *N*-(4-((4-(3-chlorophenethyl)-1,4-oxazepan-2-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 453.2 Found 453.2	Chiralpak AD-3	2nd

Example 3

(*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine (Compound 13)



Step 1: (*S*)-1-benzyl 4-*tert*-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate



[0279] To a mixture of (*S*)-*tert*-butyl 3-(hydroxymethyl)piperazine-1-carboxylate (1.00 g, 4.62 mmol) and $NaHCO_3$ (1.17 g, 13.9 mmol) in THF (5 mL) and water (5 mL) at 0 °C was added benzyl chloroformate (986 µL, 6.94 mmol). The mixture was stirred at room temperature for 4 h, then quenched by the addition of water (20 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 20 g cartridge, 7–50% EtOAc in petroleum ether) to give (*S*)-1-benzyl 4-*tert*-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate. MS = 373.2 $[M+Na]^+$.

Step 2: (*S*)-1-benzyl 4-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine -1,4-dicarboxylate



[0280] To a mixture of (*S*)-1-benzyl 4-*tert*-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate (200 mg, 0.571 mmol), 4-methylsulfonylphenol (98.0 mg, 0.571 mmol) and PPh_3 (225 mg, 0.856 mmol) in THF (4 mL) at 0 °C was added DIAD (222 µL, 1.14 mmol) dropwise. The mixture was stirred at 0 °C for 2 h, and then quenched by the addition of water (20 mL). The mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 4 g cartridge, 0–40% EtOAc in petroleum ether) to give (*S*)-1-benzyl 4-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1,4-dicarboxylate. MS = 527.3 $[M+Na]^+$.

Step 3: (*S*)-benzyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate



[0281] To a solution of (*S*)-1-benzyl 4-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1,4-dicarboxylate (600 mg, 1.12 mmol) in EtOAc (5 mL) was added HCl/EtOAc (4 M, 12 mL). The mixture was stirred at room temperature for 2 h, then concentrated in vacuo. The residue was diluted with water (20 mL) and washed with EtOAc (20 mL). The aqueous layer pH was adjusted to pH = 8–9 by addition of saturated aqueous $NaHCO_3$ and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (60 mL), dried over Na_2SO_4, filtered and concentrated in vacuo to give (*S*)-

benzyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate, which was used in the next step without further purification. MS = 405.2 $[M+H]^+$.

Step 4: (*S*)-benzyl 4-(3-chlorophenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl) piperazine-1-carboxylate



[0282] To a solution of (*S*)-benzyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (200 mg, 0.494 mmol) and 2-(3-chlorophenyl)acetaldehyde (76.0 mg, 0.494 mmol) in MeOH (2 mL) at 0 °C was added $NaBH_3CN$ (47.0 mg, 0.742 mmol) slowly. The mixture was stirred at room temperature for 1 h, then was quenched with water (0.05 mL) and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 12 g cartridge, 10–50% EtOAc in petroleum ether) to give (*S*)-benzyl 4-(3-chlorophenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate. MS = 543.2 $[M+H]^+$.

Step 5: (*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine



[0283] To a solution of (*S*)-benzyl 4-(3-chlorophenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (120 mg, 0.221 mmol) and NaI (331 mg, 2.21 mmol) in MeCN (3 mL) at 0 °C was added TMSCl (280 μL, 2.21 mmol) dropwise. The mixture was stirred at room temperature for 16 h, then was quenched with water (0.2 mL) and purified by preparative HPLC (Waters Xbridge BEH C18 column, 30–55% MeCN/10 mM NH_4HCO_3 in water) to give (*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine (**Compound 13**). ^1H NMR (400 MHz, DMSO-d_6,

24/25 H): δ 7.83 (d, *J* = 8.8 Hz, 2H), 7.32 – 7.15 (m, 6H), 4.01 – 3.94 (m, 2H), 3.32 (s, 3H), 3.15 – 3.14 (s, 1H), 2.88 – 2.85 (m, 2H), 2.76 – 2.66 (m, 4H), 2.47 – 2.44 (m, 2H), 2.07 – 2.00 (m, 1H), 1.89 (app t, *J* = 10.0 Hz, 1H). MS = 409.3 $[M+H]^+$.

[0284] The following compound in Table 11 was prepared according to procedures similar to those described for **Compound 13** using the appropriate starting materials.

Table 11

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$
14		(*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperazine	Calc'd 409.1 Found 409.1

Example 4

(*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (Compound 15)



[0285] To a solution (*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (**Intermediate G**, 56.9. mg, 0.186 mmol, HCl salt) in DCM (5 mL) was added TEA (155 µL, 1.11 mmol) and 2-(3-chlorophenyl)acetaldehyde (28.70 mg, 0.186 mmol). The mixture was stirred at room temperature for 30 min, then $NaBH(OAc)_3$ (157 mg, 0.743 mmol) was added. After stirring for 12 h, the reaction mixture was quenched with water (5 mL), and then extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (5 mL x 3), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Waters Xbridge BEH C18, 50–80% MeCN/10 mM NH_4HCO_3 in water) to give (*R*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine

(**Compound 15**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 6.8 Hz, 2H), 7.30 – 7.13 (m, 6H), 4.00 – 3.93 (m, 2H), 3.15 (s, 3H), 2.90 (d, J = 7.6 Hz, 1H), 2.77 – 2.71 (m, 3H), 2.53 – 2.52 (m, 2H), 2.05 – 1.97 (m, 3H), 1.66 – 1.64 (m, 1H), 1.64 – 1.63 (m, 1H), 1.49 – 1.41 (m, 1H), 1.17 – 1.12 (m, 1H). MS = 408.2 $[M+H]^+$.

[0286] The following compound in Table 12 was prepared according to procedures similar to those described for **Compound 15** using the appropriate starting materials.

Table 12

No.	Intermediate	Structure	IUPAC Name	Exact Mass $[M+H]^+$
16	**H**		(*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine	Calc'd 408.1 Found 408.1

Example 5

1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol (Compound 17)

(*R*) or (*S*)-1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol (Compound 18)

(*S*) or (*R*)-1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol (Compound 19)



Step 1: 1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol



[0287] To a solution of (*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (**Intermediate H,** 500 mg, 1.63 mmol, HCl salt) and 2-(3-chlorophenyl)oxirane (379 mg, 2.45 mmol) in EtOH (10 mL) was added TEA (455 µL, 3.27 mmol). The mixture was stirred at 80 °C for 8 h, then cooled to room temperature and quenched by the addition of water (1 mL), filtered, and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Phenomenex Gemini-NX, 25–55% MeCN/10 mM NH_4HCO_3 in water) to give 1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol (**Compound 17**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, *J* = 8.8 Hz, 2H), 7.38 (s, 1H), 7.30 – 7.27 (m, 3H), 7.16 – 7.13 (m, 2H), 5.14 (s, 1H), 4.70 – 4.69 (m, 1H), 3.99 – 3.92 (m, 2H), 3.15 (s, 3H), 2.95 – 2.85 (m, 1H), 2.75 – 2.74 (m, 1H), 2.46 – 2.45 (m, 1H), 2.41 – 2.35 (m, 1H), 2.17 – 1.98 (m, 3H), 1.72 – 1.60 (m, 2H), 1.50 – 1.45 (m, 1H), 1.15 – 1.12 (m, 1H). MS = 424.1 $[M+H]^+$.

Step 2: (*R*) or (*S*)-1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol (Compound 18); (*S*) or (*R*)-1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol (Compound 19)



[0288] 1-(3-chlorophenyl)-2-[(3*S*)-3-[(4-methylsulfonylphenoxy)methyl]-1-piperidyl]ethanol (**Compound 17**, 400 mg, 0.944 mmol) was separated by preparative chiral SFC (DAICEL CHIRALPAK AD-3, 55% ethanol with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 18**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, *J*

= 8.8 Hz, 2H), 7.38 (s, 1H), 7.30 – 7.25 (m, 3H), 7.16 – 7.13 (m, 2H), 5.14 (d, *J* = 3.6 Hz, 1H), 4.71 – 4.70 (m, 1H), 3.95 – 3.94 (m, 2H), 3.15 (s, 3H), 2.87 – 2.74 (m, 2H), 2.46 – 2.41 (m, 1H), 2.40 – 2.38 (m, 1H), 2.15 – 1.98 (m, 3H), 1.69 – 1.60 (m, 2H), 1.50 – 1.49 (m, 1H), 1.17 – 1.12 (m, 1H). MS = 424.1 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 19**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, *J* = 8.8 Hz, 2H), 7.39 – 7.13 (m, 6H), 5.15 (s, 1H), 4.71 (s, 1H), 3.99 – 3.90 (m, 2H), 3.15 (s, 3H), 2.96 – 2.94 (m, 1H), 2.77 – 2.75 (m, 1H), 2.46 – 2.41 (m, 1H), 2.40 – 2.38 (m, 1H), 2.14 – 2.04 (m, 3H), 1.73 – 1.61 (m, 2H), 1.49 – 1.46 (m, 1H), 1.14 – 1.12 (m, 1H). MS = 424.1 $[M+H]^+$.

[0289] The following compounds in Table 13 were prepared according to procedures similar to those described for **Compound 17** using the appropriate starting materials.

Table 13

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$	Chiral Column	Chiral Elution Order
20		1-(3-chlorophenyl)-2-((*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol	Calc'd 424.1 Found 424.3	n/a	n/a
21		(*R*) or (*S*)-1-(3-chlorophenyl)-2-((*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol	Calc'd 424.1 Found 424.2	Chiralpak AD-3	1st

22		(*S*) or (*R*)-1-(3-chlorophenyl)-2-((*R*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethanol	Calc'd 424.1 Found 424.2	Chiralpak AD-3	2nd
114		3-chloro-5-[(1*S* or 1*R*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 449.1 Found 449.1	prep-HPLC Phenomenex Gemini-NX 80	1st
115		3-chloro-5-[(1*R* or 1*S*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 449.1 Found 449.1	prep-HPLC Phenomenex Gemini-NX 80	2nd

116		3-[(1*R* or 1*S*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 415.2 Found 415.2	prep-HPLC Phenomenex Gemini-NX	2nd
117		3-[(1*S* or 1*R*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 415.2 Found 415.2	prep-HPLC Phenomenex Gemini-NX	1st
214		(1*R*) or (1*S*)-1-(3-chlorophenyl)-2-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethan-1-ol	Calc'd 424.1 Found 424.2	prep-HPLC Phenomenex Gemini-NX	1st
215		(1*S*) or (1*R*)-1-(3-chlorophenyl)-2-	Calc'd 424.1	prep-HPLC Phenome	2nd

		[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethan-1-ol	Found 424.2	nex Gemini-NX	
118		5-[(1*R* or 1*S*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile	Calc'd 440.2 Found 440.2	prep-HPLC Phenomenex C18	1st
119		5-[(1*S* or 1*R*)-1-hydroxy-2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile	Calc'd 440.2 Found 440.0	prep-HPLC Phenomenex C18	2nd
120		3-chloro-5-{1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonyl	Calc'd 449.1 Found 449.0	n/a	n/a

		phenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile			
121		3-chloro-5-[(1*S* or 1*R*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 449.1 Found 449.0	Phenomenex-Cellulose-2	1st
122		3-chloro-5-[(1*R* or 1*S*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 449.1 Found 449.0	Phenomenex-Cellulose-2	2nd
123		1-(3-chlorophenyl)-2-((3*S*,4*S*)-3-methyl-4-((4-	Calc'd 424.1 Found 424.1	n/a	n/a

		(methylsulfonyl) phenoxy)methyl) pyrrolidin-1-yl)ethan-1-ol			
124		(1*R* or 1*S*)-1-(3-chlorophenyl)-2-[(3*S*,4*S*)-3-[(4-methanesulfonyl phenoxy)methyl] -4-methylpyrrolidin -1-yl]ethan-1-ol	Calc'd 424.1 Found 424.0	Phenome nex-Cellulose-2	1st
125		(1*S* or 1*R*)-1-(3-chlorophenyl)-2-[(3*S*,4*S*)-3-[(4-methanesulfonyl phenoxy)methyl] -4-methylpyrrolidin -1-yl]ethan-1-ol	Calc'd 424.1 Found 424.0	Phenome nex-Cellulose-2	2nd
126		3-[1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonyl phenoxy)methyl] -4-methylpyrrolidin -1-yl]ethyl]benzonitrile	Calc'd 415.2 Found 415.0	n/a	n/a

127		3-[(1*S* or 1*R*)-1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 415.2 Found 415.0	Chiralpk AD	1st
128		3-[(1*R* or 1*S*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzonitrile	Calc'd 415.2 Found 415.0	Chiralpk AD	2nd
129		5-{1-hydroxy-2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile	Calc'd 440.2 Found 440.2	n/a	n/a

130		5-[(1*R* or 1*S*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile	Calc'd 440.2 Found 440.2	Chiralpk AD	1st
131		5-[(1*S* or 1*R*)-1-hydroxy-2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl]benzene-1,3-dicarbonitrile	Calc'd 440.2 Found 440.2	Chiralpk AD	2nd

Example 6

(*S*)-1-((*R*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine or (*S*)-1-((*S*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (Compound 23)



[0290] A solution of (*R*) or (*S*)-1-(3-chlorophenyl)-2-((*S*)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-1-yl)ethan-1-ol (**Compound 18**, 50.0 mg, 0.118 mmol) in THF (2 mL) at 0° C was added NaH (5.66 mg, 0.142 mmol, 60% dispersion in mineral oil). After stirring at 0 °C for 1 h, MeI (8.08 µL, 0.130 mmol) was added and the mixture was allowed to warm to room temperature. After stirring for 1 h, the reaction mixture was cooled to 0 °C and quenched by the addition of water (5 mL), and extracted with EtOAc (5 mL x 3). The combined organic layers were washed with brine (5 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Waters Xbridge BEH C18 column, 35–70% MeCN/10 mM NH_4HCO_3 in water) to give (*S*)-1-((*R*) -2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine or (*S*)-1-((*S*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (**Compound 23**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, *J* = 8.8 Hz, 2H), 7.37 – 7.34 (m, 3H), 7.27 – 7.25 (m, 1H), 7.15 – 7.13 (m, 2H), 4.38 (t, *J* = 6.0 Hz, 1H), 3.93 – 3.89 (m, 2H), 3.15 (s, 3H), 3.13 (s, 3H), 2.80 – 2.77 (m, 2H), 2.43 – 2.40 (m, 2H), 2.15 – 2.08 (m, 2H), 1.96 – 1.95 (m, 1H), 1.70 – 1.59 (m, 2H), 1.45 – 1.43 (m, 1H), 1.14 – 1.11 (m, 1H). MS = 438.1 $[M+H]^+$.

[0291] The following compounds in Table 14 were prepared according to procedures similar to those described for **Compound 23** using the appropriate starting materials.

Table 14

No.	Starting Material	Structure	IUPAC Name	Exact Mass $[M+H]^+$
24	**Compound 19**		(*S*)-1-((*S*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine or (*S*)-1-((*R*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-	Calc'd 438.1 Found 438.1

			(methylsulfonyl)phenoxy)methyl)piperidine	
25	**Compound 21**		(*R*)-1-((*R*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine or (*R*)-1-((*S*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine	Calc'd 438.1 Found 438.3
26	**Compound 22**		(*R*)-1-((*S*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine or (*R*)-1-((*R*)-2-(3-chlorophenyl)-2-methoxyethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine	Calc'd 438.1 Found 438.3

Example 7

***rac-trans* or *cis*-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (Compound 27)**

***rac-cis* or *trans*-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (Compound 28)**



Step 1: *tert*-butyl 4-hydroxy-3-(hydroxymethyl)piperidine-1-carboxylate



[0292] To a 0 °C solution of 1-*tert*-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate (5.00 g, 18.4 mmol) in EtOH (55 mL) was added $NaBH_4$ (6.97 g, 184 mmol) slowly. The mixture was stirred at 0 °C for 5 h, and was then quenched with ice water (40 mL). After stirring for 30 min, the solution was extracted with EtOAc (40 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over Na_2SO_4, filtered and concentrated in vacuo to give *tert*-butyl 4-hydroxy-3-(hydroxymethyl)piperidine-1-carboxylate, which was used in the next step without further purification. MS = 176.0 $[M–C_4H_7+H]^+$.

Step 2: *tert*-butyl 4-hydroxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate



[0293] To a solution of *tert*-butyl 4-hydroxy-3-(hydroxymethyl)piperidine-1-carboxylate (2.80 g, 12.1 mmol) and 1-fluoro-4-methylsulfonyl-benzene (2.11 g, 12.1 mmol) in DMF (28 mL) was added K_2CO_3 (4.18 g, 30.3 mmol). The mixture was stirred at 100 °C for 15 h. After cooling to room temperature, the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (10 mL x 2), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 20 g cartridge, 0–65% EtOAc in petroleum

ether) to give *tert*-butyl 4-hydroxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate. MS = 408.1 $[M+Na]^+$.

Step 3: 3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol



[0294] A solution of *tert*-butyl 4-hydroxy-3-[(4-methylsulfonylphenoxy)methyl]piperidine-1-carboxylate (1.20 g, 3.11 mmol) in HCl/EtOAc (4 M, 15 mL) was stirred at room temperature for 2 h and then concentrated in vacuo to give 3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (HCl salt), which was used in the next step without further purification. MS = 286.0 $[M+H]^+$.

Step 4: *rac-trans* or *cis*-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (Compound 27); *rac-cis* or *trans*-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (Compound 28)



[0295] To a solution of 3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (970 mg, 3.01 mmol, HCl salt) and 2-(3-chlorophenyl)acetaldehyde (559 mg, 3.62 mmol) in MeOH (10 mL) was added TEA (0.839 mL, 6.03 mmol) and AcOH (34.48 μL, 0.603 mmol). After stirring for 30 min, $NaBH_3CN$ (568 mg, 9.04 mmol) was added. The mixture was stirred at room temperature for 10 h, then was quenched with ice water (10 mL). The mixture was concentrated to remove solvent and extracted with EtOAc (10 mL x 3). The combined organic layers were

washed with brine (5 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Waters Xbridge BEH C18 column, 30–50% MeCN/10 mM NH_4HCO_3 in water). The first eluting enantiomeric mixture of the title compound, **Compound 27**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.86 – 7.81 (m, 2H), 7.33 – 7.14 (m, 6H), 4.81 – 4.78 (m, 1H), 4.26 (app dd, J = 10.0 Hz, 3.2 Hz, 1H), 4.01 (app dd, J = 9.6 Hz, 8.0 Hz, 1H), 3.48 – 3.36 (m, 1H), 3.15 (s, 3H), 3.02 (d, J = 10.0 Hz, 1H), 2.88 – 2.86 (m, 1H), 2.7 – 2.71 (m, 2H), 2.62 – 2.58 (m, 1H), 2.31 – 2.22 (m, 1H), 2.05 – 1.95 (m, 2H), 1.88 – 1.82 (m, 2H), 1.50 – 1.41 (m, 1H). MS = 424.3 $[M+H]^+$. The second eluting enantiomeric mixture of the title compound, **Compound 28**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 8.8 Hz, 2H), 7.28 – 7.13 (m, 6H), 4.69 (s, 1H), 4.16 – 4.12 (m, 1H), 4.04 – 3.99 (m, 1H), 3.85 (s, 1H), 3.15 (s, 3H), 2.76 – 2.68 (m, 2H), 2.61 – 2.55 (m, 2H), 2.49 – 2.33 (m, 4H), 2.10 – 2.09 (m, 1H), 1.66 – 1.52 (m, 2H). MS = 424.2 $[M+H]^+$.

Example 8

(3*S*,4*R*) or (3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (Compound 29)

(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (Compound 30)



[0296] A solution of *rac-trans*- or *rac-cis*-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol (**Compound 27**, 0.035 g, 0.083 mmol) in MeOH (1 mL) was separated by preparative chiral SFC (DAICEL CHIRALPAK IG-3, 60% MeOH with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 29**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 – 7.80 (m, 2H), 7.32 – 7.14 (m, 6H), 4.79 (d, J = 5.2 Hz, 1H), 4.25 (app dd, J = 10.0 Hz, 2.8 Hz, 1H), 4.01 (app t, J = 8.4 Hz, 1H), 3.46 – 3.38 (m, 1H), 3.15 (s, 3H), 3.06 – 2.97 (m, 1H), 2.92 – 2.82 (m, 1H), 2.77 – 2.68 (m, 2H), 2.64 – 2.56 (m, 2H), 2.07 – 1.95 (m, 2H), 1.89 – 1.77 (m, 2H), 1.51 – 1.40 (m, 1H). MS = 424.2

$[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 30**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 – 7.82 (m, 2H), 7.30 – 7.14 (m, 6H), 4.79 (d, J = 5.2 Hz, 1H), 4.25 (app dd, J = 9.6 Hz, 2.8 Hz, 1H), 4.03 – 3.98 (m, 1H), 3.29 (s, 1H), 3.15 (s, 3H), 3.02 (d, J = 10.4 Hz, 1H), 2.86 (d, J = 10.4 Hz, 1H), 2.77 – 2.64 (m, 2H), 2.62 – 2.54 (m, 2H), 2.06 – 1.95 (m, 2H), 1.87 – 1.76 (m, 2H), 1.50 – 1.40 (m, 1H). MS = 424.3 $[M+H]^+$.

[0297] The following compounds in Table 15 were prepared according to procedures similar to those described for **Compound 29** using the appropriate starting materials.

Table 15

No.	Starting Material	Structure	IUPAC Name	Chiral Column	Chiral Elution Order	Exact Mass $[M+H]^+$
31	**Compound 28**		(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)piperidin-4-ol	DAICEL CHIRAL PAK IG-3	1st	Calc'd 424.1 Found 424.2
32	**Compound 28**		(3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) or (3*R*,4*R*) -1-(3-chlorophenethyl)-3-((4-(methylsulfo	DAICEL CHIRAL PAK IG-3	2nd	Calc'd 424.1 Found 424.3

			nyl)phenoxy) methyl)piperi din-4-ol			

Example 9

***rac-trans* or *cis*-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine (Compound 33)**

***rac-cis* or *trans*-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine (Compound 34)**



Step 1: *tert*-butyl 3-(hydroxymethyl)-4-methoxypiperidine-1-carboxylate



[0298] To a 0 °C solution of 1-(*tert*-butoxycarbonyl)-4-methoxypiperidine-3-carboxylic acid (900 mg, 3.47 mmol) in THF (10 mL) was added BH_3•THF (1.0 M, 6.94 mL) dropwise. The mixture was warmed to room temperature and stirred for 2 h. The reaction mixture was cooled to 0 °C and quenched with MeOH (20 mL), and then the adjusted pH=7 by the dropwise addition of aqueous $NaHCO_3$. The mixture was extracted with EtOAc (50 mL x 3), and the combined organic layers were dried over Na_2SO_4, filtered and concentrated in vacuo to give *tert*-butyl 3-(hydroxymethyl)-4-methoxypiperidine-1-carboxylate, which was used in the next step without further purification. MS = 190.2 $[M–C_4H_7+H]^+$.

Step 2: *tert*-butyl 4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate



[0299] To a mixture of 1-fluoro-4-methylsulfonyl-benzene (508 mg, 2.91 mmol) and *tert*-butyl 3-(hydroxymethyl)-4-methoxy-piperidine-1-carboxylate (715 mg, 2.91 mmol) in DMF (10 mL) was added Cs_2CO_3 (2.85 g, 8.74 mmol). The mixture was stirred at 100 °C for 15 h, then was cooled to room temperature. The reaction mixture was diluted with water (30 mL), and then extracted with EtOAc (50 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 20 g cartridge, 0–50% EtOAc in petroleum ether) to give *tert*-butyl 4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate. MS = 344.2 [M–C_4H_7+H]$^+$.

Step 3: 4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine



[0300] To a 0 °C solution of *tert*-butyl 4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine-1-carboxylate (790 mg, 1.98 mmol) in EtOAc was added HCl/EtOAc (4 M, 10 mL). The mixture was warmed to room temperature and stirred for 1 h. The reaction mixture was filtered, and the filter cake was washed with petroleum ether (10 mL x 3) and concentrated under reduced pressure to give 4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (HCl salt), which was used in the next step without further purification. MS = 300.1 [M+H]$^+$.

Step 4: *rac-trans* or *cis*-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine (Compound 33); *rac-cis* or *trans*-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine (Compound 34)



[0301] To a mixture of 4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (527 mg, 1.57 mmol, HCl salt) and 2-(3-chlorophenyl)acetaldehyde (485 mg, 3.14 mmol) in MeOH (8 mL) was added TEA (218 µL, 1.57 mmol) and HOAc (19.1 µL, 0.333 mmol). After stirring at room temperature for 3 h, $NaBH_3CN$ (197 mg, 3.14 mmol) was added. The mixture was stirred at room temperature for 27 h, then was quenched with water (1 mL) and concentrated in vacuo. The residue was purified by reverse phase preparative HPLC (Kromasil C18 column, 45–65% MeCN/10 mM NH_4HCO_3 in water). The first eluting enantiomeric mixture of the title compound, **Compound 33** : ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 (d, J = 2.0 Hz, 2H), 7.31 – 7.15 (m, 6H), 4.19 – 403 (m, 2H), 3.25 (s, 3H), 3.24 (s, 3H), 3.16 – 3.13 (m, 1H), 2.98 – 2.84 (m, 2H), 2.75 – 2.50 (m, 4H), 2.12 – 2.05 (m, 4H), 1.37 – 1.35 (m, 1H). MS = 438.2 $[M+H]^+$. The second eluting enantiomeric mixture of the title compound, **Compound 34**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.28 – 7.14 (m, 6H), 4.10 – 4.02 (m, 2H), 3.48 (s, 1H), 3.31 (s, 3H), 3.25 (s, 3H), 2.73 – 2.67 (m, 2H), 2.57 – 2.52 (m, 6H), 2.33 – 2.26 (m, 1H), 1.76 – 1.60 (m, 2H). MS = 438.2 $[M+H]^+$.

Example 10

(3*S*,4*R*) or (3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (Compound 35)

(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine (Compound 36)



[0302] *Rac-trans* or *cis*-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy) methyl)piperidine (**Compound 33**, 120 mg, 0.275 mmol) was separated by preparative chiral SFC (DAICEL CHIRALPAK AD-3, 50% MeOH with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 35**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 (d, J = 8.8 Hz, 2H), 7.30 – 7.15 (m, 6H), 4.19 – 4.16 (m, 1H), 4.07 – 4.03 (m, 1H), 3.25 (s, 3H), 3.15 (s, 3H), 3.08 (s, 1H), 2.98 – 2.85 (m, 2H), 2.75 – 2.53 (m, 4H), 2.10 – 1.97 (m, 4H), 1.38 – 1.35 (m, 1H). MS = 438.2 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 36**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.4 Hz, 2H), 7.31 – 7.15 (m, 6H), 4.19 – 4.03 (m, 2H), 3.25 (s, 3H), 3.15 (s, 3H), 3.12 (s, 1H), 2.99 – 2.85 (m, 2H), 2.75 – 2.71 (m, 4H), 2.10 – 1.98 (m, 4H), 1.37 – 1.23 (m, 1H). MS = 438.2 $[M+H]^+$.

[0303] The following compounds in Table 16 were prepared according to procedures similar to those described for **Compounds 35 and 36** using the appropriate starting materials.

Table 16

No.	Starting Material	Structure	IUPAC Name	Chiral Column	Chiral Elution Order	Exact Mass $[M+H]^+$
37	**Compound 34**		(3*R*,4*R*) or (3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) -1-(3-chlorophenethyl)	DAICEL CHIRAL PAK AD-3	1st	Calc'd 438.1 Found 438.2

			-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine			
38	**Compound 34**		(3*S*,4*S*) or (3*R*,4*S*) or (3*S*,4*R*) or (3*R*,4*R*)-1-(3-chlorophenethyl)-4-methoxy-3-((4-(methylsulfonyl)phenoxy)methyl)piperidine	DAICEL CHIRAL PAK AD-3	2nd	Calc'd 438.1 Found 438.2

Example 11

1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (Compound 39)

(*S*) or (*R*)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (Compound 40)

(*R*) or (*S*)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (Compound 41)



Step 1: *tert*-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2*H*)-carboxylate



[0304] To a solution of *tert*-butyl 3-oxopiperidine-1-carboxylate (2.00 g, 10.0 mmol) in THF (20 mL) at –78 °C was added LiHMDS (6.02 mL, 2 M, 12.1 mmol) dropwise. After 30 min, 1,1,1-trifluoro-N-phenyl-N-(trifluoromethylsulfonyl)methanesulfonamide (4.30 g, 12.1 mmol) was added. The mixture was warmed to room temperature and stirred for 2 h, and then quenched with aqueous NH_4Cl (10 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 10 g cartridge, 0–100% EtOAc in petroleum ether) to give *tert*-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2*H*)-carboxylate. MS = 354.0 $[M+Na]^+$.

Step 2: (*E*)-*tert*-butyl 5-(4-(methylsulfonyl)styryl)-3,4-dihydropyridine-1(2*H*)-carboxylate



[0305] A solution of *tert*-butyl 5-(((trifluoromethyl)sulfonyl)oxy)-3,4-dihydropyridine-1(2*H*)-carboxylate (682 mg, 2.06 mmol), 1-(methylsulfonyl)-4-vinylbenzene (250 mg, 1.37 mmol), TEA (573 µL, 4.12 mmol), PPh_3 (14.39 mg, 0.055 mmol), and $Pd(OAc)_2$ (6.16 mg, 0.027 mmol) in DMF (5 mL) was sparged with N_2, then stirred at 60 °C for 5 h. The reaction mixture was cooled to room temperature, filtered, and the filtrate was concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 10 g cartridge, 0–10% EtOAc in petroleum ether) to give (*E*)-*tert*-butyl 5-(4-(methylsulfonyl)styryl)-3,4-dihydropyridine-1(2*H*)-carboxylate. MS = 364.1 $[M+H]^+$.

Step 3: *tert*-butyl 3-(4-(methylsulfonyl)phenethyl)piperidine-1-carboxylate



[0306] To a solution of (*E*)-*tert*-butyl 5-(4-(methylsulfonyl)styryl)-3,4-dihydropyridine-1(2*H*)-carboxylate (230 mg, 0.633 mmol) in MeOH (3 mL) was added Pd/C (50 mg, 10% by weight). The mixture was purged with H_2 twice and stirred under H_2 (15 Psi) at room temperature for 3 h. The reaction solution was filtered through celite, and the filtrate was concentrated in vacuo to give *tert*-butyl 3-(4-(methylsulfonyl)phenethyl)piperidine-1-carboxylate, which was used in the next step without further purification. MS = 390.1 $[M+Na]^+$.

Step 4: 3-(4-(methylsulfonyl)phenethyl)piperidine



[0307] A solution of *tert*-butyl 3-(4-(methylsulfonyl)phenethyl)piperidine-1-carboxylate (250 mg, 0.680 mmol) in HCl/EtOAc (4 M, 5 mL) was stirred at room temperature for 1 h. The reaction was concentrated in vacuo to give 3-(4-(methylsulfonyl)phenethyl)piperidine (HCl salt), which was used in the next step without further purification. MS = 268.3 $[M+H]^+$.

Step 5: 1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (Compound 39)



[0308] A solution of 3-(4-(methylsulfonyl)phenethyl)piperidine (0.23 g, 0.757 mmol, HCl salt) and 2-(3-chlorophenyl)acetaldehyde (117 mg, 0.757 mmol) in MeOH (5 mL) was

stirred at room temperature for 1 h, and then $NaBH_3CN$ (95.1 mg, 1.51 mmol) was added. After stirring for an additional 15 h at room temperature, the mixture was quenched with water (1 mL) and mixture was adjusted to pH 7 via the dropwise addition of aqueous 2 M HCl. The mixture was concentrated under reduced pressure and MeOH (3 mL) was added to the residue. The crude residue was purified by reverse phase preparative HPLC (Waters Xbridge BEH C18 column, 35–65% MeCN/10 mM NH_4HCO_3 in water) to give 1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (**Compound 39**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.32 – 7.15 (m, 4H), 3.31 (s, 3H), 2.80 – 2.68 (m, 6H), 2.48 – 2.44 (m, 2H), 1.99 – 1.90 (m, 1H), 1.74 – 1.37 (m, 7H), 0.94 – 0.86 (m, 1H). MS = 406.2 $[M+H]^+$.

Step 6: (*S*) or (*R*)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (Compound 40); (*R*) or (*S*)-1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (Compound 41)



[0309] 1-(3-chlorophenethyl)-3-(4-(methylsulfonyl)phenethyl)piperidine (**Compound 39**, 250 mg, 0.616 mmol) was separated by preparative chiral SFC (DAICEL CHIRALPAK AD-3, 50% MeOH with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 40**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.32 – 7.17 (m, 4H), 3.18 (s, 3H), 2.84 – 2.68 (m, 6H), 2.48 – 2.44 (m, 2H), 1.93 – 1.90 (m, 1H), 1.74 – 1.41 (m, 7H), 0.92 – 0.89 (m, 1H). MS = 406.1 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 41:** ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.82 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.4 Hz, 2H), 7.31 – 7.19 (m, 4H), 3.18 (s, 3H), 2.85 – 2.68 (m, 6H), 2.48 – 2.44 (m, 2H), 1.99 – 1.90 (m, 1H), 1.74 – 1.41 (m, 7H), 0.92 – 0.89 (m, 1H). MS = 406.1 $[M+H]^+$.

Example 12

1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine (Compound 42)

(*S*) or (*R*)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine (Compound 43)

(*R*) or (S)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 44)



Step 1: *tert*-butyl 2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine- 1-carboxylate



[0310] A mixture of *tert*-butyl 4-(hydroxymethyl)-2,2-dimethylpyrrolidine-1-carboxylate (500 mg, 2.18 mmol), 1-fluoro-4-methylsulfonyl-benzene (380 mg, 2.18 mmol) and Cs_2CO_3 (2.13 g, 6.54 mmol) in DMF (5 mL) was stirred at 100 °C for 16 h. The reaction mixture was cooled to room temperature, quenched by the addition of water (15 mL), and then extracted with EtOAc (15 mL x 3). The combined organic layers were washed with water (15 mL x 3), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal

phase silica gel chromatography (Biotage 12 g cartridge, 0–45% EtOAc in petroleum ether) to give *tert*-butyl 2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate. MS = 406.2 $[M+Na]^+$.

Step 2: 2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine



[0311] To a solution of *tert*-butyl 2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate (0.85 g, 2.22 mmol) in DCM (10 mL) was added TFA (4 mL). The mixture was stirred at room temperature for 1.5 h, and then was quenched by the addition of water (15 mL). The mixture was concentrated under reduced pressure to remove DCM, and the resulting aqueous layer was extracted with EtOAc (15 mL x 5). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give 2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (TFA salt). MS = 284.1 $[M+H]^+$.

Step 3: 1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl) pyrrolidine (Compound 42)



[0312] To a solution of 2-(3-chlorophenyl)acetaldehyde (982 mg, 6.35 mmol) and TEA (663 μL, 4.76 mmol) in MeOH (5 mL) was added 2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (450 mg, 1.18 mmol, TFA salt). After stirring at room temperature for 30 min, the reaction was cooled to 0 °C and $NaBH_3CN$ (299 mg, 4.76 mmol) was added. The resulting mixture was stirred at room temperature for 24 h, then was

quenched by the addition of water (0.5 mL) and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Waters Xbridge BEH C18 column, 50–80% MeCN/10 mM NH_4HCO_3 in water) to give 1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (**Compound 42**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.30 – 7.14 (m, 6H), 3.95 (d, J = 7.2 Hz, 2H), 3.15 (s, 3H), 2.83 – 2.75 (m, 2H), 2.70 – 2.62 (m, 3H), 2.60 – 2.54 (m, 1H), 2.47 – 2.41 (m, 1H), 1.81 (app dd, J = 12.4 Hz, 9.2 Hz, 1H), 1.34 (app dd, J = 12.4 Hz, 6.8 Hz, 1H), 0.95 (s, 3H), 0.89 (s, 3H). MS = 422.1 $[M+H]^+$.

Step 4: (*S*) or (*R*)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy) methyl) pyrrolidine (Compound 43); (*R*) or (*S*)-1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 44)



[0313] 1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (**Compound 42**, 140 g, 332 mmol) was separated by preparative chiral SFC (DAICEL CHIRALPAK AD-3, 38% MeOH with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 43:** ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.30 – 7.14 (m, 6H), 3.95 (d, J = 7.2 Hz, 2H), 3.15 (s, 3H), 2.83 – 2.76 (m, 2H), 2.70 – 2.62 (m, 3H), 2.55 – 2.54 (m, 1H), 2.46 – 2.45 (m, 1H), 1.81 (app dd, J = 12.0 Hz, 9.2 Hz, 1H), 1.34 (app dd, J = 12.4 Hz, 7.2 Hz, 1H), 0.94 (s, 3H), 0.89 (s, 3H). MS = 422.1 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 44:** ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.30 – 7.14 (m, 6H), 3.95 (d, J = 7.2 Hz, 2H), 3.15 (s, 3H), 2.81 – 2.80 (m, 2H), 2.68 – 2.64 (m, 3H), 2.56 – 2.54 (m, 1H), 2.46 – 2.45 (m, 1H), 1.81 (app dd, J = 12.4 Hz 9.2 Hz, 1H), 1.34 (d, J = 12.4 Hz, 7.2 Hz, 1H), 0.95 (s, 3H), 0.89 (s, 3H). MS = 422.1 $[M+H]^+$.

Example 13

***rac-trans-N*-(4-((1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 45)**

***N*-(4-(((3*S*,4*S*) or (3*R*,4*R*) -1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 46)**

***N*-(4-(((3*R*,4*R*) or (3*S*,4*S*) -1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 47)**



Step 1: *rac-trans-tert*-butyl-3-methyl-4-((4-(*N*-methylmethylsulfonamido)phenoxy)methyl)pyrrolidine-1-carboxylate



[0314] To a solution of *N*-(4-bromophenyl)-N-methylmethanesulfonamide (300 mg, 1.14 mmol), copper(I) iodide (11 mg, 0.057 mmol), cesium carbonate (0.554 g, 1.704 mmol), and 3,4,7,8-tetramethyl-1,10-phenanthroline (27 mg, 0.11 mmol) in toluene (1.62 mL) was added *rac-trans-tert*-butyl-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate (0.245 g, 1.14 mmol). The mixture was sparged with nitrogen for 1 min and sealed. The reaction was heated to 100 °C for 16 h. After cooling to room temperature, the mixture was diluted with EtOAc (10 mL) and filtered, solids were washed with EtOAc (10 mL x 2), and the filtrate was concentrated in vacuo. The crude residue was dissolved in EtOAc (10 mL) and washed with

aqueous 20% citric acid (10 mL). The aqueous layer was extracted with EtOAc (10 mL) and the combined organic layers were dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 25 g cartridge, 0–7% MeOH in DCM) to give *rac-trans-tert*-butyl-3-methyl-4-((4-(*N*-methylmethylsulfonamido)phenoxy)methyl)pyrrolidine-1-carboxylate. MS = 421.1 $[M+Na]^+$.

Step 2: *rac-trans-N*-methyl-*N*-(4-((-4-methylpyrrolidin-3-yl)methoxy)phenyl)methanesulfonamide



[0315] *rac-trans-tert*-butyl-3-methyl-4-((4-(*N*-methylmethylsulfonamido)phenoxy)methyl)pyrrolidine-1-carboxylate was dissolved in 20% TFA in DCM (3 mL) and allowed to stir at room temperature for 1 h. The reaction was concentrated in vacuo. The crude residue was dissolved in water (10 mL) and washed with DCM (10 mL). The aqueous layer was adjusted to pH = 10 with the dropwise addition of 1 M NaOH. The aqueous layer was extracted with DCM (10 mL x 2), and the combined organic layers were dried over Na_2SO_4, filtered and concentrated in vacuo to give *rac-trans-N*-methyl-*N*-(4-((4-methylpyrrolidin-3-yl)methoxy)phenyl)methanesulfonamide, which was taken to the next step without purification. MS = 298.8 $[M+H]^+$.

Step 3: *rac-trans-N*-(4-((1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 45)



[0316] To a solution of *rac-trans-tert*-butyl-3-methyl-4-((4-(*N*-methylmethylsulfonamido)phenoxy)methyl)pyrrolidine-1-carboxylate (54 mg, 0.18 mmol) and

K_2CO_3 (0.10 g, 0.72 mmol) in MeCN (0.9 mL) was added 1-(2-bromoethyl)-3-chlorobenzene (0.048 g, 0.22 mmol). The mixture was heated to 70 ºC and allowed to stir for 12 h. After cooling to the reaction to room temperature, the mixture was concentrated in vacuo. Water (10 mL) was added and the mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Phenomenex Kinetex C18 column, 0–40% MeCN/water with 0.1% formic acid modifier) to give *rac-trans-N*-(4-((1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (**Compound 45**) ^{1}H NMR (500 MHz, $CDCl_3$): δ 7.24 – 7.20 (m, 2H), 7.17 – 7.10 (m, 3H), 7.04 – 7.02 (m, 1H), 6.84 – 6.79 (m, 2H), 3.94 – 3.84 (m, 2H), 3.21 (s, 3H), 3.16 – 3.11 (m, 1H), 2.96 – 2.89 (m, 2H), 2.88 – 2.77 (m, 4H), 2.76 (s, 3H), 2.37 (t, J = 9.1 Hz, 1H), 2.27 – 2.18 (m, 1H), 2.18 – 2.07 (m, 1H), 1.10 (d, J = 6.7 Hz, 3H). MS = 437.1 $[M+H]^+$.

Step 4: *N*-(4-(((3*S*,4*S*) or (3*R*,4*R*) -1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 46); *N*-(4-(((3*R*,4*R*) or (3*S*,4*S*) -1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 47)



[0317] *rac-trans-N*-(4-((1-(3-chlorophenethyl)-4-methylpyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide (**Compound 45**, 26.2 mg, 0.060 mmol) was separated by preparative chiral SFC (Chiralcel OD-H column, 30% isopropanol with 0.25% isopropylamine in CO_2). The first eluting enantiomer of the title compound, **Compound 46**: ^{1}H NMR (500 MHz, DMSO-d_6): δ 7.34 – 7.16 (m, 6H), 6.98 – 6.92 (m, 2H), 3.94 – 3.91 (m, 1H), 3.87 – 3.84 (m, 1H), 3.18 (s, 3H), 2.90 (s, 3H), 2.85 (app dd, J = 8.8, 7.3 Hz, 1H), 2.74 – 2.71 (m, 2H), 2.66 – 2.55 (m, 4H), 2.11 – 2.05 (m, 1H), 2.05 – 2.04 (m, 1H), 1.94 – 1.88 (m, 1H), 1.06 (d, J = 6.8 Hz, 3H). MS = 437.1 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 47:** ^{1}H NMR (500 MHz, DMSO-d_6): δ 7.36 – 7.15 (m, 6H), 6.98 – 6.92

(m, 2H), 3.94 – 3.91 (m, 1H), 3.87 – 3.84 (m, 1H), 3.18 (s, 3H), 2.90 (s, 3H), 2.84 (app dd, J = 8.7, 7.3 Hz, 1H), 2.74 – 2.71 (m, 2H), 2.66 – 2.53 (m, 4H), 2.12 – 2.01 (m, 2H), 1.94 – 1.88 (m, 1H), 1.06 (d, J = 6.7 Hz, 3H). MS = 437.1 $[M+H]^+$.

[0318] The following compounds in Table 17 were prepared according to procedures similar to steps 1–3 described for **Compound 45** using the appropriate starting materials.

Table 17

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$
48		*trans*-*N*-(4-(3-((3-chlorophenethyl)amino)cyclobutoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 409.1 Found 409.0
49		(*S*)-*N*-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 423.1 Found 423.0
50		(*R*)-*N*-(4-((1-(3-chlorophenethyl)pyrrolidin-3-yl)methoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 423.1 Found 423.0
51		(*S*)-1-(3-chlorophenethyl)-3-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine	Calc'd 394.1 Found 394.1

Example 14

rac-trans-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 52)



Step 1: *rac-trans-tert*-butyl-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate



[0319] To a solution of 1-fluoro-4-methanesulfonylbenzene (0.405 g, 2.32 mmol) and *rac-trans-tert*-butyl-3-(hydroxymethyl)-4-methylpyrrolidine-1-carboxylate (1000 mg, 4.65 mmol) in DMF (4.6 mL) was added K_2CO_3 (1.28 g, 9.29 mmol). The reaction was heated to 110 °C for 16 h. The reaction mixture was cooled to room temperature and water (50 mL) was added. The mixture was extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase flash chromatography (Biotage 25g cartridge, 0–10% MeOH in DCM) to give *rac-trans-tert*-butyl-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidine-1-carboxylate. MS = 392.0 $[M+Na]^+$.

Step 2: *rac-trans*-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine



[0320] To a solution of *rac-trans-tert*-butyl-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidine-1-carboxylate (900 mg, 2.44 mmol) in MeOH (5 mL) was added HCl in

dioxane (4 M, 5 mL). The reaction was allowed to stir for 2 h at room temperature. The reaction mixture was concentrated in vacuo to give *rac-trans*-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidine (HCl salt), which was taken to the next step without purification. MS = 269.9 $[M+H]^+$.

Step 3: *rac-trans*-1-(3-chlorophenethyl)-3-methyl-4-((4 (methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 52)



[0321] A mixture of *rac-trans*-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidine (100 mg, 0.327 mmol, HCl salt), 1-(2-bromoethyl)-3-chlorobenzene (0.086 g, 0.392 mmol), and K_2CO_3 (0.181 g, 1.308 mmol) was suspended in MeCN (1.6 mL). The resulting mixture was heated to 70 °C and allowed to stir for 18 h. The reaction was cooled to room temperature and concentrated in vacuo. Water (25 mL) was added, and the mixture was extracted with EtOAc (25 mL x 3). The combined organic layers were washed with brine (25 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Phenomenex Kinetex C18 column, 5–50% MeCN/water with 0.1% formic acid modifier) to give *rac-trans*-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (**Compound 52**) ^{1}H NMR (500 MHz, CD_3CN): δ 7.84 (d, J = 8.9 Hz, 2H), 7.31 – 7.15 (m, 4H), 7.09 (d, J = 8.9 Hz, 2H), 4.10 – 4.07 (m, 1H), 4.03 – 3.99 (m, 1H), 3.16 – 3.09 (m, 1H), 3.01 (s, 3H), 3.00 – 2.93 (m, 1H), 2.92 – 2.79 (m, 5H), 2.44 – 2.37 (m, 1H), 2.29 – 2.19 (m, 1H), 2.16 – 2.05 (m, 1H), 1.12 (d, J = 6.7 Hz, 3H). MS = 408.1 $[M+H]^+$.

[0322] The following compounds in Table 18 were prepared according to procedures similar to steps 1–3 described for **Compound 52** using the appropriate starting materials.

Table 18

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$

132		5-{2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile	Calc'd 424.2 Found 424.1
133		(3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine	Calc'd 408.1 Found 408.1
134		(2*S*,5*S*)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine	Calc'd 422.1 Found 422.2
160		(2*R*,5*S*)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperidine	Calc'd 422.1 Found 422.2

Example 15

***rac-trans* or *cis*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 53)**

***rac-cis* or *trans*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 54)**



Step 1: *tert*-butyl 4-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate



[0323] To a 0 °C solution of 1-(*tert*-butoxycarbonyl)-5-methylpyrrolidine-3-carboxylic acid (450 mg, 1.96 mmol) in THF (10 mL) was added BH_3•THF (1 M, 3.14 mL). The mixture was warmed to room temperature and stirred for 2 h. The reaction mixture was cooled to 0 °C, quenched with aqueous 2 M HCl (20 mL), and stirred at room temperature for 20 min. The mixture was extracted with EtOAc (20 mL x 3). The combined organic layers were washed with saturated aqueous $NaHCO_3$ (40 mL), brine (40 mL), dried over Na_2SO_4, filtered and concentrated in vacuo to give *tert*-butyl 4-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate, which was used in the next step without further purification. MS = 160.1 $[M–C_4H_7+H]^+$.

Step 2: 1-(3-chlorophenethyl)-2,2-dimethyl-4-((4-(methylsulfonyl)phenoxy)methyl) pyrrolidine



[0324] A mixture of *tert*-butyl 4-(hydroxymethyl)-2-methylpyrrolidine-1-carboxylate (380 mg, 1.77 mmol), 1-fluoro-4-(methylsulfonyl)benzene (399 mg, 2.29 mmol) and Cs_2CO_3 (1.73 g, 5.30 mmol) in DMF (6 mL) was stirred at 100 °C for 16 h. After cooling to room temperature, the mixture was poured into water (30 mL) at 0 °C and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with water (60 mL), brine (60 mL), dried over Na_2SO_4, filtered and concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 12 g cartridge, 25–50% EtOAc in petroleum ether) to give tert-butyl 2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate. MS = 314.1 $[M+Na]^+$.

Step 3: 2-methyl-4-[(4-methylsulfonylphenoxy) methyl]pyrrolidine



[0325] To a 0 °C solution of *tert*-butyl 2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate (570 mg, 1.54 mmol) in DCM (5 mL) was added TFA (2.5 mL, 33.7 mmol). The mixture was warmed to room temperature and stirred for 1 h, then was concentrated under reduced pressure. The residue was dissolved in aqueous $NaHCO_3$ (15 mL) and was extracted with a solution of 1:3 isopropanol : DCM (15 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and the filtrate was concentrated in vacuo to give 2-methyl-4-[(4-methylsulfonylphenoxy) methyl]pyrrolidine, which was used in the next step without further purification. MS = 270.1 $[M+H]^+$.

Step 4: *rac-trans* or *cis*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 53); *rac-cis* or *trans*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 54)



[0326] A mixture of 2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (350 mg, 1.30 mmol) and 2-(3-chlorophenyl)acetaldehyde (261 mg, 1.69 mmol) in MeOH (4 mL) was stirred at room temperature for 10 min. After cooling to 0 °C, $NaBH_3CN$ (122 mg, 1.95 mmol) was added, and the mixture was stirred at room temperature for 1 h. The mixture was quenched by the addition of water (0.3 mL) and purified by reverse phase preparative HPLC (Waters Xbridge C18 column, 45–65% MeCN/10 mM NH_4HCO_3 in water). The first eluting enantiomeric mixture of the title compound, **Compound 53**: ^{1}H NMR (400 MHz, DMSO-d_6): δ

7.83 (d, J = 8.4 Hz, 2H), 7.33 – 7.20 (m, 4H), 7.16 – 7.14 (m, 2H), 4.0 – 3.94 (m, 2H), 3.35 – 3.33 (m, 1H), 3.15 (s, 3H), 2.97 – 2.95 (m, 1H), 2.78 – 2.71 (m, 2H), 2.57 – 2.56 (m, 1H), 2.46 – 2.45 (m, 1H), 2.29 – 2.28 (m, 1H), 2.06 – 2.01 (m, 1H), 1.73 – 1.71 (m, 1H), 1.54 – 1.53 (m, 1H), 1.01 (d, J = 6.0 Hz, 3H). MS = 408.2 $[M+H]^+$. The second eluting enantiomeric mixture of the title compound, **Compound 54**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.31 (s, 1H), 7.25 – 7.14 (m, 5H), 3.96 – 3.89 (m, 2H), 3.16 (s, 3H), 3.08 – 3.06 (m, 1H), 2.94 – 2.93 (m, 1H), 2.76 – 2.68 (m, 2H), 2.48 – 2.47 (m, 1H), 2.34 – 2.29 (m, 3H), 2.13 – 2.09 (m, 1H), 1.09 – 1.00 (m, 4H). MS = 408.2 $[M+H]^+$.

Example 16

(2*R*,4*S*) or (2*R*,4*R*) or (2*S*,4*R*) or (2*S*,4*S*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 55)

(2*R*,4*R*) or (2*S*,4*R*) or (2*S*,4*S*) *or* (2*R*,4*S*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 56)



[0327] *rac-trans* or *cis*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (**Compound 53**, 230 mg, 0.563 mmol) was separated by preparative chiral SFC (DAICEL CHIRALPAK AD-3, 44% MeOH with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 55**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.33 – 7.21 (m, 4H), 7.17 – 7.14 (m, 2H), 4.04 – 3.94 (m, 2H), 3.32 – 3.31 (m, 1H), 3.15 (s, 3H), 2.98 – 2.96 (m, 1H), 2.78 – 2.70 (m, 2H), 2.56 – 2.55 (m, 1H), 2.44 – 2.43 (m, 1H), 2.27 – 2.26 (m, 1H), 2.03 – 2.02 (m, 1H), 1.76 – 1.72 (m, 1H), 1.57 – 1.49 (m, 1H), 1.01 (d, J = 4.8 Hz, 3H). MS = 408.2 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 56**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.33 – 7.22 (m, 4H), 7.17 – 7.14 (m, 2H), 4.04 – 3.93 (m, 2H), 3.36 – 3.35 (m,

1H), 3.15 (s, 3H), 2.98 – 2.97 (m, 1H), 2.78 – 2.70 (m, 2H), 2.57 – 2.56 (m, 1H), 2.47 – 2.46 (m, 1H), 2.33 – 2.28 (m, 1H), 2.07 – 2.04 (m, 1H), 1.73 – 1.72 (m, 1H), 1.54 – 1.51 (m, 1H), 1.01 (d, J = 6.0 Hz, 3H). MS = 408.2 $[M+H]^+$.

Example 17

(2*S*,4*R*) or (2*S*,4*S*) *or* (2*R*,4*S*) or (2*R*,4*R*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 57)

(2*S*,4*S*) *or* (2*R*,4*S*) or (2*R*,4*R*) *or* (2*S*,4*R*)-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (Compound 58)



[0328] *rac-cis* or *trans*-1-(3-chlorophenethyl)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine (**Compound 54**, 160 mg, 0.392 μmol) was separated by preparative chiral SFC (DAICEL CHIRALPAK AD-3, 33% MeOH with 0.1% NH_4OH in CO_2). The first eluting enantiomer of the title compound, **Compound 57**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.31 (s, 1H), 7.23 – 7.14 (m, 5H), 3.95 – 3.88 (m, 2H), 3.15 (s, 3H), 3.06 – 3.05 (m, 1H), 2.94 – 2.93 (m, 1H), 2.71 – 2.67 (m, 2H), 2.53 – 2.52 (m, 1H), 2.33 – 2.25 (m, 3H), 2.14 – 2.13 (m, 1H), 1.11 – 0.96 (m, 4H). MS = 408.2 $[M+H]^+$. The second eluting enantiomer of the title compound, **Compound 58**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.31 (s, 1H), 7.27 – 7.14 (m, 5H), 3.95 – 3.91 (m, 2H), 3.15 (s, 3H), 3.08 – 3.05 (m, 1H), 2.98 – 2.89 (m, 1H), 2.76 – 2.67 (m, 2H), 2.53 – 2.52 (m, 1H), 2.33 – 2.28 (m, 3H), 2.2 – 2.11 (m, 1H), 1.09 – 0.99 (m, 1H), 0.96 – 0.85 (m, 3H). MS = 408.2 $[M+H]^+$.

[0329] The following compounds in Table 19 were prepared according to procedures similar to those described for **Example 15** to **17** using the appropriate starting materials.

Table 19

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$	Chiral purification column	Chiral Elution order
135		*rac-cis* or t*rans*-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 399.2 Found 399.1	Prep-HPLC Waters Xbridge BEH C18	1st
136		*rac-trans* or *cis*-3-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 399.2 Found 399.1	Prep-HPLC Waters Xbridge BEH C18	2nd
137		3-{2-[(2*S*,4*R* or 2*R*,4*S* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 399.2 Found 399.1	Chiralpak AD	1st

138		3-{2-[(2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 399.2 Found 399.1	Chiralpak AD	2nd
139		3-{2-[(2*S*,4*R* or 2*R*,4*S* or 2*S*,4*S* or 2*R*,4*R*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 399.2 Found 399.1	Chiralpak AD	1st
140		3-{2-[(2*S*,4*R* or 2*R*,4*S* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 399.2 Found 399.1	Chiralpak AD	2nd

141		5-chloro-3-{2-[(2*R*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}-2-methylbenzonitrile	Calc'd 447.1 Found 447.2	n/a	n/a
142		3-chloro-5-[(2*R* or 2*S*)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile	Calc'd 447.1 Found 447.2	prep-HPLC Waters Xbridge BEH C18	2nd
143		3-chloro-5-[(2*S* or 2*R*)-1-[(2R,4S)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile	Calc'd 447.1 Found 447.2	prep-HPLC Waters Xbridge BEH C18	1st

144		5-chloro-3-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}-2-methylbenzonitrile	Calc'd 447.1 Found 447.2	n/a	n/a
145		5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzene-1,3-dicarbonitrile	Calc'd 424.2 Found 424.1	n/a	n/a
146		3-chloro-5-[1-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile	Calc'd 447.1 Found 447.1	n/a	n/a

147		3-chloro-5-[(2*R* or 2*S*)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile	Calc'd 447.1 Found 447.1	Chiralpk AD	1st
148		3-chloro-5-[(2*S* or 2*R*)-1-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]propan-2-yl]benzonitrile	Calc'd 447.1 Found 447.1	Chiralpk AD	2nd
149		3-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 399.2 Found 399.1	n/a	n/a
150		*rac-cis*-1-[2-(3-chlorophenyl)ethyl]-3-[(4-	Calc'd 408.1	n/a	n/a

		methanesulfonylphenoxy)methyl]-4-methylpyrrolidine	Found 408.3		
151		(3*R*,4*S* or 3*S*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine	Calc'd 408.1 Found 408.3	Chiralcel OJ	1st
152		(3*S*,4*R* or 3*R*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine	Calc'd 408.1 Found 408.2	Chiralcel OJ	2nd
153		(2*R*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidine	Calc'd 408.1 Found 408.1	n/a	n/a

154		(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine	Calc'd 408.1 Found 408.1	Chiralcel OD	1st
155		(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine	Calc'd 408.1 Found 408.1	Chiralcel OD	2nd

Example 18

(*S*)-*N*-(4-(3-((3-chlorophenethyl)(cyclopropylmethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 59)



[0330] A solution of (*S*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide (**Compound 86**, 30.0 mg, 0.073 mmol), (bromomethyl)cyclopropane (21.1 µL, 0.218 mmol), and K_2CO_3 (40 mg, 0.291 mmol) in MeCN

(0.73 mL) was heated at 85 °C for 18 h. After cooling to room temperature, solids were removed via filtration, and the filtrate was concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Phenomenex Kinetex C18 column, 10–70% MeCN/water with 0.1% formic acid modifier) to give (*S*)-*N*-(4-(3-((3-chlorophenethyl)(cyclopropylmethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide (**Compound 59**). ^{1}H NMR (500 MHz, DMSO-d_6, 29/31 H): δ 7.25 – 7.13 (m, 4H), 7.10 – 7.05 (m, 2H), 6.84 – 6.74 (m, 2H), 3.86 – 3.73 (m, 2H), 3.70 – 3.67 (m, 1H), 3.08 (s, 3H), 2.79 (s, 3H), 2.77 – 2.56 (m, 4H), 2.51 – 2.40 (m, 1H), 2.35 – 2.33 (m, 2H), 0.79 – 0.68 (m, 1H), 0.39 – 0.27 (m, 2H), 0.06 – -0.07 (m, 2H). MS = 467.1 $[M+H]^+$.

[0331] The following compound in Table 20 was prepared according to procedures similar to those described for **Compound 59** using the appropriate starting materials.

Table 20

No.	Starting Material	Structure	IUPAC Name	Exact Mass $[M+H]^+$
60	**Compound 86**		(*S*)-*N*-(4-(3-((3-chlorophenethyl)(ethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 441.2 Found 441.2

Example 19

(*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 61)



Step 1: (*S*)-*N*-(4-(3-bromo-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide



[0332] A solution of *N*-(4-hydroxyphenyl)-*N*-methylmethanesulfonamide (124 mg, 0.616 mmol), *(2S)*-3-bromo-2-methylpropan-1-ol (123 mg, 0.801 mmol), and polymer-bound PPh_3 (0.411 g, 3 mmol/g, 1.23 mmol) in toluene (2 mL) was stirred at room temperature for 20 min, and then cooled to 0 °C. Diisopropylazodioxcarboxylate (153 µL, 0.77 mmol) was added dropwise, the mixture was warmed to room temperature and then stirred for 12 h. Solids were removed by filtration and washed with DCM, and the filtrate was concentrated in vacuo. The crude residue was purified by normal phase silica gel chromatography (Biotage 10 g cartridge, 0–60% EtOAc in hexanes) to give (*S*)-*N*-(4-(3-bromo-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide. MS = 338.9 $[M+H]^+$.

Step 2: (*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide (Compound 61)



[0333] A solution of *N*-(4-((2*S*)-3-bromo-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide (155 mg, 0.461 mmol), 2-(3-chlorophenyl)ethanamine (192 µL, 1.38 mmol), and K_2CO_3 (191 mg, 1.38 mmol) in MeCN was stirred at 80 °C for 18 h. After cooling to room temperature, solids were removed by filtration and washed with DCM, and the filtrate was concentrated in vacuo. The residue was taken up in DCM (3 mL) and washed with water (3 mL). The organic layer was dried over Na_2SO_4, filtered and the filtrate was concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Phenomenex Kinetex C18 column, 0–70% MeCN/water with 0.1% formic acid modifier). A second purification was performed by normal phase silica gel chromatography (Biotage 10 g cartridge, 0–20% MeOH in DCM) to give (*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide (**Compound 61**). ^1H NMR (500 MHz, CD_3CN): δ 8.45 – 8.10 (m, 1H), 7.51 – 7.17 (m, 6H), 6.98 – 6.80 (m, 2H), 3.92 (d, *J* = 6.1 Hz, 2H), 3.24 (s, 3H), 2.98 (d, *J* = 8.8 Hz, 2H), 2.85 (s, 6H), 2.79 – 2.65 (m, 1H), 2.25 – 2.18 (m, 1H), 1.03 (dd, *J* = 6.8, 2.4 Hz, 3H). MS = 411.2 $[M+H]^+$.

Example 20

(2*S*)-1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol (Compound 62)

(2*S*)-1-((*S*) or (*R*) -2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol (Compound 63)

(2*S*)-1-((*R*) or (*S*)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2- ol (Compound 64)



Step 1: (2*S*)-1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol (Compound 62)



[0334] To a solution of (*S*)-2-((4-(methylsulfonyl)phenoxy)methyl)oxirane (**Intermediate C**, 50 mg, 0.22 mmol) in EtOH (1.5 mL) was added 2-[(3-chlorophenyl)methyl]piperidine (55 mg, 0.25 mmol). The mixture was heated to 80 ºC and allowed to stir for 18 h. After cooling the reaction to room temperature, the mixture was concentrated in vacuo. The crude residue was purified by reverse phase preparative HPLC (Phenomenex Kinetex C18 column, 0–40% MeCN/water with 0.1% formic acid modifier) to give (2*S*)-1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol (**Compound 62**). ^{1}H NMR (500 MHz, DMSO-d_6): δ 8.15 (s, 1H), 7.86 – 7.77 (m, 2H), 7.32 –

7.24 (m, 2H), 7.23 – 7.19 (m, 1H), 7.17 – 7.13 (m, 3H), 4.16 – 4.00 (m, 1H), 4.01 – 3.83 (m, 2H), 3.15 (s, 3H), 3.04 – 2.91 (m, 1H), 2.89 – 2.76 (m, 2H), 2.73 – 2.70 (m, 1H), 2.62 – 2.54 (m, 2H), 2.46 – 2.35 (m, 1H), 1.62 – 1.57 (m, 1H), 1.54 – 1.35 (m, 3H), 1.35 – 1.24 (m, 1H), 1.24 – 1.05 (m, 1H). MS = 437.9 $[M+H]^+$.

Step 2: (*S*)-1-((*S*) or (*R*) -2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol (Compound 63); (*S*)-1-((*R*) or (*S*)-2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol (Compound 64)



[0335] (2*S*)-1-(2-(3-chlorobenzyl)piperidin-1-yl)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol was separated by preparative chiral SFC (ChromegaChiral CC5 column, 45% MeOH with 0.25% isopropylamine in CO_2). The first eluting diastereomer of the title compound, **Compound 63**: ^{1}H NMR (500 MHz, CD_3CN): δ 7.91 – 7.79 (m, 2H), 7.31 – 7.27 (m, 2H), 7.23 (d, *J* = 8.0 Hz, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.13 (d, *J* = 8.8 Hz, 2H), 4.69 (br. s, 1H), 4.11 – 4.08 (m, 1H), 4.03 – 3.98 (m, 2H), 3.04 – 3.00 (m, 4H), 2.98 – 2.87 (m, 3H), 2.72 (app dd, *J* = 13.2, 9.3 Hz, 1H), 2.67 – 2.60 (m, 2H), 1.75 – 1.65 (m, 1H), 1.62 – 1.56 (m, 3H), 1.47 – 1.41 (m, 1H), 1.41 – 1.33 (m, 1H). MS = 437.9 $[M+H]^+$. The second eluting diastereomer of the title compound, **Compound 64**: ^{1}H NMR (500 MHz, CD_3CN): δ 7.86 (d, *J* = 8.6 Hz, 2H), 7.33 – 7.26 (m, 2H), 7.22 (d, *J* = 8.1 Hz, 1H), 7.18 (d, *J* = 7.6 Hz, 1H), 7.12 (d, *J* = 8.5 Hz, 2H), 4.69 (br s, 1H), 4.09 (app d, *J* = 7.2 Hz, 1H), 4.01 – 3.98 (m, 2H), 3.12 – 3.00 (m, 5H), 2.86 – 2.82 (m, 2H), 2.72 (app dd, *J* = 12.6, 4.7 Hz, 1H), 2.65 (app dd, *J* = 13.4, 8.8 Hz, 1H), 2.54 – 2.49 (m, 1H), 1.71 – 1.67 (m, 1H), 1.63 – 1.53 (m, 3H), 1.43 – 1.38 (m, 1H), 1.36 – 1.32 (m, 1H). MS = 438.0 $[M+H].^+$

[0336] The following compounds in Table 21 were prepared according to procedures similar to those described for Compounds **63** – **64** using the appropriate starting materials.

Table 21

No.	Intermediate	Structure	IUPAC Name	Exact Mass $[M+H]^+$	Chiral Column	Chiral Elution Order
65	**A**		*N*-(4-((*S*)-3-((*trans*-3-(3-chlorophenyl)cyclobutyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 439.1 Found 439.1	n/a	n/a
66	**C**		(*S*)-1-((*trans*-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol	Calc'd 410.1 Found 410.1	n/a	n/a
67	**D**		(*R*)-1-((*trans*-3-(3-chlorophenyl)cyclobutyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol	Calc'd 410.1 Found 410.1	n/a	n/a
68	**A**		*N*-(4-((2*S*)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 467.2 Found 467.1	n/a	n/a

69	**A**		*N*-(4-((*S*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 467.2 Found 467.1	Chiralcel OX-H	1st
70	**A**		*N*-(4-((*R*)- (*S*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 467.2 Found 467.1	Chiralcel OX-H	2nd
71	**B**		*N*-(4-((2*R*)-3-(3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 467.2 Found 467.0	n/a	n/a
72	**B**		*N*-(4-((*R*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-	Calc'd 467.2 Found 467.1	ChiralcelOX-H	1st

			hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide			
73	**B**		*N*-(4-((*R*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)-2,2-dimethylpyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 467.2 Found 467.1	Chiralcel OX-H	2nd
74	**A**		*N*-(4-((2*S*)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 439.1 Found 439.1	n/a	n/a
75	**A**		*N*-(4-((*S*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 439.1 Found 439.2	Chiralcel OD-H	1st
76	**A**		*N*-(4-((*S*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-	Calc'd 439.1 Found 439.1	Chiralcel OD-H	2nd

			hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide			
77	**B**		*N*-(4-((2*R*)-3-(3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 439.1 Found 438.9	n/a	n/a
78	**B**		*N*-(4-((*R*)-3-((*S*) or (*R*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 439.1 Found 439.0	Regis-pack	1st
79	**B**		*N*-(4-((*R*)-3-((*R*) or (*S*)-3-(3-chlorophenyl)pyrrolidin-1-yl)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 439.1 Found 439.0	Regis-pack	2nd
80	**A**		*N*-(4-((2*S*)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)p	Calc'd 455.1 Found 455.1	n/a	n/a

			henyl)-*N*-methylmethanesulfonamide			
81	**A**		*N*-(4-((*S*)-3-((*S*) or (*R*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 455.1 Found 454.9	Chrome gaChira l CCA	1st
82	**A**		*N*-(4-((*S*)-3-((*R*) or (*S*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 455.1 Found 454.9	Chrome gaChira l CCA	2nd
83	**B**		*N*-(4-((2*R*)-3-(2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 455.1 Found 455.0	n/a	n/a
84	**B**		*N*-(4-((*R*)-3-((*R*) or (*S*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)p	Calc'd 455.1 Found 455.1	Chrome gaChira l CCA	1st

			henyl)-*N*-methylmethanesulfonamide			
85	**B**		*N*-(4-((*R*)-3-((*S*) or (*R*)-2-(3-chlorophenyl)morpholino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 455.1 Found 455.1	Chromega Chiral CCA	2nd
86	**A**		(*S*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 413.1 Found 413.0	n/a	n/a
87	**B**		(*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 413.1 Found 413.0	n/a	n/a
88	**B**		*N*-(4-((*R*)-3-(((*S*) or (*R*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-	Calc'd 427.1 Found 427.1	Chiralcel OX-H	2nd

			methylmethanesulfonamide			
89	**B**		*N*-(4-((*R*)-3-(((*R*) or (*S*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 427.1 Found 427.1	Chiralcel OX-H	1st
90	**A**		(*S*)-*N*-(4-(3-((2,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 447.1 Found 447.0	n/a	n/a
91	**A**		(*S*)-*N*-(4-(3-((3,5-dichlorophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 447.1 Found 447.0	n/a	n/a
92	**B**		*N*-(4-((2*R*)-3-((3-(3-chlorobenzyl)tetrahydrofuran-3-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-	Calc'd 469.2 Found 469.1	n/a	n/a

			methylmethanesulfonamide			
93	**C**		(*S*)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol	Calc'd 384.1 Found 384.1	n/a	n/a
94	**D**		(*R*)-1-((3-chlorophenethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol	Calc'd 384.1 Found 384.1	n/a	n/a
95	**A**		*N*-(4-((*S*)-3-(((*S*) or (*R*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 427.1 Found 427.1	Chromega Chiral CCA	2nd
96	**A**		*N*-(4-((*S*)-3-(((*R*) or (*S*)-1-(3-chlorophenyl)propan-2-yl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 427.1 Found 427.1	Chromega Chiral CCA	1st
97	**D**		(*R*)-1-((1-(3-chlorophenyl)-2-methylpropan-2-yl)amino)-3-(4-	Calc'd 412.1 Found 412.0	n/a	n/a

			(methylsulfonyl)phenoxy)propan-2-ol			
98	**A**		(*S*)-*N*-(4-(2-hydroxy-3-((2-methoxyphenethyl)amino)propoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 409.2 Found 408.9	n/a	n/a
99	**A**		(*S*)-*N*-(4-(3-((3-cyanophenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 404.2 Found 404.3	n/a	n/a
100	**A**		(*S*)-*N*-(4-(3-((2-ethylphenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 407.2 Found 407.2	n/a	n/a
101	**A**		(*S*)-*N*-(4-(3-((2-(difluoromethoxy)phenethyl)amino)-2-hydroxypropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 445.2 Found 445.1	n/a	n/a

102	**D**		(2*R*)-1-((2-(3-chlorophenyl)-1-cyclopropylethyl)amino)-3-(4-(methylsulfonyl)phenoxy)propan-2-ol	Calc'd 424.1 Found 424.1	n/a	n/a
103	**E**		(*R*) or (*S*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 427.1 Found 427.1	Phenomenex Cellulose-2	1st
104	**E**		(*S*) or (*R*)-*N*-(4-(3-((3-chlorophenethyl)amino)-2-hydroxy-2-methylpropoxy)phenyl)-*N*-methylmethanesulfonamide	Calc'd 427.1 Found 427.1	Phenomenex Cellulose-2	2nd
105	**F**		*N*-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-*N*-methylmethanesulfonamide	Calc'd 412.1 Found 412.1	n/a	n/a

106	**F**		(*R*) or (*S*)-*N*-(4-((3-((3-chlorophenethyl)amino)-2-hydroxypropyl)amino)phenyl)-*N*-methylmethanesulfonamide	Calc'd 412.1 Found 412.1	Chiralpak IG-3	2nd

Example 21

3-{2-[(2*R*,4*S*)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 156)



Step 1: (2*R*,4*S*)-*tert*-butyl 4-((4-((1-((allyloxy)carbonyl)azetidin-3-yl)sulfonyl)phenoxy)methyl)-2-methylpyrrolidine-1-carboxylate



[0337] To a solution of allyl 3-((4-hydroxyphenyl)sulfonyl)azetidine-1-carboxylate (**Intermediate AB**, 400 mg, 1.35 mmol) in DMF (4 mL) were added K_2CO_3 (371.86 mg, 2.69 mmol) and *tert*-butyl (2*R*,4*S*)-2-methyl-4-(methylsulfonyloxymethyl)pyrrolidine-1-carboxylate (**Intermediate AF**, 434 mg, 1.48 mmol). The mixture was stirred at 80 °C for 16 h. The reaction mixture was partitioned between water (15 mL) and EtOAc (10 mL). The organic phase was

separated, washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give (2*R*,4*S*)-*tert*-butyl 4-((4-((1-((allyloxy)carbonyl)azetidin-3-yl)sulfonyl)phenoxy)methyl)-2-methylpyrrolidine-1-carboxylate. MS = 395.1 [M- $C_5H_9O_2$+H]$^+$

Step 2: allyl 3-((4-(((3*S*,5*R*)-5-methylpyrrolidin-3-yl)methoxy)phenyl)sulfonyl)azetidine-1-carboxylate



[0338] To a solution of (2*R*,4*S*)-*tert*-butyl 4-((4-((1-((allyloxy)carbonyl)azetidin-3-yl)sulfonyl)phenoxy)methyl)-2-methylpyrrolidine-1-carboxylate (730 mg, 1.48 mmol) in MeOH (2 mL) was added HCl/MeOH (4 M, 10 mL). The mixture was stirred at room temperature for 2 h. MeOH was removed under reduced pressure to give allyl 3-((4-(((3*S*,5*R*)-5-methylpyrrolidin-3-yl)methoxy)phenyl)sulfonyl)azetidine-1-carboxylate HCl salt. MS =395.2 [M+H]$^+$.

Step 3: allyl 3-[4-[[(3*S*,5*R*)-1-[2-(3-cyanophenyl)ethyl]-5-methyl-pyrrolidin-3-yl]methoxy]phenyl]sulfonylazetidine-1-carboxylate



[0339] To a mixture of allyl 3-[4-[[(3*S*,5*R*)-5-methylpyrrolidin-3-yl]methoxy]phenyl]sulfonylazetidine-1-carboxylate (120 mg, 278 µmol, HCl salt), TEA (28.2 mg, 278 µmol) and 3-(2-oxoethyl)benzonitrile (52.6 mg, 362 µmol) in MeOH (5 mL) was added AcOH (16.7 mg, 278 µmol) followed by $NaBH_3CN$ (35.0 mg, 557 µmol). The mixture was stirred at room temperature for 16 h. The reaction mixture was quenched by addition of water (5

mL) and adjusted to pH = 7 with saturated aq $NaHCO_3$. The aqueous phase was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4 g cartridge, 0–100% EtOAc:Hexane) to give allyl 3-[4-[[(3*S*,5*R*)-1-[2-(3-cyanophenyl)ethyl]-5-methyl-pyrrolidin-3-yl]methoxy]phenyl]sulfonylazetidine-1-carboxylate. MS = 524.3 $[M+H]^+$.

Step 4: 3-{2-[(2*R*,4*S*)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 156)



[0340] To a solution of allyl 3-[4-[[(3*S*,5*R*)-1-[2-(3-cyanophenyl)ethyl]-5-methyl-pyrrolidin-3-yl]methoxy]phenyl]sulfonylazetidine-1-carboxylate (60.0 mg, 115 μmol) in THF (5 mL) were added morpholine (39.9 mg, 458 μmol) and $Pd(PPh_3)_4$ (26.5 mg, 22.9 μmol). The mixture was then stirred at room temperature for 3 h. The reaction mixture was filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (ISCO 4 g cartridge, 0–100% EtOAc:Hexane, then 0-20% MeOH:EtOAc) to give a crude product. The product was further purified by preparative reverse phase HPLC (Waters Xbridge BEH C18 column, 25-55% MeCN:10 mM NH_4HCO_3 in H_2O) to give 3-{2-[(2*R*,4*S*)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (**Compound 156**). ^1H NMR (400 MHz, DMSO-d_6): δ 7.78 (d, *J* = 8.8 Hz, 2H), 7.72 (s, 1H), 7.64 – 7.57 (m, 2H), 7.42 (t, *J* = 7.6 Hz, 1H), 7.16 (d, *J* = 8.8 Hz, 2H), 4.47 – 7.39 (m, 1H), 3.90 (d, *J* = 7.2 Hz, 2H), 3.72 (t, *J* = 8.0 Hz, 2H), 3.49 (t, *J* = 8.4 Hz, 2H), 3.07 (d, *J* = 8.0 Hz, 1H), 2.99 – 2.96 (m, 1H), 2.81 – 2.75 (m, 2H), 2.35 – 2.30 (m, 5H), 2.28 – 2.12 (m, 1H), 1.07 – 1.02 (m, 1H), 0.98 (d, *J* = 6.0 Hz, 1H). MS = 440.1 $[M+H]^+$.

[0341] The following compounds in Table 22 were prepared according to procedures similar to those described for **Compound 156** using the appropriate starting materials.

Table 22

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$	Chiral column	Chiral Elution order
157		3-{2-[(2*R*,4*S*)-2-methyl-4-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 412.2 Found 412.3	n/a	n/a
158		3-{2-[(2*R*,4*S*)-2-methyl-4-({4-[(*R* or *S*)methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 412.2 Found 412.3	Chiralpak AD	1st
159		3-{2-[(2*R*,4*S*)-2-methyl-4-({4-[(*S* or *R*)methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-	Calc'd 412.2 Found 412.3	Chiralpak AD	2nd

		yl]ethyl}benzonitrile			
161		3-{2-[(2*R*,4*S*)-4-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}-5-chlorobenzonitrile	Calc'd 474.2 Found 474.2	n/a	n/a
162		3-{2-[(2*R*,4*S*)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 505.2 Found 505.3	n/a	n/a
164		3-chloro-5-{2-[(2*R*,4*S*)-4-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 539.1 Found 539.2	n/a	n/a

165		3-chloro-5-{2-[(2*R*,4*S*)-4-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}-2-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 463.1 Found 463.2	n/a	n/a
166		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 491.2 Found 491.1	n/a	n/a
167		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 539.1 Found 539.2	n/a	n/a

168		3-{2-[(3*S*,4*S*)-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 505.2 Found 505.5	n/a	n/a
169		3-{2-[(3*S*,4*S*)-3-methyl-4-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 412.2 Found 412.3	n/a	n/a
170		3-{2-[(3*S*,4*S*)-3-methyl-4-({4-[(*R* or *S*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 412.2 Found 412.3	Chiralpak IC	1st

171		3-{2-[(3*S*,4*S*)-3-methyl-4-({4-[(*S* or *R*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)pyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 412.2 Found 412.2	Chiralpak IC	2nd
172		3-{2-[(3*S*,4*S*)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 440.2 Found 440.1	n/a	n/a
173		3-{2-[(3*S*,4*S*)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-4-methylpyrrolidin-1-yl]ethyl}-5-chlorobenzonitrile	Calc'd 474.2 Found 474.2	n/a	n/a
174		3-chloro-5-{2-[(3*S*,4*S*)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]m	Calc'd 463.1 Found 463.1	n/a	n/a

		ethyl}-4-methylpyrrolidin-1-yl]ethyl}benzonitrile			
175		*rac-trans*-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine	Calc'd 514.1 Found 514.1	n/a	n/a
176		(3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine	Calc'd 514.1 Found 514.2	Chiralpak AD	1st
177		(3*S*,4*S* or 3*R*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}-4-methylpyrrolidine	Calc'd 514.1 Found 514.2	Chiralpak AD	2nd

Example 22

(3*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine

(Compound 184)



Step 1: (*S*)-*tert*-butyl 4-(3-chlorophenethyl)-2-(hydroxymethyl)piperazine-1-carboxylate



[0342] To a mixture of *tert*-butyl (2*S*)-2-(hydroxymethyl)piperazine-1-carboxylate (3.0 g, 13.9 mmol) and 2-(3-chlorophenyl)acetaldehyde (2.79 g, 18.0 mmol) in MeOH (30 mL) and AcOH (1.5 mL) was added 2-methylpyridine borane complex (1.78 g, 16.6 mmol). The mixture was stirred at 40 °C for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was diluted with water (50 mL), adjusted to pH=7 with 2 M aqueous $NaHCO_3$ and extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 40 g cartridge, 0–100% EtOAc:Hexane) to give (*S*)-*tert*-butyl 4-(3-chlorophenethyl)-2-(hydroxymethyl)piperazine-1-carboxylate. MS = 355.3 $[M+H]^+$.

Step 2: (*S*)-(4-(3-chlorophenethyl)piperazin-2-yl)methanol



[0343] A solution of (*S*)-*tert*-butyl 4-(3-chlorophenethyl)-2-(hydroxymethyl)piperazine-1-carboxylate (3.50 g, 9.86 mmol) in HCl/MeOH (4 M, 20 mL) was

stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give (*S*)-(4-(3-chlorophenethyl)piperazin-2-yl)methanol HCl salt, which was used without further purification. MS = 255.1 $[M+H]^+$.

Step 3: (3*aS*)-5-(3-chlorophenethyl)hexahydro-[1,2,3]oxathiazolo[3,4-a]pyrazine 1-oxide



[0344] To a solution of (*S*)-(4-(3-chlorophenethyl)piperazin-2-yl)methanol (2.50 g, 8.58 mmol, HCl salt) in DCM (30 mL) were added imidazole (1.75 g, 25.7 mmol) and TEA (2.17 g, 21.5 mmol). The mixture was cooled to 0 °C, and $SOCl_2$ (1.53 g, 12.9 mmol) was added. The mixture was stirred at room temperature for 16 h. The reaction mixture was quenched by addition of water (30 mL) and extracted with DCM (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 40 g cartridge, 0–100% EtOAc:Hexane) to give (3*aS*)-5-(3-chlorophenethyl)hexahydro-[1,2,3]oxathiazolo[3,4-a]pyrazine 1-oxide. MS= 301.0 $[M+H]^+$.

Step 4: (*S*)-5-(3-chlorophenethyl)hexahydro-[1,2,3]oxathiazolo[3,4-a]pyrazine 1,1-dioxide



[0345] To a solution of (3*aS*)-5-(3-chlorophenethyl)hexahydro-[1,2,3]oxathiazolo[3,4-a]pyrazine 1-oxide (1.80 g, 5.98 mmol) in MeCN (40 mL) were added $RuCl_3$ (13 mg, 59.8 µmol) and a solution of $NaIO_4$ (1.92 g, 8.98 mmol) in water (10 mL) under N_2. The mixture was stirred at room temperature for 2 h. The reaction mixture was quenched by saturated aqueous Na_2SO_3 (100 mL), then was diluted with water (40 mL) and extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over

Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 20 g cartridge, 0–100% EtOAc:Hexane) to give (*S*)-5-(3-chlorophenethyl)hexahydro-[1,2,3]oxathiazolo[3,4-a]pyrazine 1,1-dioxide. MS = 317.0 $[M+H]^+$.

Step 5: (3*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine (Compound 184)



[0346] To a mixture of 4-(3-methanesulfonylpropanesulfonyl)phenol (Intermediate AD, 48 mg, 174 μmol) and (*S*)-5-(3-chlorophenethyl)hexahydro-[1,2,3]oxathiazolo[3,4-a]pyrazine 1,1-dioxide (50 mg, 158 μmol) in DMF (3 mL) was added K_2CO_3 (33 mg, 237 μmol). The reaction was stirred at 60 °C for 16 h. The reaction mixture was filtered and the filtrate was quenched with 3.0 M aqueous HCl (106 μL). The mixture was stirred for 2 h, solids were removed by filtration, and the filtrate was concentrated in vacuo. The residue was purified by preparative reverse phase HPLC (Phenomenex Gemini-NX, 18–48% MeCN:10 mM NH_4HCO_3 in H_2O) to give (3*S*)-1-[2-(3-chlorophenyl)ethyl]-3-{[4-(3-methanesulfonylpropanesulfonyl)phenoxy]methyl}piperazine (**Compound 184**). ^{1}H NMR (400 MHz, DMSO-d_6): δ = 7.81 (d, *J* = 8.8 Hz, 2H), 7.32–7.31 (m, 1H), 7.29–7.27 (m, 1H), 7.24–7.18 (m, 4H), 4.02–3.97 (m, 2H), 3.42–3.38 (m, 3H), 3.20 (t, *J* = 8.0 Hz, 2H), 3.02–3.00 (m, 1H), 2.96 (s, 3H), 2.87 (t, *J* = 9.2 Hz, 2H), 2.76–2.66 (m, 5H), 2.06–1.87 (m, 5H). MS = 515.1 $[M+H]^+$.

[0347] The following compounds in Table 23 were prepared according to procedures similar to those described for **Compound 184** using the appropriate starting materials.

Table 23

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$	Chiral column	Chiral eluting order
182		3-chloro-5-{2-[(3*S*)-3-{[4-(2-hydroxyethanesulfonyl)phenoxy]methyl}piperazin-1-yl]ethyl}benzonitrile	Calc'd 464.1 Found 464.1	n/a	n/a
183		3-chloro-5-{2-[(3*S*)-3-{[4-(1-hydroxy-2-methylpropane-2-sulfonyl)phenoxy]methyl}piperazin-1-yl]ethyl}benzonitrile	Calc'd 492.2 Found 492.1	n/a	n/a
185		(3*S*)-3-{[4-(azetidine-3-sulfonyl)phenoxy]methyl}-1-[2-(3-chlorophenyl)ethyl]piperazine	Calc'd 450.2 Found 450.1	n/a	n/a

186		3-chloro-5-{2-[(3*S*)-3-({4-[methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile	Calc'd 447.2 Found 447.2	n/a	n/a
187		3-chloro-5-{2-[(3*S*)-3-({4-[(*S* or *R*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile	Calc'd 447.2 Found 447.2	Chiralpak IC	1st
188		3-chloro-5-{2-[(3*S*)-3-({4-[(*R* or *S*)-methyl(methylimino)oxo-λ⁶-sulfanyl]phenoxy}methyl)piperazin-1-yl]ethyl}benzonitrile	Calc'd 447.2 Found 447.1	Chiralpak IC	2nd

Example 23

3-chloro-5-{2-[(3*S*)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}benzonitrile (Compound 189)



Step 1: (*S*)-4-benzyl 1-*tert*-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate



[0348] To a mixture of (*S*)-*tert*-butyl 2-(hydroxymethyl)piperazine-1-carboxylate (4.00 g, 18.5 mmol) and $NaHCO_3$ (4.66 g, 55.5 mmol) in THF (25 mL) and H_2O (25 mL) was added CbzCl (4.73 g, 27.7 mmol) at 0 °C. Then the mixture was stirred at room temperature for 3 h. The mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 40 g cartridge, 0–40% EtOAc:Hexane) to give (*S*)-4-benzyl 1-*tert*-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate. MS = 251.1 $[M–C_5H_9O_2+H]^+$

Step 2: (*S*)-4-benzyl 1-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1,4-dicarboxylate



[0349] To a solution of (*S*)-4-benzyl 1-*tert*-butyl 2-(hydroxymethyl)piperazine-1,4-dicarboxylate (450 mg, 1.28 mmol) and 4-(methylsulfonyl)phenol (**G5**, 221 mg, 1.28 mmol) in THF (8 mL) at room temperature were added tributylphosphine (520 mg, 2.57 mmol) and

TMAD (442 mg, 2.57 mmol). The mixture was then stirred at 40 °C for 16 h under N_2. Brine was then added (10 mL) and the mixture was extracted with EtOAc (8 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0–100% EtOAc:Hexane) to give (*S*)-4-benzyl 1-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1,4-dicarboxylate which was taken to the next step without further purification. MS = 449.1 $[M–C_4H_8+H]^+$.

Step 3: (*S*)-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate



[0350] To a suspension of Pd/C (100 mg, 10% by weight in mineral oil) in MeOH (15 mL) was added (*S*)-4-benzyl 1-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1,4-dicarboxylate (500 mg, 991 µmol). The suspension was degassed under vacuum and purged with H_2 three times. The mixture was then stirred under H_2 (15 psi) at room temperature for 1 h. The mixture was filtered through a pad of Celite, and the filter cake was rinsed with MeOH (8 mL x 3). The combined filtrates were concentrated under reduced pressure. The residue was dissolved in saturated citric acid solution (30 mL) and extracted with EtOAc (10 mL x 3). The aqueous layer was adjusted to pH = 8 to 9 with saturated aqueous $NaHCO_3$, and then extracted with EtOAc (20 mL x 2). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give (*S*)-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate, which was taken to the next step without further purification. MS = 271.1 $[M–C_5H_9O_2+H]^+$.

Step 4: (*S*)-*tert*-butyl 4-(3-chloro-5-cyanophenethyl)-2-((4-(methylsulfonyl)phenoxy) methyl)piperazine-1-carboxylate



[0351] To a mixture of (*S*)-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (500 mg, 1.35 mmol) and 3-chloro-5-(2-oxoethyl)benzonitrile (606 mg, 3.37 mmol) in MeOH (10 mL) and HOAc (0.5 mL) was added $NaBH_3CN$ (170 mg, 2.70 mmol) at 0 °C. The mixture was then stirred at room temperature for 2 h under N_2. The reaction was quenched by addition of water (10 mL) at 0 °C, and then adjusted to pH = 7 with saturated aqueous $NaHCO_3$ and extracted with EtOAc (15 mL x 3). The combined organic layers were washed with brine (30 mL x 2), dried over Na_2SO_4, filtered and concentrated under reduced pressure to give a residue. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0–40% EtOAc:Hexane) to give (*S*)-*tert*-butyl 4-(3-chloro-5-cyanophenethyl)-2-((4- (methylsulfonyl)phenoxy) methyl)piperazine-1-carboxylate. MS = 534.2 $[M+H]^+$.

Step 5: 3-chloro-5-{2-[(3*S*)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}benzonitrile (Compound 189)



[0352] To a solution of (*S*)-*tert*-butyl4-(3-chloro-5-cyanophenethyl)-2-((4-(methylsulfonyl)phenoxy) methyl)piperazine-1-carboxylate (600 mg, 1.12 mmol) in EtOAc (10 mL) was added HCl/EtOAc (4 M, 15 mL). The mixture was stirred at room temperature for 1 h and then concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC (Phenomenex C18 column, 20-50% MeCN: 10 mM NH_4HCO_3 in H_2O) to give 3-

chloro-5-{2-[(3*S*)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}benzonitrile (**Compound 189**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.89 – 7.82 (m, 3H), 7.73 – 7.72 (m, 2H), 7.16 (d, J = 8.8 Hz, 2H), 4.01– 3.94 (m, 2H), 3.15 (s, 3H), 3.00 – 2.99 (m, 1H), 2.87 – 2.79 (m, 4H), 2.72 – 2.64 (m, 2H), 2.56 – 2.52 (m, 2H), 2.29 (s, 1H), 2.07 – 2.02 (m, 1H), 1.90 (t, J = 9.6 Hz, 1H). MS = 434.0 $[M+H]^+$.

[0353] The following compound in Table 24 was prepared according to procedures similar to those described for **Compound 189** using the appropriate starting materials.

Table 24

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$
190		(3*S*)-1-[2-(3,5-dichlorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine	Calc'd 443.1 Found 443.2

Example 24

(3*S*)-1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine (Compound 191)



Step 1: *tert*-butyl (*S*)-4-(5-chloro-2-methoxyphenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate



[0354] To a solution of Zn (221 mg, 3.37 mmol) and TMSCl (147 mg, 1.35 mmol) in CH_3CN (25 mL) was added two drops of 2-(bromomethyl)-4-chloro-1-methoxybenzene. The mixture was stirred at 40 °C for 1 h. Then HCHO (61 mg, 2.02 mmol), *tert*-butyl (*S*)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (250 mg, 675 µmol) and 2-(bromomethyl)-4-chloro-1-methoxybenzene (397 mg, 1.69 mmol) were added to the mixture. The reaction was stirred at 40 °C for 16 h. The reaction was concentrated and then diluted with water (25 mL) and extracted with EtOAc (25 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and the filtrate was concentrated to give a residue. The residue was purified by preparative reverse phase HPLC (Phenomenex Gemini-NX, 50-70% MeCN:10 mM NH_4HCO_3 in H_2O) to give *tert*-butyl (*S*)-4-(5-chloro-2-methoxyphenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate. MS = 539.2 $[M+H]^+$.

Step 2 (3*S*)-1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine (Compound 191)



[0355] To a solution of *tert*-butyl (*S*)-4-(5-chloro-2-methoxyphenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (60 mg, 111 µmol) in MeOH (1 mL) was added HCl/MeOH (4 M, 1 mL). The reaction mixture was stirred at room temperature for 2 h. The reaction mixture was then concentrated under reduced pressure to give (3*S*)-1-[2-(5-chloro-2-methoxyphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine HCl salt

(**Compound 191**). MS = 439.2 $[M+H]^+$, ^1H NMR (400 MHz, DMSO-d_6): δ 7.93 – 7.89 (m, 2H), 7.32 – 7.25 (m, 4H), 7.03 (d, *J*=8.8 Hz, 1H), 4.51 – 4.43 (m, 2H), 4.20 – 4.19 (m, 1H), 4.0 – 4.01 (m, 1H), 3.83 – 3.81 (m, 4H), 3.60 – 3.56 (m, 3H), 3.43 – 3.35 (m, 4H), 3.18 (s, 3H), 3.08 – 3.04 (m, 2H).

[0356] The following compounds in Table 25 were prepared according to procedures similar to those described for **Compound 191** using the appropriate starting materials.

Table 25

No.	Structure	IUPAC Name	Exact Mass $[M+H]^+$
192		(3*S*)-1-{2-[5-chloro-2-(difluoromethoxy)phenyl]ethyl}-3-[(4-methanesulfonylphenoxy)methyl]piperazine	Calc'd 475.1 Found 475.2
193		3-{2-[(3*S*)-3-[(4-methanesulfonylphenoxy)methyl]piperazin-1-yl]ethyl}-5-(trifluoromethyl)benzonitrile	Calc'd 468.2 Found 468.2
194		3-chloro-5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 433.1 Found 433.1
195		3-fluoro-5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-	Calc'd 417.2 Found 417.2

		methylpyrrolidin-1-yl]ethyl}benzonitrile	
196		3-bromo-5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile	Calc'd 477.1 Found 477.1
181		(3*S*,4*S*)-1-[2-(3-chloro-5-fluorophenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidine	Calc'd 426.1 Found 426.1

Example 25

(3*S*)-1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine (Compound 197)



Step 1: (*S*)-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate



[0357] To a suspension of Pd/C (100 mg, 10% by weight in mineral oil) in MeOH (15 mL) was added (*S*)-4-benzyl 1-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1,4-dicarboxylate (500 mg, 991 mmol). The suspension was degassed under vacuum and purged

with H_2 three times. The mixture was then stirred under H_2 (15 psi) at room temperature for 4 h. The mixture was filtered through a pad of Celite, and the filter cake was rinsed with MeOH (8 mL x 3). The combined filtrate was concentrated under reduced presure. The residue was dissolved in EtOAc (30 mL) and saturated citric acid solution (30 mL). The organic layer was separated, and the aqueous layer was extracted with EtOAc (15 mL). The aqueous layer was adjusted to pH>7 by addition of solid $NaHCO_3$, and then extracted with EtOAc (20 mL x 2). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure to give (*S*)-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate, which was taken to the next step without further purification. MS = 271.1 $[M-C_5H_9O_2+H]^+$.

Step 2: (*S*)-*tert*-butyl 4-(2-bromo-5-chlorophenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate



[0358] To a solution of (*S*)-*tert*-butyl 2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (170 mg, 459 µmol) and 2-(2-bromo-5-chloro-phenyl)acetaldehyde (107 mg, 459 µmol) in DCM (5 mL) at room temperature was added AcOH (459 µmol, 26 uL) followed by $NaBH(OAc)_3$ (146 mg, 688 µmol). The mixture was then stirred for 1 h. To the mixture was added saturated aqueous $NaHCO_3$ (15 mL) and DCM (10 mL). The organic layer was separated, and the aqueous layer was extracted with DCM (10 mL). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0–40% EtOAc:Hexane) to give (*S*)-*tert*-butyl 4-(2-bromo-5-chlorophenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate. MS = 587.2/589.2 $[M+H]^+$

Step 3: (*S*)-*tert*-butyl 4-(5-chloro-2-methylphenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate



[0359] To a mixture of (*S*)-*tert*-butyl 4-(2-bromo-5-chlorophenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (130 mg, 221 μmol), methylboronic acid (27 mg, 442 μmol) and K_2CO_3 (61 mg, 442 μmol) in 1,4-dioxane (4 mL) and H_2O (0.4 mL) was added $Pd(dppf)Cl_2•CH_2Cl_2$ (18 mg, 22.1 μmol) at room temperature under N_2. The resulting mixture was then stirred at 100 °C for 16 h under N_2. The mixture was cooled to room temperature and concentrated under reduced presure. The residue was purified by flash silica gel chromatography (Biotage 12 g cartridge, 0–100% EtOAc:Hexane) to give (*S*)-*tert*-butyl 4-(5-chloro-2-methylphenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate, which was taken to the next step without further purification. MS = 523.3 $[M+H]^+$.

Step 4: (3*S*)-1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine (Compound 197)



[0360] A mixture of (*S*)-*tert*-butyl 4-(5-chloro-2-methylphenethyl)-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (120 mg, 229 μmol) in HCl/EtOAc (4 M, 8 mL) was stirred at room temperature for 0.5 h. The mixture was concentrated under reduced pressure. The solid residue was washed with EtOAc (8 mL), and then purified by preparative reverse phase HPLC (Waters Xbridge BEH C18 column, 30-60% MeCN:10 mM NH_4HCO_3 in H_2O) to give (3*S*)-1-[2-(5-chloro-2-methylphenyl)ethyl]-3-[(4-methanesulfonylphenoxy)methyl]piperazine (**Compound 197**). ^1H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 9.2 Hz, 2H), 7.23 (s, 1H), 7.18 – 7.13 (m, 4H), 4.02 – 3.96 (m, 2H), 3.15 (s, 3H),

3.04 – 2.95 (m, 1H), 2.92 – 2.86 (m, 2H), 2.79 – 2.64 (m, 4H), 2.47 – 2.43 (m, 3H), 2.32 (s, 3H), 2.10 – 2.00 (m, 1H), 1.92 – 1.87 (m, 1H). MS = 423.3 $[M+H]^+$.

Example 26

3-{2-[(3S,4S)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}-5-methylbenzonitrile (Compound 198)



Step 1: **3-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}-5-methylbenzonitrile (Compound 198)**

[0361] A vial was charged with 3-bromo-5-{2-[(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methylpyrrolidin-1-yl]ethyl}benzonitrile (100 mg, 0.209 mmol), methylboronic acid (190 mg, 0.314 mmol), K_2CO_3 (58 mg, 0.419 mmol), tetrakis(triphenylphosphine)palladium(0) (10 mg, 0.008 mmol), Toluene (1.0 mL) and H_2O (0.21 mL). The mixture was then sparged with nitrogen gas for 1 minute and then heated to 100 °C for 16 h. Reaction was partitioned with H_2O and EtOAc and extracted 3 times. The combined organics layers were dried over Na_2SO_4, filtered and concentrated. The crude oil was purified by prep-HPLC (5-50% MeCN in H_2O with 0.1% formic acid modifier) to give 3-{2-[(3*S*,4*S*)-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidin-1-yl]ethyl}-5-methylbenzonitrile (**Compound 198**). ^1H NMR (500 MHz, $CDCl_3$): δ 7.82 – 7.77 (m, 2H), 7.27 – 7.17 (m, 3H), 6.97 – 6.92 (m, 2H), 5.00-3.49 (m, 3H), 4.02 – 3.93 (m, 2H), 3.15 (t, *J* = 8.5 Hz, 1H), 2.96 (d, *J* = 1.2 Hz, 3H), 2.92 (t, *J* = 7.4 Hz, 2H), 2.85 (d, *J* = 5.5 Hz, 2H), 2.84 – 2.80 (m, 1H), 2.80 – 2.73 (m, 1H), 2.34 (t, *J* = 9.0 Hz, 1H), 2.28 – 2.21 (m, 1H), 2.18-2.10 (m, 1H), 1.11 (d, *J* = 6.6 Hz, 3H). MS = 413.2 $[M+H]^+$.

Example 27

***rac-cis* or *trans*-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 199)**

3-chloro-5-(2-((2*S*,4*R* or 2*R*,4*S* or 2*R*,4*R* or 2*S*,4*S*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile (Compound 200)

3-chloro-5-(2-((2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile (Compound 201)

***rac-trans* or *cis*-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 202)**

3-chloro-5-(2-((2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile (Compound 203)

3-chloro-5-(2-((2*R*,4*S* or 2*S*,4*R* or 2*S*,4*S* or 2*R*.4*R*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile (Compound 204)



Step 1: *rac-cis* or *trans*-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 199) and *rac-trans* or *cis*-3-chloro-5-{2-[4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 202)



[0362] To a mixture of Zn (23 mg, 356 µmol) in MeCN (2 mL) were added three drops of 3-(bromomethyl)-5-chloro-benzonitrile in 0.1 mL of MeCN and TMSCl (200 µmol, 25 uL). The mixture was stirred at 50 °C for 20 min. Then 3-(bromomethyl)-5-chloro-benzonitrile (39 mg, 167 µmol), 2-methyl-4-[(4-methylsulfonylphenoxy)methyl]pyrrolidine (30 mg, 111 µmol) and paraformaldehyde (20 mg, 222 µmol) were added to the mixture successively. The resulting mixture was stirred at room temperature for 1 h. To the mixture was added H_2O (10 mL), then the mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and the filtrate was concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC (Waters Xbridge BEH C18 column, 40-65% MeCN:10 mM NH_4HCO_3 in H_2O). The first eluting isomer (**Compound 199**) : ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 – 7.81 (m, 3H), 7.76 – 7.74 (m, 2H), 7.17 – 7.14 (m, 2H), 4.04 – 3.93 (m, 2H), 3.35 – 3.34 (m, 1H), 3.15 (s, 3H), 3.01 – 2.98 (m, 1H), 2.80 – 2.70 (m, 2H), 2.46-2.45 (m, 2H), 2.33-2.30 (m, 1H), 2.03 (t, J = 7.2 Hz, 1H), 1.72 – 1.71 (m, 1H), 1.53 – 1.52 (m, 1H), 0.98 (d, J = 6.0 Hz, 3H). MS = 433.2 $[M+H]^+$. The second eluting isomer (**Compound 202**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 – 7.80 (m, 3H), 7.72 – 7.70 (m, 2H), 7.14 (d, J = 8.8 Hz, 2H), 3.89 – 3.87 (m, 2H), 3.15 (s, 3H), 3.07 – 3.04 (m, 1H), 2.96 – 2.95 (m, 1H), 2.78 – 2.76 (m, 2H), 2.52 – 2.51 (m, 1H), 2.33 – 2.27 (m, 3H), 2.11 – 2.07 (m, 1H), 1.06 – 1.01 (m, 1H), 0.96 (d, J = 6.0 Hz, 3H). MS = 433.2 $[M+H]^+$.

Step 2: 3-chloro-5-{2-[(2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 200) and 3-chloro-5-{2-[(2*S*,4*R* or 2*R*,4*S* or 2*R*,4*R* or 2*S*,4*S*)-4-[(4-methanesulfonylphenoxy)methyl]-2-methylpyrrolidin-1-yl]ethyl}benzonitrile (Compound 201)



[0363] The first eluting isomer from Step 1 was further purified by preparative chiral SFC (CHIRALPAK AD, 60% ethanol with 0.1% NH_4OH in CO_2). The first eluting isomer of the title compound (**Compound 200**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.8 – 7.82 (m, 3H), 7.76 – 7.74 (m, 2H), 7.15 (d, J = 8.8 Hz, 2H), 4.04 – 3.95 (m, 2H), 3.35 – 3.34 (m, 1H), 3.15 (s, 3H), 3.01 – 2.98 (m, 1H), 2.83 – 2.75 (m, 2H), 2.52 – 2.50 (m, 2H), 2.31 – 2.29 (m, 1H), 2.03 (t, J = 7.2 Hz, 1H), 1.72 – 1.71 (m, 1H), 1.53 – 1.50 (m, 1H), 0.98 (d, J = 6.0 Hz, 3H). MS = 433.2 $[M+H]^+$

The second eluting isomer of the title compound (**Compound 201**). ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 – 7.82 (m, 3H), 7.76 – 7.74 (m, 2H), 7.15 (d, J = 8.8 Hz, 2H), 4.04 – 3.95 (m, 2H), 3.35 – 3.32 (m, 1H), 3.15 (s, 3H), 3.01 – 2.98 (m, 1H), 2.83 – 2.76 (m, 2H), 2.52 – 2.50 (m, 2H), 2.31 – 2.29 (m, 1H), 2.05 – 2.03 (m, 1H), 1.72 – 1.71 (m, 1H), 1.53 – 1.50 (m, 1H), 0.98 (d, J = 5.6 Hz, 3H). MS = 433.2 $[M+H]^+$.

Step 3: 3-chloro-5-(2-((2*R*,4*S* or 2*S*,4*R* or 2*R*,4*R* or 2*S*,4*S*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile (Compound 203) and 3-chloro-5-(2-((2*R*,4*S* or 2*S*,4*R* or 2*S*,4*S* or 2*R*.4*R*)-2-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-1-yl)ethyl)benzonitrile (Compound 204)



[0364] The second eluting isomer from Step 1 (150 mg, 346 μmol) was further purified by preparative chiral SFC (CHIRALPAK AD, 42% ethanol with 0.1% NH_4OH in CO_2).

The first eluting isomer of the title compound (**Compound 203**): ^{1}H NMR (DMSO-d_6, 400 MHz): δ 7.84 – 7.81 (m, 3H), 7.73 – 7.70 (m, 2H), 7.14 (d, J = 8.8 Hz, 2H), 3.90 – 3.88 (m, 2H), 3.15 (s, 3H), 3.07 – 3.04 (m, 1H), 2.97 – 2.96 (m, 1H), 2.79 – 2.73 (m, 2H), 2.52 – 2.50 (m, 1H), 2.33 – 2.28 (m, 3H), 2.15 – 2.13 (m, 1H), 1.07 – 1.01 (m, 1H), 0.96 (d, J = 5.6 Hz, 3H). MS = 433.2 $[M+H]^+$.

[0365] The second eluting isomer of the title compound (**Compound 204**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.86 – 7.81 (m, 3H), 7.73 – 7.70 (m, 2H), 7.17 – 7.13 (m, 2H), 3.90 – 3.88 (m, 2H), 3.15 (s, 3H), 3.05 – 3.04 (m, 1H), 2.99 – 2.98 (m, 1H), 2.81 – 2.76 (m, 2H), 2.59 – 2.57 (m, 1H), 2.33 – 2.27 (m, 3H), 2.15 – 2.14 (m, 1H), 1.07 – 1.01 (m, 1H), 0.96 (d, J = 5.6 Hz, 3H). MS = 433.2 $[M+H]^+$.

Example 28

rac-cis-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 205)

(3_R_,4_R_ or 3_S_,4_S_)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 206)

(3_S_,4_S_ or 3_R_,4_R_)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 207)

rac-trans-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 208)

(3_R_,4_S_ or 3_S_,4_R_)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol pyrrolidine-3-ol (Compound 209)

(3_S_,4_R_ or 3_R_,4_S_)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 210)



Step 1: *tert*-butyl 3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate



[0366] To a solution of 1-*tert*-butyl 3-ethyl 4-oxopyrrolidine-1,3-dicarboxylate (10.0 g, 38.9 mmol) in EtOH (200 mL) at 0 °C was slowly added $NaBH_4$ (14.7 g, 389 mmol). The mixture was stirred at room temperature for 15 h. The reaction mixture was quenched with ice water (300 mL), and then extracted with EtOAc (100 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 80 g cartridge, 0–100% EtOAc:Hexane) to give *tert*-butyl 3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate. MS = 162.1 $[M–C_4H_8+H]^+$.

Step 2: *tert*-butyl 3-hydroxy-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate



[0367] To a mixture of 1-fluoro-4-methylsulfonyl-benzene (5.21 g, 29.92 mmol) and *tert*-butyl 3-hydroxy-4-(hydroxymethyl)pyrrolidine-1-carboxylate (6.50 g, 29.9 mmol) in DMF

(50 mL) was added K_2CO_3 (8.27 g, 59.84 mmol). The mixture was stirred at 100 °C for 60 h. The reaction mixture was diluted with water (150 mL), and then extracted with EtOAc (50 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 80 g cartridge, 0–50% EtOAc:Hexane) to give *tert*-butyl 3-hydroxy-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate. MS = 316.1 $[M–C_4H_8+H]^+$.

Step 3: *tert*-butyl 3-((4-(methylsulfonyl)phenoxy)methyl)-4-oxopyrrolidine-1-carboxylate



[0368] To a solution of *tert*-butyl 3-hydroxy-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate (4.90 g, 13.2 mmol) in DCM (50 mL) at 0 °C was added DMP (6.71 g, 15.8 mmol). The mixture was stirred at room temperature for 15 h. The reaction mixture was cooled to 0 °C, quenched with saturated aqueous Na_2SO_3 (100 mL), concentrated, then extracted with EtOAc (50 mL x 5). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by flash silica gel chromatography (Biotage 40 g cartridge, 0–100% EtOAc:Hexane) to give *tert*-butyl 3-((4-(methylsulfonyl)phenoxy)methyl)-4-oxopyrrolidine-1-carboxylate. MS = 314.1 $[M–C_4H_8+H]^+$.

Step 4: *rac-cis*--*tert*-butyl 3-hydroxy-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate and *rac-trans*--*tert*-butyl 3-hydroxy-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate



Cis



Trans

[0369] A solution of *tert*-butyl 3-((4-(methylsulfonyl)phenoxy)methyl)-4-oxopyrrolidine-1-carboxylate (370 mg, 1.00 mmol) in THF (2 mL) was degassed and purged with N_2 three times. The mixture was cooled to 0 °C and MeMgBr (3 M in 2-MeTHF, 667 uL, 2.0 mmol) was added dropwise. The mixture was stirred at room temperature for 3 h under N_2 atmosphere. The reaction mixture was cooled to 0 °C, quenched with water (10 mL), and extracted with EtOAc (15 mL x 3). The combined organic layers were dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by preparative reverse phase HPLC (Phenomenex Gemini-NX, 20-50% MeCN: 10 mM NH_4HCO_3 in H_2O) to give *rac-cis-tert*-butyl 3-hydroxy-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate (the first eluting isomer in HPLC). MS = 330.1 $[M–C_4H_8+H]^+$. And *rac-trans-tert*-butyl 3-hydroxy-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidine-1-carboxylate (the second eluting isomer in HPLC). MS = 330.1 $[M–C_4H_8+H]^+$.

Step 5: *rac-cis*-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol



[0370] To a solution of the 1st eluting isomer from **Step 4** (40.0 mg, 104 μmol) in DCM (0.3 mL) at 0 °C was added TFA (154 mg, 1.35 mmol). The mixture was stirred at room temperature for 1.5 h. The reaction mixture was concentrated under reduced pressure to give *rac-cis*-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol, which was used without further purification. MS = 286.2 $[M+H]^+$.

Step 6: *rac-cis*-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 205)



[0371] To a solution of the residue from **Step 5** (29.0 mg, 102 µmol) in MeOH (0.3 mL) were added TEA (10.3 mg, 102 µmol), HOAc (5.8 uL, 102 µmol,) and 2-(3-chlorophenyl)acetaldehyde (23.6 mg, 152 µmol). After stirred at room temperature for 1 h, $NaBH_3CN$ (9.58 mg, 152 µmol) was added. The mixture was stirred at room temperature for 2 h, then was cooled to 0 °C and quenched by addition of H_2O (0.2 mL). The residue was purified by preparative reverse phase HPLC (Waters Xbridge Prep OBD C18 column, 30-60% MeCN:10 mM NH_4HCO_3 in H_2O) to give *rac-cis*-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (**Compound 205**). ^{1}H NMR (400 MHz DMSO-d_6): δ 7.83 (d, J = 8.4 Hz, 2H), 7.31 – 7.16 (m, 6H), 4.77 (s, 1H), 4.18 – 4.14 (m, 1H), 3.94 (t, J = 8.8 Hz, 1H), 3.15 (s, 3H), 3.05 – 2.95 (m, 1H), 2.73 – 2.61 (m, 6H), 2.44 – 2.42 (m, 2H), 1.21 (s, 3H). MS = 424.2 $[M+H]^+$.

Step 7 (3*R*,4*R* or 3*S*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 206) and (3*S*,4*S* or 3*R*,4*R*)-1-(3-chlorophenethyl)-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol (Compound 207)



[0372] The material obtained from **Step 6** was further purified by chiral SFC (CHIRALPAK IG, 55% isopropanol with 0.1% NH_4OH in CO_2) The first eluting isomer of the title compound (**Compound 206**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.83 (d, J = 8.8 Hz, 2H), 7.31 –7.24 (m, 4H), 7.21 – 7.16 (m, 2H), 4.79 (s, 1H), 4.18 – 4.14 (m, 1H), 3.95 (t, J = 8.8 Hz, 1H), 3.15 (s, 3H), 3.05 – 2.95 (m, 1H), 2.71 – 2.61 (m, 6H), 2.45 – 2.35 (m, 2H), 1.21 (s, 3H). MS = 424.2 $[M+H]^+$.The second eluting isomer of the title compound (**Compound 207**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 (d, J = 8.8 Hz, 2H), 7.33 – 7.26 (m, 4H), 7.21 – 7.17 (m, 2H), 4.82 (s, 1H), 4.18 – 4.14 (m, 1H), 4.02 – 3.97 (m, 1H), 3.16 (s, 3H), 3.05 – 2.95 (m, 1H), 2.90 – 2.74 (m, 4H), 2.64 – 2.54 (m, 2H), 2.46 – 2.87 (m, 2H), 1.23 (s, 3H). MS = 424.2 $[M+H]^+$.

Step 8: *rac-trans*-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol



[0373] To a solution of the 2nd eluting isomer from **Step 4** (70.0 mg, 182 µmol) in DCM (0.6 mL) at 0 °C was added TFA (308 mg, 2.70 mmol). The mixture was stirred at room temperature for 1.5 h, then was concentrated under reduced pressure to give *rac-trans*-3-methyl-4-((4-(methylsulfonyl)phenoxy)methyl)pyrrolidin-3-ol. MS = 286.1 $[M+H]^+$.

Step 9: *rac-trans*-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 208)



[0374] To a solution of the residue from **Step 8** (51.0 mg, 179 µmol) in MeOH (0.5 mL) were added TEA (25 uL, 178.72 µmol), HOAc (10 uL, 178 µmol) and 2-(3-chlorophenyl)acetaldehyde (41.4 mg, 268 µmol). After stirred at room temperature for 1 h, $NaBH_3CN$ (16.9 mg, 268 µmol) was added, and the mixture was stirred at for 2 *h*. The reaction mixture was cooled to 0 °C and quenched by addition H_2O (0.2 mL). The residue was purified by preparative reverse phase HPLC (Waters Xbridge Prep OBD C18 column, 30-60% MeCN:10 mM NH_4HCO_3 in H_2O) to give r*ac*-t*rans*-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (**Compound 208**). ^1H NMR (400 MHz, DMSO-d_6): δ 7.85 – 7.82 (m, 2H), 7.31 – 7.11 (m, 6H), 4.58 (s, 1H), 4.29 – 4.25 (m, 1H), 3.99 (t, *J* = 8.8 Hz, 1H), 3.15 (s, 3H), 2.91 (t, *J* = 8.0 Hz, 1H), 2.74 – 2.54 (m, 7H), 2.27 – 2.20 (m, 1H), 1.32 (s, 3H). MS = 424.3 $[M+H]^+$.

Step 10: (3*R*,4*S* or 3*S*,4*R*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 209) and (3*S*,4*R* or 3*R*,4*S*)-1-[2-(3-chlorophenyl)ethyl]-4-[(4-methanesulfonylphenoxy)methyl]-3-methylpyrrolidin-3-ol (Compound 210)



[0375] The material obtained from **Step 9** (40 mg, 94 μmol) was further purified by chiral SFC (CHIRALPAK IG, 60% isopropanol with 0.1% NH_4OH in CO_2). The first eluting isomer of the title compound (**Compound 209**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 (d, J = 8.8 Hz, 2H), 7.32 – 7.26 (m, 4H), 7.21 – 7.12 (m, 2H), 4.64 (br s, 1H), 4.30 – 4.26 (m, 1H), 4.00 (t, J = 8.8 Hz, 1H), 3.15 (s, 3H), 3.10 – 2.90 (m, 2H), 2.85 – 2.65 (m, 5H), 2.30 – 2.15 (m, 2H), 1.33 (s, 3H). MS = 424.2 $[M+H]^+$. The second eluting isomer of the title compound (**Compound 210**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.84 (d, J = 8.8 Hz, 2H), 7.32 – 7.25 (m, 4H), 7.21 – 7.12 (m, 2H), 4.65 (br s, 1H), 4.30 – 4.26 (m, 1H), 4.00 (t, J = 9.2 Hz, 1H), 3.15 (s, 3H), 3.05 – 2.89 (m, 1H), 2.90 – 2.55 (m, 6H), 2.30 – 2.15 (m, 2H), 1.33 (s, 3H). MS = 424.2 $[M+H]^+$.

Example 29

1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine (Compound 211)

***rac-cis* or *trans*-(2R,5S)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine (Compound 212)**

***rac-trans* or *cis*-(2R,5S)-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine (Compound 213)**



Step 1: 1-(*tert*-butoxycarbonyl)-4-(3-chlorophenethyl)-5-methylpiperazine-2-carboxylic acid



[0376] To a solution of 1-(*tert*-butoxycarbonyl)-5-methylpiperazine-2-carboxylic acid (950 mg, 3.89 mmol,) and 2-(3-chlorophenyl)acetaldehyde (721 mg, 4.67 mmol) in MeOH (10 mL) and AcOH (0.5 mL) was added 2-methylpyridine borane complex (624 mg, 5.83 mmol). The mixture was stirred at 40 °C for 2 h. The reaction mixture was concentrated under reduced pressure to remove MeOH. The residue was diluted with saturated aqueous $NaHCO_3$ (30 mL) and extracted with 3:1 DCM/iPrOH(10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Biotage 12 g cartridge, 0–9% MeOH/DCM) to give 1-(*tert*-butoxycarbonyl)-4-(3-chlorophenethyl)-5-methylpiperazine-2-carboxylic acid. MS = 383.1 $[M+H]^+$.

Step 2: *tert*-butyl 4-(3-chlorophenethyl)-2-(hydroxymethyl)-5-methylpiperazine-1-carboxylate



[0377] To a solution of 1-(*tert*-butoxycarbonyl)-4-(3-chlorophenethyl)-5-methylpiperazine-2-carboxylic acid (700 mg, 1.83 mmol) in THF (20 mL) was added BH_3-Me_2S (10 M in DMS, 731 uL, 7.3 mmol). The mixture was stirred at room temperature for 2 h. The reaction was poured into MeOH (20 mL) at 0 °C and stirred for 15 min. The mixture was concentrated under reduced pressure. The residue was diluted with saturated aqueous $NaHCO_3$ (30 mL) and extracted with 3:1 DCM/iPrOH (10 mL x 3). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Biotage 12 g cartridge, 2–9% MeOH/DCM) to give *tert*-butyl 4-(3-chlorophenethyl)-2-(hydroxymethyl)-5-methylpiperazine-1-carboxylate. MS = 369.2 $[M+H]^+$.

Step 3: *tert*-butyl 4-(3-chlorophenethyl)-5-methyl-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate



[0378] To a solution of *tert*-butyl 4-(3-chlorophenethyl)-2-(hydroxymethyl)-5-methylpiperazine-1-carboxylate (550 mg, 1.49 mmol) and 1-fluoro-4-methylsulfonyl-benzene (312 mg, 1.79 mmol) in DMF (10 mL) was added Cs_2CO_3 (972 mg, 2.98 mmol). The mixture was stirred at 100 °C for 40 h. The reaction mixture was cooled to 0 °C, quenched by addition of saturated aqueous NH_4Cl (50 mL) and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na_2SO_4, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (Biotage 12 g cartridge,

0–30% EtOAc:Hexane) and further purified by preparative reverse phase HPLC (Phenomenex Luna C18 column, 25-55% MeCN: 0.1% TFA in H_2O) to give *tert*-butyl 4-(3-chlorophenethyl)-5-methyl-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate. MS = 523.2 $[M+H]^+$.

Step 4: 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine (Compound 211)



[0379] A solution of *tert*-butyl 4-(3-chlorophenethyl)-5-methyl-2-((4-(methylsulfonyl)phenoxy)methyl)piperazine-1-carboxylate (70 mg, 134 µmol) in HCl/MeOH (5 mL) was stirred for 2 h at room temperature. The mixture was concentrated under reduced pressure to give 1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine **(Compound 211)**. ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.92 (d, J = 8.8 Hz, 2H), 7.44 – 7.31 (m, 3H), 7.30 – 7.23 (m, 3H), 4.60 – 4.40 (m, 2H), 4.20 – 4.00 (m, 1H), 3.70 – 3.62 (m, 5H), 3.37 – 3.23 (m, 4H), 3.23 – 2.98 (m, 4H), 1.44 (br s, 3H). MS = 423.1 $[M+H]^+$.

Step 5: *rac-cis* or *trans*-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine (Compound 212) and *rac-trans* or *cis*-1-[2-(3-chlorophenyl)ethyl]-5-[(4-methanesulfonylphenoxy)methyl]-2-methylpiperazine (Compound 213)



[0380] 1-(3-chlorophenethyl)-2-methyl-5-((4-(methylsulfonyl)phenoxy)methyl)piperazine (120 mg, 229 µmol) was further purified by chiral SFC (Chiralpak AD, 46% ethanol with 0.1% NH_4OH in CO_2). The first eluting isomer of the title compound **(Compound 212)**: ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.87 – 7.82 (m, 2H), 7.31 (s, 1H), 7.29 – 7.14 (m, 5H), 4.10 – 4.01 (m, 2H), 3.16 (s, 3H), 3.10 – 3.02 (m, 1H), 2.78 – 2.53 (m, 9H), 2.35 – 2.17 (m, 1H), 0.95 (d, J = 6.4 Hz, 3H). MS = 423.1 $[M+H]^+$. The second eluting

isomer of the title compound (**Compound 213**): ^{1}H NMR (400 MHz, DMSO-d_6): δ 7.90 (d, J = 8.8 Hz, 2H), 7.35 (s, 1H), 7.29 – 7.21 (m, 5H), 4.48 – 4.25 (m, 2H), 3.80 – 3.65 (m, 1H), 3.18 (s, 3H), 3.10 – 3.04 (m, 1H), 2.94 – 2.68 (m, 9H), 1.15 – 1.03 (m, 3H). MS = 423.1 $[M+H]^+$.

Example 30

(3*S*,4*S*)-3-[(4-methanesulfonylphenoxy)methyl]-4-methyl-1-{2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethyl}pyrrolidine (Compound 163)



Step 1: 1-[(3*S*,4*S*)-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidin-1-yl]-2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethenone



[0381] A 20 mL vial was charged with (3*S*,4*S*)-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidine hydrochloride (100 mg, 0.327 mmol), [3-(pentafluoro-λ⁶-sulfanyl)phenyl]acetic acid (0.171 g, 0.654 mmol), EDCI HCl (0.094 g, 0.49 mmol), 1-hydroxybenzotriazole hydrate (0.075 g, 0.49 mmol), and DMF (1.6 mL). Lastly added to this mixture was DIEA (0.127 g, 0.981 mmol). The reaction mixture was stirred at room temperature for 3 h. The reaction mixture was poured into H_2O (20 mL) and extracted with EtOAc (3x 30mL). The combined organic layers were washed with brine, dried over $MgSO_4$, filtered and concentrated under reduced pressure to give crude 1-[(3*S*,4*S*)-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidin-1-yl]-2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethanone as a yellow oil. MS = 514.0 $[M+H]^+$.

Step 2: (3*S*,4*S*)-3-(4-methanesulfonylphenoxymethyl)-4-methyl-1-{2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethyl}pyrrolidine (Compound 163)



[0382] To a solution of 1-[(3*S*,4*S*)-3-(4-methanesulfonylphenoxymethyl)-4-methylpyrrolidin-1-yl]-2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethanone (155 mg, 0.302 mmol) in THF (1.5 mL) at 0 °C was added $LiAlH_4$ (1 M in THF, 0.905 mL, 0.905 mmol) dropwise. The mixture was stirred at room temperature for 1 h. The reaction was cooled to 0 °C, quenched with H_2O and extracted with DCM (20 mL x2). The combined organics were dried over Na_2SO_4, filtered and concentrated. The resulting crude oil was purified by prep-HPLC (5-90% MeCN in H_2O with 0.1% formic acid modifier) to give (3*S*,4*S*)-3-(4-methanesulfonylphenoxymethyl)-4-methyl-1-{2-[3-(pentafluoro-λ⁶-sulfanyl)phenyl]ethyl}pyrrolidine **(Compound 163)**. 1H NMR (500 MHz, $CDCl_3$) δ 7.82 – 7.78 (m, 2H), 7.57 – 7.54 (m, 1H), 7.54 – 7.52 (m, 1H), 7.36 – 7.30 (m, 2H), 6.97 – 6.92 (m, 2H), 4.03 – 3.94 (m, 2H), 3.26 (dd, *J* = 9.9 Hz, 7.4 Hz, 1H), 3.08 – 2.99 (m, 2H), 2.97 – 2.86 (m, 7H), 2.45 (t, *J* = 9.4 Hz, 1H), 2.34 – 2.25 (m, 1H), 2.23 – 2.14 (m, 1H), 1.12 (d, *J* = 6.7 Hz, 3H). . MS = 500.1 $[M+H]^+$.

Biological Examples

Example B-1

[0383] This example shows that compounds of the present disclosure are able to inhibit calcium transport by APOL1.

[0384] A HEK293 clonal cell line was generated to stably express GCaMP6f, a genetically encoded calcium indicator, and inducibly express APOL1 G2 (HEK T-REx/GCaMP6f/APOL1 G2 K6.3). Cells were maintained in the following standard complete medium: DMEM with 4.5 g/L glucose and sodium pyruvate (BioWhittaker, Lonza, BE12-614F), supplemented with 10% FBS Performance Plus (Gibco, 16000044), 1% penicillin-streptomycin (BioWhittaker, DE17-602E), 2 mM ultraglutamine-1 (BioWhittaker cat. BE 17-605/U1), 50

μg/mL Zeocin (InvivoGen, ant-zn), 2.5 μg/mL Blasticidin (InvivoGen, ant-bl-5), and 25 μg/mL Hygromycin (InvivoGen, ant-hg). Standard propagation conditions consisted of plating $9x10^6$, $4x10^6$, $2x10^6$ cells in a T225 flasks to be processed after 2, 3, or 4 days, respectively.

[0385] A source plate was generated containing 20 serially diluted compounds in DMSO (duplicate 8-point dose response). Next, 0.8 μL of compounds were transferred from the source plate to a destination plate prefilled with 79.2 μL of Ca^{2+} free Tyrode's buffer (130 mM NaCl, 5 mM KCl, 1 mM $MgCl_2$, 5 mM $NaHCO_3$, 20 mM HEPES at pH 7.4). The destination plate was placed on a plate shaker (5 seconds at 2000 rpm) to mix. This process resulted in a destination plate with 2X concentrated compound solutions. All transfer and mixing steps were conducted with an CyBi®-Well dispenser.

[0386] Cells were split by gently washing with DPBS (Euroclone, ECB4004L), followed by a 5-minute incubation (humidified, 37°C with 5% CO_2) with trypsin-EDTA solution (Euroclone, ECB3052D). Detached cells were diluted with standard complete medium without selective agents, counted, and plated in a 384 MTP microplate (GR4332CPL, Twin Helix) (10,000 cells/well in 25 μl/well) using a MATRIX WellMate dispenser. Plates were placed into a humidified incubator (37°C with 5% CO_2) overnight. The following day, 20 μL of doxycycline (Sigma, D9891) at 20 ng/mL in standard complete medium was added to cells with a CyBi ®Drop dispenser to induce APOL1 G2 expression. After a 6-hour incubation (humidified, 37°C with 5% CO_2), cells were washed 3 times with Ca^{2+} free Tyrode's Buffer (130 mM NaCl, 5 mM KCl, 1 mM $MgCl_2$, 5 mM $NaHCO_3$, 20 mM HEPES at pH 7.4) using a BIOTEK Microplate washer, such that 10 μL of buffer remained in each well after the final wash. Assay plates were then stored at room temperature for 10 minutes. Next, 10μL of diluted compounds were transferred to the assay plate from the 2X compound plate using a CyBi®-Well dispenser. Compound incubation was then carried out at room temperature for 10 minutes. The assay plate was transferred to the FLIProom temperature^{ETRA} and 20 μL of 10 mM Ca^{2+} (final concentration = 5 mM) Tyrode's buffer was injected.

[0387] Table B1 below summarizes the data from this experiment. Unless otherwise specified, AC_{50} and values are reported as the geometric mean of at least 2 assay runs on separate days. Each run represents the average of a technical replicate, where each compound was assayed twice in the same plate. A superscript † symbol indicates a value from the average of a technical replicate from a single assay run, where each compound was assayed twice in the same plate.

[0388] The AC_{50} values in Table B1 below reflect the compound's ability to prevent calcium influx by inhibiting APOL1. As shown in the table, compounds of the present disclosure are able to potently inhibit APOL1-mediated calcium transport at sub micromolar concentrations. Compounds in Table B1 are referred to by the corresponding Compound Number in Table 1, which is also referred to in the synthetic examples. When one or more of the numbered compounds are identified by stereochemistry (for example, (*R*)- or (*S*)-), the specific stereoisomer for which data is provided in Table B1 may be identified by the elution order of such compound as described in the synthetic examples. To illustrate, Compound 2 is the first-eluting enantiomer of step 4 of Example 1 and Compound 3 is the second-eluting enantiomer of step 4 of Example 1. Further, by way of illustration, Compound 27 is the first-eluting enantiomeric mixture in step 4 of Example 7 and Compound 28 is the second-eluting enantiomeric mixture in step 4 of Example 7. Then, Compound 27 is separated into Compound 29 (the first-eluting enantiomer) and Compound 30 (the second-eluting enantiomer) in Example 8, and Compound 28 is separated into Compound 31 (the first-eluting enantiomer) and Compound 32 (the second-eluting enantiomer) in Example 8. Absolute stereochemistry of such compounds may be identified by methods known in the art.

Table B1

Compound No.	APOL1 G2 FLIPR AC_{50} (μM)
1	≤0.253
2	1.01†
3	0.205†
4	1.07†
5	10.1†
6	0.942
7	<0.253
8	0.266
9	0.151†
10	1.72†
11	1.19
12	2.39
13	0.143
14	3.34†
15	0.287†
16	0.231†
17	1.37†
18	5.73†
19	0.48
20	1.76†
21	0.623
22	6.41†
23	0.64†
24	0.501
25	0.469†
26	1.54†
27	1.50†
28	2.00†

29	1.98†
30	0.864†
31	1.02†
32	0.731†
33	10.8†
34	0.991†
35	3.78†
36	14.2†
37	3.84†
38	<0.253
39	0.249
40	<0.118†
41	2.11†
42	0.477
43	0.237†
44	2.22†
45	0.0712
46	0.0902
47	0.434
48	1.92†
49	0.847
50	1.32†
51	0.727
52	0.079†
53	0.856†
54	<0.114
55	1.29†
56	0.580†
57	<5.00
58	0.0727†
59	0.245

60	<0.267
61	0.376
62	0.396
63	0.637
64	0.570
65	0.258†
66	0.468
67	0.34†
68	0.916
69	12.87†
70	0.295†
71	0.943
72	0.314†
73	3.06†
74	1.29†
75	0.558
76	2.83
77	1.67†
78	7.01†
79	1.29†
80	13.9†
81	>25.0
82	4.35
83	>25.0†
84	>25.0†
85	8.48†
86	0.557
87	0.352
88	0.338
89	0.449
90	0.515

91	0.472
92	0.682†
93	6.54
94	1.62
95	1.54
96	3.77
97	0.314†
98	3.92
99	4.14†
100	1.26
101	1.30†
102	2.19†
103	10.9†
104	<0.382
105	0.946†
106	2.79†
107	0.0919
108	0.144
109	<0.105
110	0.0914
111	0.494
112	>0.159
113	0.907
114	0.709
115	0.756
116	0.374
117	1.08
118	0.936
119	0.784
120	0.461
121	0.270

122	0.709
123	0.376
124	0.148
125	2.35
126	0.704
127	2.48
128	0.349
129	1.04
130	2.17
131	0.394
132	0.510
133	0.0383
134	0.277
135	>12.5
136	0.207
137	>10.0
138	2.50
139	>10.0
140	0.107
141	0.737
142	1.23
143	3.16
144	0.423
145	0.356
146	0.937
147	1.11
148	0.615
149	0.0998
150	0.721
151	0.31
152	1.99

153	0.374
154	0.098
155	1.98
156	0.311
157	0.441
158	0.352
159	0.358
160	0.382
161	0.878
162	0.233
163	1.15
164	0.364
165	0.409
166	0.256
167	0.314
168	0.179
169	0.0797
170	0.0375
171	0.212
172	0.104
173	0.491
174	0.157
175	<0.0728
176	0.063
177	2.86
181	<0.0961
182	0.396
183	0.149
184	0.215
185	0.322
186	6.98
187	0.198

188	0.511
189	0.634
190	0.170
191	0.228
192	0.260
193	1.45
194	0.151
195	0.236
196	0.108
197	0.334
198	0.197
199	0.817
200	0.836
201	0.620
202	0.860
203	9.30
204	0.456
205	<0.236
206	>25.0
207	0.340
208	<0.420
209	3.74
210	0.898
211	<0.118
212	2.55
213	0.877
214	0.428
215	0.229

Example B-2

[0389] This example shows that the compounds of the present disclosure are able to reduce cell death caused by overexpression of APOL1.

[0390] A HEK293 clonal cell line overexpressing APOL1 G2 (HEK293/T-REx APOL1 G2/clone #2) was maintained in 1x DMEM-GlutaMax (Gibco, 10569-010) media with

10% tetracycline-free FBS (Takara Bio USA, 631101), 5 μg/mL Blasticidin (Gibco, A1113903), and 100 μg/mL Zeocin (Invitrogen, R25001) in T75 flasks. In preparation for the assay, this media was aspirated and 2 mL of prewarmed TrypLE Express (Gibco, 12605-010) was added to a flask to detach cells. The flask was then incubated (humidified, 37°C with 5% CO2) for 3-5 minutes. Afterwards, 8 mL of prewarmed cell assay media (1x DMEM-GlutaMax media with 10% tetracycline-free FBS) was added to the trypsinized cells. The suspension was gently mixed, and cells were counted using a Countess Cell Counting Chamber (Invitrogen). The suspension was diluted using cell assay media to generate a working stock solution (166,667 cells/mL). Using a MultiDrop Combi (Thermo Electron Corp), 30 μL (final cell density = 5,000 cells/well) of the working stock solution was dispensed into each well of white 384-well assay ready plates (Nunc™, 164610) containing 6 ng/mL doxycycline, to induce APOL1 expression, and compound. All compounds were plated in a duplicate 8-point dilution series that consisted of 3-fold stepwise dilutions (0.5% DMSO final). Assay plates were incubated (humidified, 37°C with 5% CO2) for 17 hours. After the incubation, the plates were equilibrated at room temperature for 1 hour. Next, 15 μl of CellTiter-Glo® reagent (Promega, G7570) was added to each well using a MultiDrop Combi. Plates were placed on an orbital shaker (500 rpm) for 5 minutes to induce cell lysis and then incubated at room temperature for 10 minutes. Luminescence was measured on an Envision plate reader. Collaborative Drug Discovery software was utilized for graphing data. Plots were generated using a four parameter logistic curve fit.

[0391] Table B2 below provides the results from this experiment. Unless otherwise specified, EC_{50} values are reported as the geometric mean of at least 2 assay runs on separate days. Each run represents the average of a technical replicate, where each compound was assayed twice in the same plate. A superscript † symbol indicates a value from the average of a technical replicate from a single assay run, where each compound was assayed twice in the same plate. Compounds in Table B2 are referred to by the corresponding Compound Number in Table 1, which is also referred to in the synthetic examples. When one or more of the numbered compounds are identified by stereochemistry (for example, (*R*)- or (*S*)-), the specific stereoisomer for which data is provided in Table B2 may be identified by the elution order of such compound as described in the synthetic examples. To illustrate, Compound 2 is the first-eluting enantiomer of step 4 of Example 1 and Compound 3 is the second-eluting enantiomer of step 4 of Example 1. Further, by way of illustration, Compound 27 is the first-eluting enantiomeric mixture in step 4 of Example 7 and Compound 28 is the second-eluting

enantiomeric mixture in step 4 of Example 7. Then, Compound 27 is separated into Compound 29 (the first-eluting enantiomer) and Compound 30 (the second-eluting enantiomer) in Example 8, and Compound 28 is separated into Compound 31 (the first-eluting enantiomer) and Compound 32 (the second-eluting enantiomer) in Example 8. Absolute stereochemistry of such compounds may be identified by methods known in the art.

[0392] Rescue EC_{50} values reported in Table B2 below represent the half-maximal effective concentration for reversal of cell death caused by overexpression of APOL1. This example demonstrates that compounds of the present disclosure are able to reduce cell death caused by overexpression of APOL1 at sub micromolar concentration.

Table B2

Compound No.	APOL1 G2 HEK293 Rescue EC_{50} (μM)
1	0.528
2	2.96
3	0.295
4	2.35
5	5.37
6	0.495
7	0.322
8	0.132
9	0.263
10	2.45
11	1.00
12	3.00
13	0.445
14	>30.0
15	0.567†
16	0.329†
17	0.671
18	6.32
19	0.374
20	1.36
21	1.02
22	6.59
23	0.677
24	0.334
25	1.01
26	2.24
27	2.13
28	2.34

29	>12.2
30	2.41
31	>7.89
32	5.77
33	>8.67
34	0.779
35	6.13
36	>30
37	>6.15
38	0.407
39	0.904
40	0.746
41	2.82
42	0.059
43	0.031
44	2.43
45	<0.0137
46	0.021
47	0.516
48	2.54
49	0.957
50	2.02
51	1.49
52	0.124
53	1.12
54	>30
55	1.68
56	1.68
57	1.68
58	<0.041
59	1.06

60	0.306
61	0.933
62	0.642
63	3.96†
64	1.12†
65	0.955
66	1.38†
67	1.35
68	0.591
69	>30
70	0.303
71	1.96
72	1.22
73	>17.8
74	2.58
75	1.46
76	>6.28
77	>6.30
78	>30.0
79	>13.7
80	13.0
81	>30.0
82	>24.3
83	>30.0
84	>30.0
85	>18.0
86	>4.11
87	1.85
88	0.698
89	2.02
90	1.46

91	1.04
92	>9.79
93	>30
94	8.37
95	6.90
96	>30.0
97	0.46
98	>20
99	>30.0
100	2.73
101	10.1
102	>21.8
103	>30.0
104	1.86
105	>12.4
106	6.24
107	0.0809
108	0.0504
109	0.500
110	0.135
111	1.88
112	0.0298
113	1.07
114	0.439
115	0.0447
116	0.076
117	1.24
118	4.04
119	0.133
120	0.195
121	0.100

122	1.34
123	0.300
124	0.242
125	1.55
126	0.560
127	> 10.0
128	0.366
129	0.723
130	> 10.0
131	0.460
132	0.0437
133	0.135
134	0.908
135	5.73
136	0.11
137	4.62
138	1.97
139	3.23
140	0.0459
141	0.0789
142	0.131
143	0.349
144	0.256
145	0.243
146	0.273
147	0.618
148	0.0808
149	0.272
150	1.47
151	1.34
152	4.72

153	0.0278
154	0.167
155	2.49
156	0.178
157	0.0389
158	0.039
159	0.0249
160	0.584
161	0.191
162	0.0279
163	> 0.385
164	0.0341
165	0.0302
166	0.0179
167	0.0672
168	0.126
169	0.182
170	0.076
171	0.146
172	0.203
173	0.201
174	0.0361
175	0.143
176	< 0.0472
177	1.83
181	0.325
182	0.399
183	0.157
184	0.622
185	0.239
186	0.631
187	0.436

188	0.303
189	0.922
190	0.291
191	0.663
192	0.915
193	0.782
194	0.107
195	0.226
196	0.110
197	0.369
198	0.0715
199	2.44
200	1.99
201	1.68
202	0.089
203	3.54
204	0.0423
205	1.59
206	> 30.0
207	0.933
208	3.57
209	> 19.5
210	3.12
211	1.36
212	> 14.3
213	0.964
214	0.679
215	0.0422

[0393] All publications, patent applications, patents, and other references mentioned herein are expressly incorporated by reference in their entireties, to the same extent as if each were incorporated by reference individually.

[0394] It is to be understood that, while the disclosure has been described in conjunction with the above embodiments, the foregoing description and examples are intended to

illustrate and not limit the scope of the disclosure. Other aspects, advantages and modifications within the scope of the disclosure will be apparent to those skilled in the art to which the disclosure pertains.

CLAIMS

What is claimed is:

1. A compound of formula (A'):



(A'),

or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

Q is absent or is -N-(C_{1-6}alkyl);

Y is O or -N-(C_{1-6}alkyl),

provided that, when Q is -N(C_{1-6}alkyl), then Y is O;

R^a, R^b, and R^c are each independently H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl,

or any two of R^a, R^b, and R^c are taken, together with the atoms to which they are attached, to form a C_{3-6}cycloalkyl or a 3-6 membered heterocyclyl, and the other of R^a, R^b, and R^c is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl of R^a, R^b, or R^c is independently optionally substituted with one or more -OH, C_{1-6}alkoxy, or -$S(O)_2$-C_{1-6}alkyl;

L is selected from the group consisting of:

(i) 

, wherein

A is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^x is H,

or R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy;

R^1 and R^2 are independently H, halo, or -OH,

or one of R^1 and R^2 is taken together with R^x, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH;

R^3 is H, -OH, halo, or C_{1-6}alkoxy; and

R^4 and R^5 are independently H,

or R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that either:

(1) R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is

substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, or

(2) R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

(ii)  , wherein

E is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

p is 0 or 1,

provided that, when *p* is 1, then E is O;

R^6 is H or -OH;

R^y is H,

or R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

or R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^7 is H,

or R^7 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl;

R^8 and R^9 are independently H or C_{1-6}alkyl,

or one of R^8 and R^9 is taken together with R^y, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl,
or one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and the other of R^8 and R^9 is H or C_{1-6}alkyl; and

R^{10} is H,

or R^{10} is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl,

provided that:

(1) R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(2) R^y is taken together with one of R^8 and R^9, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, or

(3) one of R^8 and R^9 is taken together with R^{10} and the atoms to which they are attached, to form a C_{3-8}cycloalkyl, and

(iii) 

, wherein

G is O, NH, N(C_{1-6}alkyl), CH_2, or CH(C_{1-6}alkyl);

R^z is H or C_{1-6}alkyl, wherein the C_{1-6}alkyl is optionally substituted with one or more C_{3-8}cycloalkyl;

R^{11} and R^{12} are independently H, -OH, halo, or C_{1-6}alkyl; and

R^{13} and R^{14} are independently H, C_{1-6}alkyl, or C_{3-8}cycloalkyl,

or R^{13} and R^{14} are taken, together with the atoms to which they are attached, to form a 3-8 membered heterocyclyl,

wherein, for each of (i)-(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X^1-X^4; and

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, C_{1-6}alkoxy, or SF_5, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

2. The compound of claim 1, wherein the compound is a compound of formula (A):



(A),

or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

X^1, X^2, X^3, and X^4 are, independently of each other, H, halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo,

provided that at least one of X^1, X^2, X^3, and X^4 is halo, -CN, C_{1-6}alkyl, or C_{1-6}alkoxy, wherein the C_{1-6}alkyl or C_{1-6}alkoxy is optionally substituted with one or more halo.

3. The compound of claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is ,



such that the compound is of formula (I):



(I),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

4. The compound of claim 3, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is O, such that the compound is of formula (I-A):



(I-A1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

5. The compound of claim 4, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8

membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy.

6. The compound of claim 4, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-6 membered heterocyclyl, wherein the 5-6 membered heterocyclyl is substituted with *n* independently selected R^g substituents, wherein *n* is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy.

7. The compound of claim 5 or claim 6, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-B1):



(I-B1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

8. The compound of claim 7, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0.

9. The compound of claim 7, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 1 or 2.

10. The compound of claim 7 or claim 9, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein each R^g is, independently at

each occurrence, $C_{1\text{-}6}$alkyl.

11. The compound of any one of claims 7, 9, and 10, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^g is, independently at each occurrence, methyl.

12. The compound of claim 5 or claim 6, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-C1):



(I-C1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

13. The compound of claim 5 or claim 6, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-D1):



(I-D1),

wherein or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

14. The compound of claim 12 or claim 13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0.

15. The compound of claim 12 or claim 13, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 1 or 2.

16. The compound of any one of claims 12, 13, and 15, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^g is, independently at each occurrence, -OH or $C_{1\text{-}6}$alkoxy.

17. The compound of any one of claims 12, 13, 15, and 16, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^g is, independently at each occurrence, -OH or methoxy.

18. The compound of claim 5 or claim 6, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-E1):



(I-E1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

19. The compound of claim 18, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0.

20. The compound of claim 5, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-F1):



(I-F1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

21. The compound of claim 20, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0.

22. The compound of claim 5, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-G1):



(I-G1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

23. The compound of claim 22, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0.

24. The compound of 4, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^4 and R^5 are taken, together with the atoms to which they are attached, to form a C_{3-8}cycloalkyl.

25. The compound of claim 4 or claim 24, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-H1):



(I-H1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

26. The compound of claim 25, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1, R^2, and R^3 are each H.

27. The compound of claim 3, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is CH_2, such that the compound is of formula (I-A3):



(I-A3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

28. The compound of claim 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected R^g substituents, wherein n is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is H, halo, or -OH.

29. The compound of claim 27, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^x is taken together with one of R^1 and R^2, and the atoms to which they are attached, to form a 5-6 membered heterocyclyl, wherein the 5-6 membered heterocyclyl is substituted with n independently selected R^g substituents, wherein n is an integer from 0-6, and R^g is -OH, halo, C_{1-6}alkyl, or C_{1-6}alkoxy, and the other of R^1 and R^2 is

H, halo, or -OH.

30. The compound of claim 28 or claim 29, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (I-C3):



(I-C3),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

31. The compound of claim 30, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *n* is 0.

32. The compound of any one of claims 1-24 and 27-31, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3, R^4, and R^5 are each H.

33. The compound of any one of claims 1-24 and 27-31, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is -OH, halo, or C_{1-6}alkoxy, R^4 is H, and R^5 is H.

34. The compound of claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is



, such that the compound is of formula (II):



(II),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

35. The compound of claim 34, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein E is O, such that the compound is of formula (II-A1):



(II-A1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

36. The compound of claim 35, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl.

37. The compound of claim 35, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^y is taken together with R^7, and the atoms to which they are attached, to form a 5-6 membered heterocyclyl.

38. The compound of any one of claims 35 to 37, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *p* is 1.

39. The compound of any one of claims 35 to 38, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (II-B1):



(II-B1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

40. The compound of any one of claims 35 to 37, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein *p* is 0.

41. The compound of any one of claims 35 to 37 and 40, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is

of formula (II-C1):



(II-C1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

42. The compound of any one of claims 35 to 37, 40, and 41, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is -OH, R^8 is $C_{1\text{-}6}$alkyl, and R^9 is $C_{1\text{-}6}$alkyl.

43. The compound of any one of claims 35 to 37 and 40 to 42, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is -OH, R^8 is methyl, and R^9 is methyl.

44. The compound of any one of claims 35 to 37 and 40, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (II-D1):



(II-D1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

45. The compound of any one of claims 35 to 41 and 44, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is -OH, R^8 is H, and R^9 is H.

46. The compound of claim 35, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-8}cycloalkyl.

47. The compound of claim 35, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein one of R^8 and R^9 is taken together with R^{10}, and the atoms to which they are attached, to form a C_{3-6}cycloalkyl.

48. The compound of any one of claims 35, 38, 46, and 47, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (II-E1):



(II-E1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

49. The compound of any one of claims 35, 38, 46, and 48, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^6 is -OH and R^7

is H.

50. The compound of claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein L is ,



such that the compound is of formula (III):



(III),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

51. The compound of any one of claims 1 to 50, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is absent.

52. The compound of any one of claims 1 to 51, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y is O.

53. The compound of any one of claims 1 to 51, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y is -N-(C_{1-6}alkyl).

54. The compound of any one of claims 1 to 51 and 53, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Y is -N-CH_3.

55. The compound of any one of claims 1 to 50 and 52, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is -N-(C_{1-}

$_6$alkyl).

56. The compound of any one of claims 1 to 50, 52, and 55, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is -N-CH_3.

57. The compound of any one of claims 1 to 56, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^a, R^b, and R^c are each independently H.

58. The compound of any one of claims 1 to 57, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1 is H, X^2 is H, one of X^3 and X^4 is halo, and the other of X^3 and X^4 is H.

59. The compound of any one of claims 1 to 58, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X^1 is H, X^2 is H, one of X^3 and X^4 is chloro, and the other of X^3 and X^4 is H.

60. The compound of claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is absent, Y is O, and R^a, R^b, and R^c are each independently H, such that the compound is of formula (B-2):



(B-2),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

61. The compound of claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is absent, Y is -N(CH_3), and

R^a, R^b, and R^c are each independently H, such that the compound is of formula (B-5):



(B-5),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

62. The compound of claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein Q is -N(CH_3), Y is O, and R^a, R^b, and R^c are each independently H, such that the compound is of formula (C-1):



(C-1),

or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

63. The compound of claim 1 or claim 2, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is a compound of Table 1, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing.

64. A pharmaceutical composition, comprising (i) a compound of any one of claims 1 to 63, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the

foregoing, and (ii) one or more pharmaceutically acceptable excipients.

65. A method of modulating APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of any one or claims 1 to 63, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 64.

66. A method of inhibiting APOL1 in a cell, comprising exposing the cell to a composition comprising an effective amount of a compound of any one or claims 1 to 63, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 64.

67. A method of treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of any one of claims 1 to 63, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 64.

68. The method of claim 67, wherein the disease, disorder, or condition is a kidney disease.

69. The method of claim 67 or claim 68, wherein the disease, disorder, or condition is a chronic kidney disease (CKD).

70. The method of claim 67, wherein the disease, disorder, or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN), sickle-cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19 associated nephropathy, preeclampsia, and sepsis.

71. A method of delaying the development of an APOL1-mediated disease, disorder, or condition, comprising administering a therapeutically effective amount of a compound of any one of claims 1 to 63, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable

salt of any of the foregoing, or a pharmaceutical composition of claim 64, to an individual who is at risk of developing an APOL1-mediated disease, disorder, or condition.

72. The method of claim 71, wherein the APOL1-mediated disease, disorder, or condition is a kidney disease.

73. The method of claim 71 or claim 72, wherein the APOL1-mediated disease, disorder, or condition is a chronic kidney disease.

74. The method of claim 71, wherein the APOL1-mediated disease, disorder, or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN), sickle-cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19 associated nephropathy, preeclampsia, and sepsis.

75. The method of any one of claims 67 to 74, wherein the individual has an APOL1 mutation.

76. The method of claim 75, wherein the APOL1 mutation is a gain-of-function mutation.

77. A kit, comprising (i) a compound of any one of claims 1 to 63, or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a pharmaceutical composition of claim 64, and (ii) instructions for use in treating an APOL1-mediated disease, disorder, or condition in an individual in need thereof.

78. The kit of claim 77, wherein the disease, disorder, or condition is a kidney disease.

79. The kit of claim 77 or claim 78, wherein the disease, disorder, or condition is a chronic kidney disease (CKD).

80. The kit of any one of claims 77 to 79, wherein the disease, disorder, or condition is selected from the group consisting of chronic kidney disease, focal segmental glomerulosclerosis (FSGS), hypertension-attributed kidney disease, human immunodeficiency virus-associated nephropathy (HIVAN), sickle-cell nephropathy, lupus nephritis, diabetic kidney disease, APOL1-associated nephropathy, viral nephropathy, COVID-19 associated nephropathy, preeclampsia, and sepsis.

81. The kit of any one of claims 77 to 80, wherein the individual has an APOL1 mutation.

82. The kit of claim 81, wherein the APOL1 mutation is a gain-of-function mutation.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 22/17086

A. CLASSIFICATION OF SUBJECT MATTER

IPC - C07D 403/12; C07D 405/14 (2022.01)

CPC - A61K 31/404; A61K 31/675; A61K 31/69

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
See Search History document

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
See Search History document

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
See Search History document

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PubChem-CID-44287171, Create Date: 19 November 2009 (19.11.2009), pg 2, figure.	1-5,60
A	CONNORS et al. "The Synthesis and Potassium Channel Blocking Activity of Some (4-Methanesulfonamidophenoxy)propanolamines as Potential Class III Antiarrhythmic Agents", J. Med. Chem. 1991. 34, pp 1570-1577, especially: pg 1570, col 1, formula 2.	1-5,60
A	WO 2002/012184 A1 (CHEMBIONEX CO LTD) 14 February 2002 (14.02.2002), especially: pg 10, ln 16-26, 2-phenyl-1-[1-((S)-1-phenylethyl)-aziridine-2-yl]-ethane.	1-5,60
A	PARK et al. "METABOLISM OF FLUORINE-CONTAINING DRUGS", Annu. Rev. Pharmacol. Toxicol. 2001. 41: pp 443-70, especially: pg 443, para 2; pg 450, para 6.	1-5,60

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"D" document cited by the applicant in the international application
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
6 June 2022	JUL 05 2022
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, Virginia 22313-1450 Facsimile No. 571-273-8300	Authorized officer Kari Rodriquez Telephone No. PCT Helpdesk: 571-272-4300

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 22/17086

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☒ Claims Nos.: 7-19,25-26,30-33,38-45,48-49,51-59,64-82
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
(see extra sheet)

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-5,60

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 22/17086

--BOX III - LACK OF UNITY--

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I+: Claims 1-6, 20-24, 27-29, 34-37, 46-47, 50 and 60-63 directed to a compound of Formula (A') or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. The compound of Formula (A') will be searched to the extent that it encompasses the first species of claim 1, wherein Q is absent; Y is O; Ra, Rb, and Rc are each H; L is (i), wherein A is O; Rx is taken together with R1 and the atoms to which they are attached, to form a 3-membered heterocyclyl, wherein the 3-membered heterocyclyl is substituted with n Rg substituents, wherein n is 0; R2 is H; R3 is H; R4 and R5 are H; provided that (1) Rx is taken together with one of R1 and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rg substituents, wherein n is an integer from 0-6, and Rg is -OH, halo, C1_6alkyl, or C1_6alkoxy. It is believed that claims 1-5 and 60 encompass this first named invention, and thus these claims will be searched without fee to the extent that they encompass the first species of claim 1. Applicant is invited to elect additional compounds of Formula (A'), wherein each additional compound elected will require one additional invention fee. Applicants must specify the claims that encompass any additionally elected compound. Applicants must further indicate, if applicable, the claims which encompass the first named invention, if different than what was indicated above for this group. Failure to clearly identify how any paid additional invention fees are to be applied to the "+" group(s) will result in only the first claimed invention to be searched. Additionally, an exemplary election wherein different actual variables are selected is suggested. An exemplary election would be a compound of claim 1, wherein Q is -N-(C1alkyl); Y is O; provided that, when Q is -N(C1_6alkyl), then Y is O; Ra, Rb, and Rc are each H; L is (i), wherein Rx is taken together with R1 and the atoms to which they are attached, to form a 3-membered heterocyclyl, wherein the 3-membered heterocyclyl is substituted with n Rg substituents, wherein n is 0; R2 is H; R3 is H; R4 and R5 are H; provided that (1) Rx is taken together with one of R1 and R2, and the atoms to which they are attached, to form a 3-8 membered heterocyclyl, wherein the 3-8 membered heterocyclyl is substituted with n independently selected Rg substituents, wherein n is an integer from 0-6, and Rg is -OH, halo, C1_6alkyl, or C1_6alkoxy (i.e. claims 1-5 and 62).

The groups of inventions listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Special Technical Features:

Group I+ includes the technical feature of a unique compound of Formula (A'), which is not required by any other invention of Group I+.

Common technical features:

The inventions of Groups I+ share the technical feature of a compound having the structure of Formula (A').

These shared technical features, however, do not provide a contribution over the prior art, as being obvious over the document entitled PubChem-CID-44287171 (hereinafter 'PubChem-171')

PubChem-171 teaches a compound of formula (A'): wherein Q is N(C1alkyl); Y is O; provided that, when Q is -N(C1_6alkyl), then Y is O; Ra, Rb and Rc are H; L is (iii); G is O; Rz is H; R11 is OH; R12 is H; R13 is H; R14 is H; X1, X2, X3 and X4 are H wherein, for each of (i) -(iii), # denotes the point of attachment to the phenyl ring bearing moiety Q, and ## denotes the point of attachment to the phenyl ring bearing moieties X1-X4 (pg 2, figure), but PubChem-171 does not teach the compound provided that at least one of Xl, X2, X3, and X4 is halo, -CN, C1_6alkyl, C1_6alkoxy, or SF5, wherein the C1_6alkyl or C1_6alkoxy is optionally substituted with one or more halo. However, it would have been obvious to know that replacement of a hydrogen atom by a fluorine atom is predicted to enhance the pharmacological profile of an existing compound, particularly on a phenyl ring (as evidenced by separately attaches supporting document entitled "METABOLISM OF FLUORINE-CONTAINING DRUGS" by Park et al.; see pg 443, para 2, Fluorine substitution can also have a profound effect on drug disposition, in terms of distribution, drug clearance, route(s), and extent of drug metabolism (12). Such changes can be used constructively by medicinal chemists to improve both the safety and the efficacy of a drug; see also pg 450, para 6, The presence of the fluorine group in aromatic systems serves two purposes. First, the presence of fluorine per se can block oxidation at a specific position. Second, fluorine decreases the rate of reaction of the pi-system of the benzene ring with activated cytochrome P450(FeO)3+). Thus, it would also have been obvious to prepare the analog of PubChem-171 wherein one of Xl, X2, X3, and X4 is halo by routine experimentation in the course of development and commercialization.

As said compound was known in the art at the time of the invention, this cannot be considered a special technical feature that would otherwise unify the inventions of Group I+.

The inventions of Group I+ thus lack unity under PCT Rule 13.

*Item 4 (contd): Claims 7-19, 25-26, 30-33, 38-45, 48-49, 51-59 and 64-82 are unsearchable because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). These claims are therefore, not included in the above analysis.